The Purification of Human Adult Progenitor Cell Types to Promote Angiogenesis by Sherman, Stephen E
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
2-27-2019 10:00 AM 
The Purification of Human Adult Progenitor Cell Types to Promote 
Angiogenesis 
Stephen E. Sherman 
The University of Western Ontario 
Supervisor 
Hess, David A. 
The University of Western Ontario 
Graduate Program in Physiology and Pharmacology 
A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of 
Philosophy 
© Stephen E. Sherman 2019 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Cardiovascular Diseases Commons, Circulatory and Respiratory Physiology Commons, 
Medical Cell Biology Commons, and the Medical Physiology Commons 
Recommended Citation 
Sherman, Stephen E., "The Purification of Human Adult Progenitor Cell Types to Promote Angiogenesis" 
(2019). Electronic Thesis and Dissertation Repository. 6026. 
https://ir.lib.uwo.ca/etd/6026 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
Abstract 
Cellular transplantation strategies have aimed to combat critical limb ischemia (CLI) by 
inducing endogenous blood vessel regeneration. Transplantation of mesenchymal stromal 
cells (MSC) for CLI has proven safe and well-tolerated but demonstrated only modestly 
improved clinical outcomes explained in part by a lack of MSC survival and/or potency in 
ischemic tissues. This thesis focuses on the development of improved transplantation 
strategies for patients with CLI utilizing purified pro-angiogenic subsets of MSC and 
endothelial colony forming cells (ECFC) seeded within decellularized adipose tissue (DAT) 
bioscaffolds. First, I investigated whether purification of bone marrow-derived MSC based 
on a conserved stem cell function, high ALDH-activity, could isolate a pro-vascular MSC 
subset after culture. Conditioned media generated by ALDHhi MSC promoted endothelial cell 
proliferation, survival, and tube forming functions under serum-free conditions, and a robust 
recruitment of mouse derived endothelial cells was observed after subcutaneous implantation 
of ALDHhi MSC within immunodeficient mice. Interestingly, isolating ECFC based on high 
ALDH-activity did not improve endothelial cell functions. Instead, isolation of ECFC 
expressing the progenitor cell surface marker, CD34 purified for ECFC with a mature 
endothelial cell surface phenotype and diminished colony- and tubule-forming functions in 
vitro. Before transplanting ECFC and MSC within human DAT scaffolds, I sought to 
develop robust methodologies to extract cells from DAT scaffolds, without generation of 
autofluorescent debris that impaired flow cytometric cellular evaluations. After protease 
dissociation, DAT scaffolds were centrifuged using a density gradient to produce samples 
with >99% purity. This method enabled accurate quantification of changes in ECFC surface 
marker expression alongside a decline in ECFC proliferation when co-cultured with MSC on 
DAT scaffolds in vitro. After intramuscular injection, or DAT scaffold implantation of ECFC 
and/or MSC into NOD.SCID mice with acute unilateral hindlimb ischemia, the level of blood 
perfusion in the ischemic limb was unaffected compared to saline injection. Importantly, 
implanted DAT scaffolds became vascularized and enhanced survival of ECFC or MSC. 
Taken together, this body of work indicates the importance of purifying pro-regenerative 
subsets to maximize cellular potency for clinical benefit.  
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Chapter 1  
1 Introductioni 
 Vascular disease 
According to the American Heart Association, cardiovascular disease (CVD) is broadly 
defined as a class of diseases which affect the heart or blood vessels. Specifically, CVD 
includes life-threatening ailments including: heart disease, heart attack, stroke, peripheral 
artery disease, heart failure, arrhythmia, or heart valve problems. CVD is the leading 
cause of death worldwide1 accounting for one in three deaths in North America2, 3. In 
Canada, the cost of CVD to the health care system alone totals more than $22 billion per 
year4. Unfortunately, the etiology of CVD is multi-factorial, influenced by genetic and 
non-genetic factors and often presenting with comorbidities (i.e. diabetes, obesity, etc.). 
Regardless, the pathogenesis of CVD is often accelerated by life style choices including: 
diet, smoking, physical activity, and uncontrolled blood pressure and cholesterol2, 3. In 
regard to hypertension, approximately 23% of the adult population in Canada are 
hypertensive5. As the prevalence of CVD increases, projections estimate that 45.1% of 
Americans will have some form of CVD by 20352, in return increasing health care costs 
>2-fold6. Thus, current research aims on developing effective and novel therapeutic 
strategies to prevent or to reverse the morbidities of CVD. 
1.1.1 Atherosclerosis 
Atherosclerosis is a chronic blood vessel disorder characterized by the progressive 
narrowing of blood vessels through a complex inflammatory process. Chronic 
inflammation in the vascular endothelium will lead to the formation of fibrous tissues that 
contain a dense core of lipid and cellular material known as plaques7, 8.  
_______________ 
i Parts of this chapter have been previously published: Sherman SE, Hess DA. 
Immunogenicity and Immunomodulation of Fetal Stem Cells. In Fetal Stem Cells in 
Regenerative Medicine 2016 (pp. 57-79). Springer, New York, NY. 
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The early stages of atherosclerosis begins with the deposition of lipid droplets within the 
intimal layers of the vasculature in response to a fat-laden environment9, 10. Dyslipidemia 
will promote a pro-inflammatory environment that will alter endothelial cell expression 
of chemoattractant and adhesion molecules to permit circulating monocytes to invade 
into the vessel intima11.  Infiltrating monocytes will rapidly differentiate into 
macrophages that scavenge extracellular lipids from the interstitium. The accumulation of 
cytosolic lipids in macrophages will convert these macrophages into foam cells, 
explained in great detail by Moore et al.12. As the number of foam cells accumulate in the 
developing intimal lesion, the plaques present with the earliest visible feature called the 
‘fatty streak’13. At this stage, the inflammatory signals released by foam cells induce 
proliferation of smooth muscle cells, thickening the intimal layer and forming a fibrous 
cap around the foam cells14, 15. Foam cells and smooth muscle cells within the lipid core 
become apoptotic, releasing accumulated cholesterols and lipoproteins, intensifying the 
pro-inflammatory environment16. If efferocytosis is impaired, the inflammatory process is 
unable to resolve in these early lesions. The accumulation of dead cell bi-products 
develops into a ‘vulnerable plaque’ whereby invading leukocytes can disrupt the structure 
of the atherosclerotic plaque17. The rupturing of the plaque exposes the thrombotic core 
to the circulating blood, in return leading to thrombosis formation and vessel occlusion18. 
Thrombotic events have been implicated in >75% of fatal heart attacks in addition to 
other acute ischemic pathologies such as stroke19, 20. The risk factors for developing 
atherosclerosis include: diabetes, hypertension, smoking, lack of physical activity and 
dyslipidemia2, 21. 
1.1.2 Coronary Artery disease 
Of the atherosclerotic-related diseases, coronary artery disease (CAD) remains one of the 
most deadly forms of heart disease accounting for 1 in 6 deaths in the United States22. 
CAD is characterized by the blockage of the major vessels surrounding the heart due to 
atherosclerotic plaque buildup. Typically, CAD progression will lead to myocardial 
infarction and eventual heart failure where the mortality rate is approximately 60% within 
5 years of diagnosis23. Treatment options for CAD have been progressively improving 
since the use of coronary artery bypass surgery24 including the use of anti-platelet 
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therapies25 and exercise26. Unfortunately, for patients with late stage progressive heart 
failure, treatment options are limited to highly invasive procedures such as heart 
transplantation or ventricular assist devices27. Although the rates of diagnosis have been 
steadily increasing, mortality rates have been decreasing for several decades 28, 29. The 
development of cell-based therapies for CAD is still in its infancy but holds promise for 
the CVD field30.  
1.1.3 Peripheral artery disease 
Peripheral artery disease (PAD) is a disease of the circulatory system characterized by 
ischemia in the lower extremities due to a partial or complete occlusion of blood vessels 
with chronic atherosclerotic plaque accumulation. Clinically, PAD is defined as an ankle-
brachial index (ABI) ≤ 0.9, with or without pain during moderate exercise. In Canada, 
approximately 800,000 individuals are affected by PAD with more than 8.5 million 
Americans suffering from PAD2, 31, 32. With a lack of public awareness of PAD33 and as 
many as 40% of PAD patients being symptom free, many cases go undiagnosed32, 34-36. 
Unfortunately, as the severity of atherosclerosis increases, an individual’s risk for life-
threatening cardiovascular complications will increase 6-fold31. The current treatment for 
PAD include pharmacological therapies to minimize clotting, smoking cessation, surgical 
intervention, and/or exercise programs37, 38. When left untreated, ischemia in the lower 
extremity will become so severe that the patients will experience severe resting pain, non-
healing ulcers, and increased risk of infection in the ischemic limb. This is known as 
critical limb ischemia (CLI), the most severe form of PAD39. Current statistics indicate 
that 30% of patients within one year of diagnosis will require limb amputation and 
greater than 60% of patients will have died from cardiovascular complications within 5 
years of diagnosis40. Unfortunately, patients with CLI often exhibit co-morbidities such 
as diabetes which impairs endothelial cell functions, accelerating disease progression and 
symptomatology41. Stimulation of angiogenesis through pharmacological targets, gene 
therapy, or cellular therapy are under investigation to prevent amputations and prolong 
patient lifespan38. The development of cellular therapies for CLI is a central theme within 
this thesis. 
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 Vascular biology 
Blood vessels are dynamic structures whose primary function is to direct blood flow 
throughout the body and mediate the exchange of gases, nutrients and waste to maintain 
homeostasis. Blood vessels are organized in a hierarchical structure with few blood 
vessels of larger diameter and many small, microscopic vessels42. The vascular plexus 
begins with the arteries that mediate the transport of oxygenated blood which will branch 
into smaller vessels known as arterioles. Upon further branching, the arterioles will 
become capillaries which are the smallest functional unit of the vascular system where 
the erythrocytes release oxygen and gain carbon dioxide. The capillary system will 
anastomose to form venules which carry deoxygenated blood. Venules will continue to 
anastomose into larger veins which deliver the deoxygenated blood back to the heart43. 
Systemically, the larger vessels support the movement of large volumes of blood and deal 
with higher blood pressures required to deliver blood to the tissues and return to the 
heart44. In contrast, the primary function of the smaller blood vessels is to mediate the 
exchange of nutrients and wastes at the cellular level to maintain organ homeostasis45.  
Lastly, the final component to the vascular system is the lymphatic vessels. Like the 
vascular plexus, the lymphatic system is organized in a hierarchical structure of few large 
ducts with many capillaries. Contrary to the vascular system, the lymphatic system 
promotes a one-way flow of lymphatic fluid (interstitial fluid) towards the heart. Lymph 
is exchanged from the blood capillaries to the lymphatic capillaries. Like blood 
capillaries, the capillaries of the lymphatic system anastomose into larger collecting 
vessels. Collecting vessels then pass through lymph nodes and drain into larger trunks 
which ultimately drain into ducts which returns the lymph to the blood stream46.  
1.2.1 Blood Vessel anatomy 
Arteries (0.1-10mm diameter) are composed of three layers which enable these vessels to 
withstand the high blood pressures from the heart. The outermost layer is called the 
Tunica externa and is primarily comprised of elastic fibers which provide elasticity and 
support to the vessel. The Tunica media is a layer of smooth muscle cells which lies 
adjacent to the Tunica externa and is separated from the Tunica intima by a basement 
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membrane. The Tunica intima is the innermost layer of the artery which is comprised of a 
layer of continuous endothelial cells which interface with the blood47.  
Like arteries, arterioles (100-300 µm diameter) can also be divided into the three 
segments: Tunica externa, media, and intima. Arterioles differ from arteries in their 
tunica externa and media thicknesses which give arterioles a smaller diameter than 
arteries. Like arteries, arterioles are lined with a continuous endothelial layer48, 49. 
Capillaries are the smallest units of the vasculature system and are comprised of only a 
single layer of endothelial cells which interact with pericytes. The architecture of the 
endothelial cells in capillaries is usually continuous but can be fenestrated to mediate 
specific functions within different organs50-52.  
Venules interface with the capillaries to bring deoxygenated blood back to the heart. 
These vessels are similar to arterioles except these vessels contain microscopic valves to 
prevent the backflow of blood due to the low blood pressures after travel through the 
capillaries53. 
Veins are large blood vessels which bring blood back to the heart. Like arteries, 
arterioles, and venules, veins contain three vessel layers: Tunica externa, media, and 
intima. Veins differ from arteries in their relatively thin structures and large diameter 
lumens. Veins also contain valves to prevent the backflow of blood as it travels to the 
heart47.  
1.2.2 Endothelial cells 
Endothelial cells are the functional units of blood vessels and are the cells that are 
responsible for lining blood vessels and directly interacting with the blood. Endothelial 
cells are highly specialized and must function in a tissue-specific manner to ensure 
optimal performance of each organ system. The tissue-specific phenotype of endothelial 
cells is determined by tissue interactions via cell-contact mechanisms as well as paracrine 
signaling54, 55. For example, the phenotypic differences observed between the blood brain 
barrier endothelium and the endothelium within somatic tissue is due to tissue signaling 
of the local microenvironment56. Furthermore, the permeability and dilation of vessels is 
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a complex, multifactorial process which is tightly controlled by endothelial cells exposed 
to specific physical and chemical cues57. For example, endothelial cells exposed to shear 
stress will produce nitric oxide synthase58 which has vasodilatory effects as well as 
cardio-protective effects and down-stream chemotactic properties for mesenchymal 
stromal cells59. 
In healthy tissues, endothelial cells in blood vessels are typically quiescent and have slow 
cell turnover rates. Cellular quiescence and survival is primarily mediated by the delicate 
balance of maintenance and survival cues such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF), angiopoietin (ANGPT), and NOTCH 
signaling60, 61. When endothelial cells are exposed to higher levels of these signals, this 
will initiate endothelial cell migration and proliferation to form new vasculature in a 
process called angiogenesis62. Importantly, endothelial cells are also crucial in mediating 
inflammatory responses by up-regulating cell surface proteins to promote thrombosis and 
to promote extravasation of immune cells into damaged tissues63, 64.  
1.2.3 Pericytes 
The vascular structure depends on two main cell types: endothelial cells, and perivascular 
cells. In the vasculature, these cell types interact with one another in a complex and delicate 
balance between growth, survival, regression and death 65. Perivascular cells, or pericytes, 
wrap around the endothelial cells that make up blood vessels and provide structural support 
as well as cellular communication through direct contact and perivascular mechanisms. 
More importantly, pericytes also play a key role in the regulation of vessel formation during 
angiogenesis66. In mature vessels, pericytes interact with endothelial cells through platelet-
derived growth factor (PDGF) to promote vessel stability and quiescence67. Although 
closely associated with endothelial cells, pericytes do not express common endothelial 
markers such as CD31, CD44, or von Willebrand factor (vWF). These CD146+ CD31- cells 
can be isolated from almost every human adult and fetal tissue including the umbilical cord 
and placenta68. Pericytes have also been thought to reside on a phenotype continuum which 
includes vascular smooth muscle cells and mesenchymal stromal cells (MSC)67, 68.  
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1.2.4 Vascular smooth muscle cells 
Vascular smooth muscle cells (vSMC) are specialized cells which reside within the 
Tunica media of larger blood vessels and help to regulate vessel integrity and tone. A 
primary role for vSMC is to regulate conductance of blood flow through vasomotor 
responses. Specifically, the vasomotor responses within vasculature involves contraction 
or relaxation of vSMC to control blood conductance by constricting or dilating blood 
vessels, respectively69. The ability for vSMC to contract or relax is tightly controlled by 
the balance of depolarizing and hyperpolarizing currents generated by ion channels on the 
plasma membrane70, 71. These electrical responses within arterial structures are capable of 
propagating across the length of vessels through gap junctional connections of coupled 
vSMC. The conduction of vasomotor responses is not observed in the venous 
circulation72. The initiation of the vasomotor response is driven by endothelial cells 
responding to physical and chemical signals in the blood. In response to these circulating 
stimuli, endothelial cells release factors such as nitric oxide and endothelin-1 directly on 
vSMC to modulate vessel tone73, 74. In healthy tissues, vascular smooth muscle cells 
proliferate at extremely low rates and express contractile proteins to control blood flow 
distribution14. The differentiation and regulation of cell function and phenotype is tightly 
controlled by the microenvironment and is dependent on the interactions with endothelial 
cells75. In disease conditions such as atherosclerosis, vascular smooth muscle cells exhibit 
a phenotype switch which causes the cells to become proliferative and may promote the 
formation of the fibrotic cap14. 
1.2.5 Development of the vascular system 
The cardiovascular system is the first organ system to begin its function during 
embryogenesis. The development of circulation is required to develop and maturate all 
the other organ systems during development76. Development of the vasculature begins by 
the formation of blood islands within the mesodermal layer of the developing yolk sac77. 
The outer cells of the blood island then give rise to Angioblasts through a common 
hematopoietic/endothelial cell precursor known as the hemangioblast78, 79.  Angioblasts 
then begin to migrate outward and assemble into vascular structures through a process 
known as vasculogenesis. The proliferation and migration of angioblasts inevitably give 
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rise to a labyrinth of small capillaries known as the primary vascular plexus through 
VEGF signaling mechanisms76, 80. Once the primary vascular plexus is formed from 
angioblast proliferation and migration, endothelial cells begin to sprout from preexisting 
capillaries in response to VEGF released from developing organs81. During these 
processes, the primitive heart pushes blood through these early vascular networks which 
begin to specialize endothelial cells to adopting an arterial or venous identity82. The 
development of arterial and venous identities are tightly controlled by multiple signaling 
mechanisms crucial to establish and mantain functional vascular system83. Through 
angiogenesis, endothelial cells continue to populate developing organs and subsequently 
maturate80.  
1.2.6 Hemangioblasts 
The concept of a common ancestor between hematopoietic and endothelial cell lineages 
began with the observations of the close developmental proximity of hematopoietic and 
endothelial cell development alongside several shared features such as surface phenotype 
and transcriptional programs84. Subsequent studies indicated that there in fact was a 
common cell type that gave rise to both hematopoietic and endothelial cells which was 
termed the hemangioblast85. During development, the earliest distinguishing phenotype 
of the hemangioblast is vascular endothelial growth factor receptor 2 (VEGFR2), the 
primary receptor for VEGF-A80. Hemangioblasts have also been demonstrated to require 
T cell acute lymphocytic leukemia protein (SCL) for development86. Hemangioblasts 
have been demonstrated to populate both the blood islands and the aortic floor during 
cardiac development79, 85. Although controversial, accumulating evidence suggests the 
existence of the hemangioblast persisting into adulthood87. 
 Neovascular formation 
Neovessel formation in adult organisms can occur in two possible ways: angiogenesis or 
vasculogenesis. Angiogenesis is thought to occur by activation of vessel-resident 
endothelial cells that become primed to respond to regions of hypoxia through local 
secretion of pro-angiogenic factors. After activation, the endothelial cells begin 
proliferating to direct the formation of the new vessel towards the site of ischemia88. If 
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stable perfusion is established in the neovessels, perivascular cells will stabilize this new 
blood vessel network and the endothelial cells will become quiescent 65, 89. 
Vasculogenesis, on the other hand, is the formation of new blood vessels by means of 
circulating endothelial progenitor cells (EPC). Circulating EPC are capable of 
spontaneously forming tubules in vitro and have been shown to directly incorporate into 
newly forming blood vessels in vivo 90, 91. 
1.3.1 Hypoxic responses 
Cellular responses to a lack of oxygen are crucial to promoting neovessel formation in the 
embryo and in the adult. The primary signaling pathway that mediates these responses is 
the hypoxia inducible factor (HIF) pathway. HIF-1 is a basic helix-loop-helix 
transcription factor which is the primary mediator for transcription of VEGF and other 
hypoxia-inducible genes92, 93. HIF-1 can only bind to DNA and promote transcription as a 
heterodimer containing an alpha subunit (HIFα) and a beta subunit (HIFβ or aryl 
hydrocarbon nuclear transporter; ARNT)94. Under normal oxygen conditions, HIF-prolyl 
hydroxylase (HPH) uses oxygen as a co-substrate to ubiquitinate HIF-1α and target it for 
degradation in the proteasome95. During hypoxia, HIF-1α is stabilized by the lack of 
ubiquitination by HPH which enables dimerization with HIFβ and subsequent 
localization to the nucleus. Once activated, the HIF pathway targets many genes that 
control angiogenesis, cell metabolism, vascular tone, and even erythropoiesis96. Lastly, 
the hypoxic response is heavily involved in many pathologic manifestations such as: 
cancer, wound healing, PAD, sleep apnea, and pulmonary arterial hypertension, making it 
an attractive target for many therapies97. 
1.3.2 Angiogenesis 
The formation of new blood vessels form pre-existing vasculature is termed angiogenesis. 
Angiogenesis is a complex, multi-step process which is mediated through the delicate 
balance of signaling proteins to maintain endothelial cell quiescence or proliferation and 
migration62. Angiogenesis can be divided into two main groups: intussusceptive or 
sprouting angiogenesis98, 99. 
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Intussusceptive angiogenesis is characterized by the splitting of pre-existing vessels to 
form daughter vessels, a phenomena first observed in the rat lung during a developmental 
process called microvascular maturation100. The act of vessel intussusception requires the 
formation of an intraluminal pillar within the blood vessel to induce splitting. The 
formation of pillars is thought to occur rapidly without requiring endothelial cell 
proliferation, expertly reviewed by Burri et al.101. Intussusceptive angiogenesis has been 
found in various organs of the body and is thought to be mediated through ANGPT 
signaling to increase vessel density in maturing organs102-104. 
Sprouting angiogenesis is a more involved process compared to intussusceptive 
angiogenesis beginning with the tissue response to hypoxia and subsequent release of 
angiogenic factors such as bFGF, VEGF, and ANGPT 92. These factors will activate 
endothelial cells to remodel the vascular structure and surrounding ECM. Endothelial cell 
proliferation drives the migration of the sprouting vessel to revascularize the hypoxic 
tissues99. Although endothelial cells are the primary driver for sprouting angiogenesis, 
many hematopoietic cell types contribute to facilitate capillary formation and aid in the 
joining of migrating endothelial tip cells105-107. 
1.3.3 Vasculogenesis 
During development, the differentiation of lateral plate mesoderm to form angioblasts 
marks the beginning of vasculogenesis. Briefly defined, vasculogenesis is the de-novo 
formation of blood vessels from endothelial precursors or progenitor cells76, 82. After the 
vascular plexus is formed by the VEGFR2+ (hem)angioblasts, vasculogenesis is primarily 
replaced by angiogenesis to produce the blood vessels of the developing organism108. 
Although a short-lived process, experimental evidence to demonstrate post-natal 
vasculogenesis is now abundant.  
The conceptualization of postnatal vasculogenesis began with pre-clinical studies 
involving the use of cytokines and growth factors to promote neovascularization in 
patients with CLI. In these initial studies, VEGF expression declined with age and in 
disease states which suggested the need for progenitor cell types to replenish these 
“exhausted” tissues109. Because hematopoietic and endothelial precursors share a 
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common progenitor during development, the observations of hematopoietic stem cells 
persisting in the adult led Asahara to purify putative endothelial progenitor cells (EPC) 
using the hematopoietic progenitor cell marker, CD34110. The resulting putative EPC 
isolated from human blood demonstrated endothelial-like properties in vitro. After 
transplantation of the CD34+ peripheral blood mononuclear cells (MNC) into mice that 
underwent femoral artery ligation (FAL) surgery, the human cells engrafting in the 
mouse vasculature co-expressed CD31. This seminal work established the field of 
postnatal EPC biology which has been instrumental in understanding endothelial cell 
biology.  
1.3.4 Arteriogenesis 
During the development of the vascular system, the formation of high-resistance, low 
flow vasculature known as “collateral vessels” enables the vascular system to compensate 
in times of high flow or vessel blockage. The primary utility of collateral vessels is to 
undergo a morphogenic process into large-conductance arteries in a process known as 
arteriogenesis111. When blood flow is blocked in large vessels, the collateral vasculature 
morphologically changes to accommodate the high blood flow and act as a bi-pass 
mechanism, protecting from ischemia112, 113. Contrary to neo-vessel formation, the 
induction of arteriogenesis is not regulated by hypoxia114. The initiation of arteriogenesis 
is caused by an increase in blood volume passing through collateral vessels, thereby 
increasing the shear stress on these vessels. The increase in shear stress mechanically 
influences endothelial cell transcription through the opening of chloride channels and 
phosphorylation of focal adhesions. As a result, endothelial cells within collateral vessels 
begin to express monocyte chemoattractant protein-1 (MCP-1) and intracellular adhesion 
molecule-1 (ICAM-1), primarily attracting monocytes from the circulation115, 116. 
Concurrently, shear stress induces nitric oxide (NO) and PDGF release from endothelial 
cells causing vasodilation to accommodate blood flow and attracting pericytes and 
vascular smooth muscle cells to stabilize the vessel117. Collectively, the recruitment of 
circulating monocytes, pericytes, and vascular smooth muscle cells facilitates the 
remodeling of the vessel structure to form a functional, high-conductance artery115, 117, 118.  
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1.3.5 Pro-angiogenic Cytokines and endothelial cell activation 
1.3.5.1 VEGF and NOTCH 
The VEGF and NOTCH signaling pathways are one of the most studied pathways 
in endothelial cell biology. The VEGF protein family which contains members 
(VEGF-A through to VEGF-E) that signal through tyrosine receptor kinases: 
VEGFR1, VEGFR2, and VEGFR3119. VEGF exerts pleiotropic effects on 
endothelial cells where low levels of VEGF signaling promotes cell survival and 
quiescence. On the other hand, high levels of VEGF signaling activates 
endothelial cells for angiogenesis89. In a normal physiological state, pericytes 
provide low levels of VEGF to endothelial cells to promote quiescence. However, 
endothelial cells will activate upon exposure to higher concentrations of VEGF 
released from hypoxic tissues, marking the beginning of angiogenesis. Activated 
endothelial cells begin by loosening tight junctions and secreting matrix 
metalloproteinases (MMP) to break free from the basement membrane shared by 
pericytes120. Subsequently, endothelial cells will migrate towards the VEGF 
signals. Notably, the endothelial cell with the highest VEGF exposure will 
become a “tip cell”. Endothelial tip cells guide the growing vessel towards the 
angiogenic stimuli through many extended filopodia which sense the environment 
as the vessel grows121, 122.  
During the phenotypic change into a tip cell, the expression of the NOTCH 
ligand, delta-like 4 (DLL4) is upregulated. NOTCH is a evolutionarily conserved, 
contact-dependent signaling pathway which is involved in cell fate decisions such 
as proliferation, apoptosis and differentiation 82, 123. The primary function of 
NOTCH/DLL4 signaling during angiogenesis is to regulate endothelial tip cell 
formation. The NOTCH signaling pathway will prevent tip cell formation through 
the down-regulation of VEGF receptors on signal receiving cells, acting as a 
counterbalance to VEGF signaling124. Thus, with the heightened expression of 
DLL4 on tip cells, the adjacent endothelial cells will decrease VEGFR2 and 
become less likely to become a tip cell in a process called lateral inhibition120, 125. 
The endothelial cells adjacent to the tip cell then become “stalk” cells which drive 
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vessel elongation through proliferation89, 123, 125, 126. Once the sprouting vessel 
invades the hypoxic tissues, macrophages have been demonstrated to facilitate the 
joining of incoming vessels to complete the circuit before blood flow can be re-
established106, 127. 
1.3.5.2 Angiopoietin 
The angiopoietins are a well-studied endothelial-specific growth factor family 
which contain 4 isoforms (ANGPT 1-4) all capable of binding to the receptor 
tyrosine kinase with immunoglobulin and epidermal growth factor homology 
domain (TIE-2)119.  The major isoforms involved in endothelial cell functions is 
ANGPT1 and ANGPT2. Interestingly, both ANGPT-1&2 can bind to TIE 2 but 
ANGPT-1 is the only ligand capable of phosphorylating TIE-2. ANGPT-2 has been 
implicated in providing antagonistic functions to ANGPT-1128. ANGPT-1 signaling 
is also thought to be context dependent and can act to promote vessel growth on 
mobilized endothelial cells62. Largely, ANGPT-1 signaling promotes endothelial 
cell quiescence, basement membrane deposition, and further stabilizes pericyte 
interactions129. Upon activation, endothelial tip cells will secrete ANGPT-2 to 
antagonize TIE-2 signaling and promote pericyte detachment, further destabilizing 
the vessel130, 131.  
1.3.6 Vessel patterning and Guidance cues. 
Ephrin signaling plays an important role in several developmental processes and are a 
major player in the regulation of tissue patterning and axon/blood vessel guidance. Like 
NOTCH signaling, ephrin receptors (Eph) and ligands (Ephrin) are membrane-bound and 
require cell-contact to signal126, 132. Ephrin signaling is also bi-directional, meaning that 
ligand-expressing cells can signal through ligand-receptor interactions133, 134. Eph4, is 
found on cells of the venous circulation whereas EphrinB2, the ligand for Eph4, marks 
cells of the arterial circulation. It is thought that the expression of Eph4 and EphrinB2 are 
primarily to maintain arterial and venous identity62, 82, 135. Ephrin’s bi-directional 
signaling cascades have been implicated in vessel wall assembly with pericytes and 
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vascular smooth muscle cells expressing EphrinB2136. Ephrins have also been implicated 
in promoting vessel sprouting and migration of activated endothelial cells137. 
Semaphorins are a large family of soluble guidance signals that all share a 500 amino 
acid sema domain138. Semaphorins play a crucial role in the regulation of blood vessel 
and axon growth in development and in adult tissues. There are 2 main receptor types 
which bind semaphorins and initiate intracellular signaling: the Plexin family and 
Neuropilins (NPN). The primary function of semaphorin-signaling through plexin 
receptors is to reduce cell adhesion through destabilization of the actin cytoskeleton. 
Neuropilins on the other hand, are thought to modify the growth cone of migrating 
cells126, 139. Collectively, semaphorins are largely implicated with repulsive cues during 
sprouting angiogenesis. However, semaphorins can elicit a repulsive or attractive signal 
to cells depending on protein kinase G activity within the cell140.  
1.3.7 Extracellular matrix remodeling during neovessel formation. 
Once endothelial cells become activated, the basement membrane common to endothelial 
cells and pericytes must be degraded to enable vessel sprouting (angiogenesis) or 
remodeling (arteriogenesis)141. To perform this function, endothelial cells secrete matrix 
metalloproteinases (MMPs), a family of endopeptidases involved in extracellular matrix 
(ECM) remodeling processes142. Endothelial cells secrete various MMPs which may be 
regulated by the tissue microenvironment143. To ensure that matrix remodeling does not 
occur in excess, tissue inhibitors of matrix metalloproteinases (TIMPs) are secreted to 
limit ECM degradation by MMPs144. Thus, proper angiogenesis depends on a fine 
balance between MMP and TIMP activities where too little MMP activity will prevent 
angiogenic sprouting and too much activity will prevent the formation of stable 
vasculature145. Lastly, an important feature of MMP-mediated ECM remodeling is 
through the release of pro-angiogenic factors sequestered in the ECM to further promote 
angiogenesis and tip cell migration146. 
1.3.8 Vessel remodeling. 
After angiogenic sprouts invade the hypoxic tissues, there are many connections made 
between different sprouts but also dead ends which failed to form a circuit to the systemic 
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circulation. The resulting microvasculature in these sites of angiogenesis are randomly 
oriented and chaotic, creating turbid and inefficient blood flow104, 147. These new vessels 
also lack pericyte stabilization and thus, are poorly perfused and leaky148. Therefore, 
vessel maturation and remodeling of the newly developed vascular tree to select for 
efficient vessels needs to occur. 
Vessel maturation is primarily mediated through endothelial cell secretion of PDGF 
which is responsible for recruiting pericytes to wrap and stabilize vessels 149. 
Additionally, ANGPT-1 and transforming growth factor-β (TGF-β) are secreted by 
endothelial cells to promote pericyte-endothelial cell binding89, 150. Finally, the pericyte-
endothelial interactions promote matrix deposition to form a common basement 
membrane at the interface between the two cell populations. Up-regulation of N-cadherin 
(N-CAD) and vascular endothelial cadherin (VE-CAD) stabilizes cell-cell interactions 
within the vessel to minimize leakiness149.  
Remodeling of the chaotic vascular network through the pruning of inefficient vascular 
connections is regulated by multiple mechanisms. First, the secretion of pro-angiogenic 
factors will decrease as the newly invading vasculature will provide the hypoxic tissues 
with oxygen. As vascularization of the tissues reaches a maximum, the lack of pro-
angiogenic signals will halt further vessel sprouting151, 152. Concurrently, the release of 
anti-angiogenic factors will counteract the survival signals from the pro-angiogenic 
factors, promoting vessel regression153. Next, the vessels that have made efficient 
connections will experience adequate sheer stress, acting as a pro-survival signal in 
endothelial cells. The vessels which carry the least blood flow will undergo apoptosis due 
to a lack of sheer stress and nutrients154. After the tissues reach an optimal partial 
pressure of oxygen, the process of vessel regression and maturation is concluded which 
marks the end of the angiogenic process (overviewed in Figure 1.1). 
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Figure 1.1 A schematic overview of sprouting angiogenesis. 
 
Figure 1.1. A schematic overview of sprouting angiogenesis. (A) Hypoxic tissues up-
regulate the secretion of pro-angiogenic factors (i.e. VEGF) through activation of the HIF 
pathway. The pro-angiogenic factors will diffuse through tissues and activate endothelial 
cells of surrounding blood vessels. (B) VEGF signaling will activate endothelial cells to 
secrete ANGPT-2 and MMPs to degrade the basement membrane and detach pericytes 
that are stabilizing the blood vessel. (C) The endothelial cell experiencing the most 
VEGF signaling will become the tip cell and begin to migrate towards the source of 
hypoxia. Tip cells promote the formation of stalk cells by decreasing VEGFR2 
expression through lateral inhibition (NOTCH/DLL4 signaling). Proliferation of the stalk 
cells will drive the migration of the vessel towards hypoxic signals. (D) After forming a 
blood vessel circuit at the source of hypoxia, endothelial cells will secrete PDGF to 
recruit pericytes to the newly formed vessels. Blood flow kinetics and vessel stabilization 
through pericyte interactions will enable vessel maturation and protect against diminished 
pro-survival signals in the microenvironment. Subsequently, the inefficient vessels are 
regressed or ‘pruned’ through apoptotic mechanisms. 
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 Cell therapy for vascular diseases 
The focus of many emerging clinical therapies for patients suffering from CVD is to 
promote angiogenesis to revascularize damaged or diseased tissues. Many of the clinical 
trials for cellular therapies have involved direct injection of bone marrow derived 
mononuclear cells (BM-MNC), a heterogeneous cell population which contains 
hematopoietic, endothelial, and mesenchymal cell lineages that directly and indirectly aid 
in neovessel formation. For example, the therapeutic angiogenesis by cell transplantation 
(TACT) trial was able to demonstrate efficacy in patients with CLI by improving ankle 
brachial pressure index as well as tissue oxygen saturation through transplantation of 
BM-MNC155. In a follow-up study to the TACT trial, there was significant improvement 
in pain scale, walking time as well as improvements in ulcer healing after 2 years post-
transplantation156. The potential for cellular therapeutics is a field of research that is 
thoroughly being explored for various diseases from cancer to CVD157, 158. 
1.4.1 Stem/progenitor cells 
The field of stem cell biology began with seminal experiments by James Till and Ernest 
McCulloch to identify a cell type in the mouse bone marrow which could engraft and 
form colonies in the spleen after whole-body irradiation159. Subsequently, two crucial 
observations eventually lead to the widely accepted definition of a stem cell: The ability 
for a cell to self-renew and the ability to differentiate160. Stem cells are also defined by 
their potency or their ability to give rise to specialized tissue types. Stem cell potency is 
arranged in a hierarchy beginning with totipotent stem cells: a cell type that can give rise 
to all the tissues of an organism including the extra-embryonic tissues161. Stem cells that 
are only able to differentiate into the 3 germ layers of the embryo proper are termed 
pluripotent. Multipotency refers to the ability for a cell to differentiate into multiple 
different cell types within a given germ layer. For example, Mesenchymal stromal cell 
(MSC) differentiation into bone, cartilage, and adipose tissues within the mesenchymal 
germ line. Unipotency refers to the ability for a cell to differentiate into a specific tissue 
type while the bottom of the hierarchy contains mature cells with minimal proliferative 
capacity162.  
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More recently, the discovery of induced pluripotent stem cells (iPSC) has enabled the 
production of pluripotent stem cells from mature, somatic cells. The seminal work of 
Takahashi and Yamanaka led to the discovery of 4 transcription factors capable of 
converting mouse or human fibroblasts into pluripotent cells163, 164. This discovery was 
instrumental in progressing the stem cell field by providing an alternative method to 
derive a pluripotent human cell type instead of using human embryonic stem cells 
(hESC). Likewise, iPSC have provided the capacity to model genetic diseases in a dish 
which has great potential to develop effective clinical treatments165.  
Importantly, tissue-resident stem/progenitor cells can be found in tissues throughout adult 
organisms. These cells are responsible for the maintenance of tissues throughout the 
lifespan of the organism166. In many cases of disease, tissue-resident stem/progenitor 
cells are overwhelmed by the severity of damage or unable to compensate properly for 
the burden of disease and fail to repair or replace damaged tissues. For example, in 
patients with CLI, the endothelial progenitor cells do not respond adequately to tissue 
ischemia167, 168. The lack of progenitor cell response is due to a concept referred to as 
stem cell exhaustion. With increased age or prolonged chronic disease states such as type 
2 diabetes, the regenerative function of the tissue-resident stem/progenitor cells can be  
gradually diminished169, 170. Thus, the use of stem cells in clinical therapies to aid in 
tissue replacement or repair is an attractive option to maximize therapeutic outcomes. 
Discussed below are two leading progenitor cell types that hold promise for cellular 
therapies to treat vascular-related diseases through the replacement of vasculature. 
1.4.2 Adult endothelial progenitor cells 
The field of postnatal vasculogenesis began with the seminal discovery of CD34+ 
peripheral blood mononuclear cells (MNC) that could incorporate into sites of ischemia 
and promote vascularization after transplantation110. This was the first demonstration of 
the existence of a circulating EPC population within adult blood. This work lead to the 
subsequent isolation of “EPC” from human bone marrow blood sources and propagation 
ex vivo. Three distinct culture techniques emerged, producing three different resulting 
cell populations termed: (1) colony  forming unit – endothelial cells (CFU-EC)110, 171, (2) 
circulating angiogenic cells (CAC)167, 172, 173, and (3) endothelial colony forming cells 
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(ECFC)174-176. Two main variables where these isolation techniques diverge is the culture 
of adherent versus the non-adherent cells of the MNC fraction, and the length of time 
before colonies emerge. The technique used to isolate CFU-EC involves the depletion of 
the adherent cells on fibronectin where the non-adherent cells are subsequently collected 
and cultured. Cell colonies from this technique formed within 4-7 days and are also 
known as early outgrowth endothelial cells110, 171, 177. The isolation of CAC involves the 
seeding of MNC on fibronectin where the non-adherent cells are removed after 3 days in 
culture and the adherent, early outgrowth cells are then formed within 10 days after 
plating167, 172, 173. Lastly, the final technique involves the culture of the adherent MNC on 
collagen until late outgrowth colonies form (approximately 14 days), termed outgrowth 
endothelial cells or endothelial colony forming cells (ECFC)174-176, 178. 
It has since become established that CFU-EC are comprised mainly of 
hematopoietic cells91, 172. Similarly, CAC are a hematopoietic population composed 
primarily of monocytes/macrophages which display endothelial-like characteristics, 
inducible with endothelial growth factors179-181. Methodologically, CACs are closest to 
ECFC. The difference between the CAC and ECFC preparations is that ECFC gets 
established after 14 days in culture whereas CAC are established and used less than 10 
days in culture. Thus, the CAC population most likely contains ECFC, but the culture 
technique used to isolate CAC does not allow ECFC to establish before the 14-day point. 
Interestingly, other groups have demonstrated that established monocytes from blood-
derived MNC begin to die off in the first 2-3 weeks of culture174, 177. Therefore, it appears 
that monocytes dominate the early CAC culture and the ECFC begin to establish and 
become selected for as monocytes decline in number. By later passages, expression of 
hematopoietic cell surface markers is diminished, and the cultures are largely endothelial 
in nature177, 182. 
In summary, it appears that culture techniques selecting for the non-adherent cell 
fraction of MNC from blood sources yield pro-angiogenic hematopoietic cells in culture. 
However, if the adherent cell fraction is used, this population is largely comprised of 
monocytes/macrophages with a minority population of endothelial cells. At this point, if 
the cultures are taken out past 14 days in endothelial cell-specific culture media, then 
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ECFC are selected for. Although there has been controversy surrounding the culture and 
identification of true EPC; the fact remains that putative endothelial progenitor cell 
content in peripheral blood MNC is used as clinical diagnostic to indicate cardiovascular 
disease risk171 and potential recovery183 in patients with cardiovascular complications. 
Despite being fairly well established that many “EPC” cultures are largely 
contaminated with hematopoietic cells, there continues to be confusing nomenclature 
whereby proangiogenic hematopoietic cells are referred to as EPC184. For example, the 
use of the term early EPC – early outgrowth EPC – versus late EPC – ECFC – adds 
confusion as the early EPC are hematopoietic cells with pro-angiogenic capacity with the 
capability to become endothelial-like177, 185. Another large contributor of the 
controversies surrounding the defining criteria of EPC is the promiscuity of both 
hematopoietic and endothelial cell surface markers. For example, the isolation and 
differentiation of monocytes into endothelial cells186 is controversial as the CD14 antigen, 
largely used for purification of monocytes, is expressed on various other cell types, 
including endothelial cells187. Experiments aiming to differentiate MNC into endothelial 
cells depends on having pure starting cell populations which is confounded by deposition 
of cell surface markers by platelet microparticles 188. 
A trademark indication of endothelial cell function is the ability to incorporate into the 
vasculature. Thus, heterogeneous cell populations can be deemed endothelial in nature 
when one of the cell types incorporate into vasculature181. The isolation of CD34+ MNC 
has been demonstrated to produce a heterogeneous population of endothelial and 
hematopoietic cells depending on the isolation and propagation techniques110, 189. 
Macrophages are also pivotal in the generation of new blood vessels by the recruitment of 
proangiogenic cell types as well as moderating the physical interaction between 
endothelial cells during sprouting angiogenesis 106. Because of the potential 
interchangeability of cell surface markers and cell-cell interactions between cells of the 
monocyte lineage and endothelial cells, defining a true EPC population remains a 
challenge. 
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1.4.3 Mesenchymal stromal cells 
In the 1970s, Alexander Friedenstein and colleagues were the first to identify clonogenic, 
plastic adherent cells from murine bone marrow termed colony forming units of 
fibroblasts (CFU-F). These cells differentiated into multiple mesodermal cell types 
including osteocytes, chondrocytes and adipocytes, but did not contribute to 
hematopoietic tissue190, 191. Soon after, similar cells from adult human bone marrow were 
characterized (reviewed in192) and were shown to engraft multiple human tissues 
(mesenchymal and non-mesenchymal) after systemic infusion. Multiple tissues within the 
human body, including both fetal and adult sources, have been shown to contain 
mesodermal precursors capable of differentiating into cartilage, bone, adipose, and 
muscle tissue193-195. In subsequent studies these cells were given many names including 
marrow stromal stem cells or more accurately mesenchymal stromal cells (MSC) based 
on their diverse differentiative potential. In 1991, Arnold Caplan coined the term 
mesenchymal stem cells to describe these cells, highlighting their developmental origin 
and considerable therapeutic potential196. These different nomenclatures have been highly 
debated in the field because not all bones are derived from embryonic mesenchymal 
tissue, and the self-renewal capacity of MSC remains highly disputed197, 198.  
In addition to the supportive role of fibroblasts in human tissues, MSC are thought to play 
an instructive role in a paracrine fashion to aid in the repair and regeneration of organs, 
and in the modulation of the immune system at sites of tissue injury199-202. MSC have 
been shown to exert their effects via both soluble factors and direct cell-cell contact, 
demonstrating their ability to ameliorate autoimmune disease conditions through anti-
inflammatory mediators and to support regenerative processes203-205. However, MSC 
from various adult sources, including human bone marrow, have been shown to possess 
considerable variability in the degree of immunosuppression and in the secretion of 
regenerative factors depending on the health status of the individual from which the cells 
are obtained206. Because of this tissue-specific heterogeneity, preclinical research has 
focused on the regenerative prowess and immunomodulatory capacity of MSC isolated 
from tissues of early ontogeny that are untouched by chronic disease pathologies207. 
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Despite establishment of unifying standards208, MSC-like populations of variable purity 
demonstrate significant heterogeneity in cell surface marker expression when isolated 
from different tissue sources. Unfortunately, little progress has been made in identifying 
uniquely-expressed cell surface markers in situ as a way to prospectively purify MSC 
from human sources. Unlike hematopoietic precursors, the MSC field has yet to develop 
an accepted means of isolating MSC from tissues using cell-surface markers or enzymatic 
progenitor functions. Recently, the isolation of a perivascular associated MSC subset 
(also known as pericytes) has been demonstrated using melanoma cell adhesion molecule 
or CD146 expressed in situ and to varying degrees during ex vivo culture68. In culture 
these perivascular MSC, which are depleted of CD34-expressing endothelial cells, meet 
the minimal criteria to define MSC by cell surface marker expression and trilineage 
differentiative capacity. Notably, CD146+ MSC can be isolated from both adult and 
placental tissues at varying frequencies. Likewise, the nerve growth factor receptor 
(CD271) may represent another cell-surface marker expressed on MSC with active 
immunomodulatory properties209. Whether or not these markers can be used 
interchangeably to purify MSC from umbilical cord of placental tissues remains a topic 
of debate. Perhaps the most consistent method to purify both adult and perinatal-derived 
MSC is through the conservation of known progenitor cell functions. One such function 
is aldehyde dehydrogenase activity (ALDH), a cytosolic enzyme highly expressed in 
precursors from multiple lineages that protects essential, or long-lived cells against 
oxidative environmental insults. High ALDH activity (ALDHhi) has been demonstrated 
as a conserved function in primitive cells from hematopoietic, mesenchymal, endothelial, 
and neural progenitor lineages210. Indeed, human adult BM ALDHhi cells form CFU-F at 
a frequency of 1 colony in approximately 1500 cells. By using ALDH function, either 
before or after MSC expansion, we can prospective enrich for progenitor cells higher in 
the MSC hierarchy, thereby reducing variability between samples and unwanted 
heterogeneity as cells are expanded ex vivo. 
The isolation of MSC from adult, fetal or perinatal sources is accomplished through very 
similar procedures. To obtain a single cell suspension from fetal tissues such as the fetal 
liver, the tissues are homogenized and strained through a filter211. Umbilical cord blood-
derived MSC has been isolated from the umbilical vein using similar protocols as BM 
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MSC212 but require the addition of collagenase prior to release adherent cells in situ213. 
Once the cells are in single cell suspension, mononuclear cells are separated through 
density gradient centrifugation and plated for selection via plastic adherence. While fetal 
tissues contain a higher frequency of MSC relative to adult sources211, the major 
disadvantage to fetal stem cells becoming a viable source of MSC is that there remains 
ethical controversy regarding the accrual of cells from pre-natal sources. These ethical 
barriers delay the use of fetal stem cells for widespread therapeutic purposes. However, 
umbilical cord and placental-derived MSC are ethically obtained at birth from normally 
discarded material and can be propagated efficiently for therapeutic application. 
The first clinical trial aimed at supporting hematopoiesis used autologous MSC 
during myeloablative therapies for breast cancer and demonstrated the ability to safely 
transplant MSC free from side effects or adverse reactions214. As MSC became 
recognized for their immunomodulatory properties, MSC became ideal candidates for 
treating the hematopoietic transplantation-induced complication graft-versus-host disease 
(GVHD). Clinical studies have demonstrated that infusion of allogeneic or autologous 
MSC increased survival rates in steroid-resistant GVHD patients without MSC-related 
toxicity or ectopic tissue formation215-217.  Other trials have also been conducted using 
MSC to treat Crohn’s disease-related fistulas, resulting in improved fistula recovery post-
surgery and increased quality of life for the patients218, 219. Type I diabetes is another 
autoimmune disease where MSC therapy currently holds promise. MSC have been shown 
to increase beta cell mass in the injured pancreas of STZ-treated mice allowing for partial 
restoration of blood glucose levels220, 221. Alongside endogenous regeneration, MSC may 
help to inhibit the autoimmune response towards beta cells, making it a very attractive 
option as a cellular therapy for type I diabetes222.  With a focus on MSC, companies such 
as Osiris Therapeutics are currently performing larger-scale clinical trials to combat 
autoimmune and inflammatory diseases including cell-based implants for diabetes. 
1.4.4 Selecting for cells with high aldehyde dehydrogenase activity 
In search to purify progenitor cell populations from the bone marrow, we have previously 
used a clinically applicable fluorescent probe (AldefluorTM) to isolate cells based on a 
conserved, functional enzyme known as ALDH223. ALDH is a cytosolic enzyme highly 
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expressed in progenitor cells from multiple lineages that protects essential, or long-lived 
cells against oxidative environmental insults. In general, as progenitor cell differentiation 
occurs towards a more restricted and expendable phenotype, ALDH-activity reduces. Our 
group has previously demonstrated that ALDHhi human hematopoietic cells display 
enhanced hematopoietic re-constitution when transplanted into irradiated, 
immunodeficient non-obese, severe-combined immunodeficient (NOD.SCID) mice224, 225. 
There have also been clinical trials to demonstrate the efficacy of transplanting ALDHhi 
BM-MNC in patients with intermittent claudication226. Although the ALDHhi fraction of 
human BM-MNC represents less than 0.8% of the total cell population, this ALDHhi 
fraction of BM-MNC is enriched for hematopoietic, endothelial, and mesenchymal 
progenitors. When isolating BM-derived ALDHhi cells, the MSC population is greatly 
enriched and form CFU-F at a frequency of 1 colony in 1500 cells relative to 1 in 
150,000 cells, the common yield of CFU-F in standard isolation procedures210. 
1.4.5 Cell free therapies using extracellular vesicles 
Cellular signaling mechanisms include the secretion of protein signals to elicit a variety 
of effects from chemotaxis to controlling cellular survival and differentiation. Many of 
these processes are mediated through the cellular release of various cytokines, 
chemokines and other effectors. A vital form of cellular communication and a quickly 
emerging field is the study of extracellular vesicles (EVs). Broadly, extracellular vesicles 
are defined as membraneous bodies released by cells which enable the exchange and 
communication of intracellular components227. EVs can be further broken down into 
more defined cellular products: Apoptotic bodies, microparticles and exosomes228. These 
different classes of EVs are largely defined by their size; for example, Apoptotic bodies 
range from 50-5000 nm, Microparticles range from 100-1000nm, and exosomes range 
from 30-100 nm229, 230. EVs have been observed within many bodily tissues such as 
saliva, blood, synovial fluid, urine etc. and thus have been an attractive target as 
biomarkers for diseases ranging from cancer to cardiovascular disease231, 232. Studies 
throughout the literature point to the idea that secreted products from cells may have 
therapeutic benefit233. For example, recent work from the Hess lab has demonstrated that 
conditioned media generated from MSC rapidly reduced hyperglycemia in diabetic mice 
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induced by streptozotocin234. Although many factors have been identified to potentiate 
these regenerative effects, the localization of these proteins within conditioned media is 
under intense investigation. Conditioned media generated from endothelial cells has been 
demonstrated to contain EVs which harbor miRNA which has been demonstrated to 
modulate immune responses during atherosclerosis235. Overall, EVs and other secreted 
products may prove beneficial as cell-free therapeutic agents and potentially even drug 
delivery vectors236. 
 Decellularized scaffolds  
The application of biomaterials in regenerative medicine is a promising treatment 
modality in many injury or disease conditions requiring tissue repair and/or replacement. 
A biomaterial represents a bio-compatible material that can integrate into tissues and may 
provide biological activity after transplantation237. Decellularized scaffolds are a subset 
of biomaterials which provide a substrate for tissues to grow or can be used as a vector 
for cell delivery strategies. Decellularized bioscaffolds represent the intact, insoluble 
ECM components of tissues which are devoid of immunogenic cellular material238. The 
major constituents of ECM include evolutionarily conserved proteins: Collagens, 
proteoglycans, glycoproteins, and other secreted, matrix-associated proteins239. These 
components of ECM lack immunogenicity and have proven safe after transplantation in 
clinical trials240, 241. Because decellularized bioscaffolds resemble native tissue, the host 
response is minimized by the mechanical behavior, biochemical composition, and tissue 
ultrastructure of the bioscaffold242. Decellularized bioscaffolds also encourage cell-ECM 
interactions which mediate intracellular signaling cascades to promote cell implantation 
and survival243, 244. Decellularized scaffolds also contain embedded growth factors to aid 
in cellular processes during the natural remodeling process245. Lastly, decellularized 
scaffolds have demonstrated the ability to re-model and degrade within tissues after 
exerting their regenerative effect, removing the concern that foreign scaffold materials 
will remain within the patient 246. Collectively, the combination of conserved ECM 
signals and 3-D architecture of decellularized bioscaffolds provide an attractive means to 
promote the survival and engraftment of transplanted cells247. 
26 
 
Decellularized bioscaffolds have been utilized in many pre-clinical trials to aid in 
revascularization therapies for patients with CVD. Many studies have focused on 
utilizing various scaffold-based platforms to promote revascularization and repair of 
cardiac tissue after myocardial infarction 248, 249. Several scaffold-based transplantation 
strategies have focused on the use of synthetic bioengineered materials for vascular 
repair. The use of synthetic materials for vascular-related therapies have been 
documented to increase vessel calcification, atherosclerosis, or result in the formation of 
excess scar tissue250, 251. Alternatively, the use of naturally-derived scaffold materials 
have been an attractive modality to encourage soft tissue repair and revascularization of 
ischemic tissues252, 253. In a mouse model of hind limb ischemia, ECM-based matrices 
were demonstrated to recruit circulating progenitor cells to the ischemic muscle and elicit 
a pro-angiogenic effect254. Similarly, decellularized adipose tissue (DAT) is an abundant 
ECM source which has been implicated to augment soft tissue reconstruction255. Without 
modifying the chemical structure of the ECM, additional processing steps have been 
developed to generate alternative DAT scaffold formats tailored for specific 
applications256. Lastly, DAT scaffolds have been demonstrated to establish a pro-
regenerative and pro-angiogenic microenvironment after transplantation in animal models 
of adipose tissue regeneration or cutaneous wound repair257, 258. 
 
 
 Thesis overview and hypotheses 
Patients with atherosclerosis-induced CLI will exhibit decreased pro-vascular cell 
functions and thus will be less responsive to pro-angiogenic therapies or autologous cell 
transplantation168, 169. ECFC have been demonstrated to be a robust and proliferative 
endothelial cell type capable of revascularization after transplantation. Similarly, MSC 
can be readily obtained from allogeneic sources, expanded efficiently in cultures, and are 
able to support angiogenesis while demonstrating very low immunogenicity259. Because 
of the complementarity between endothelial and mesenchymal cell types, ECFC and 
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MSC represent an attractive means to promote vascularization in patients with CLI260, 261. 
During the course of my thesis, I focused on the development of a cell-based 
revascularization therapy using ECFC and MSC in a xenotransplanation model of hind 
limb ischemia. Furthermore, we also included a decellularized adipose tissue (DAT) 
scaffold construct to augment cellular engraftment and investigate if the pro-vascular 
potential of these cells was affected (Figure 1.2).  
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Figure 1.2 Proposed in vivo model of revascularization through ECFC and MSC 
transplantation.
 
Figure 1.2. Proposed in vivo model of revascularization through ECFC and MSC 
transplantation. After femoral artery ligation surgery on NOD.SCID mice, (A) ECFC 
and/or MSC were injected into the hindlimb of the mouse at 3 different sites surrounding 
the surgical incision. Alternatively, (B) ECFC and/or MSC were seeded into 
decellularized adipose tissue scaffolds prior to transplantation. Scaffolds were directly 
implanted at the surgical site before the incision was closed.   
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As MSC exhibit prolonged culture, we have previously demonstrated that MSC can lose 
their regenerative capacity, suggesting that these cells become more heterogeneous 
during prolonged culture221. We have also previously demonstrated the use of ALDH 
activity to purify progenitor cells from umbilical cord blood with potent pro-angiogenic 
activities262. Thus, we hypothesized that using ALDH activity as a selection factor within 
the ECFC and MSC cell populations would purify a pro-vascular cellular subset. Herein, 
I also focused on the purification of progenitor cell types from the ECFC and MSC 
lineages using AldefluorTM (Figure 1.3). To validate the improved ability for ECFC to 
form vasculature and the MSC to recruit vasculature after purification, each cell type was 
loaded in a basement membrane extract and subcutaneously transplanted in a NOD.SCID 
mouse (Figure 1.4). The overarching hypothesis of my thesis is that both ECFC and MSC 
will contain rare progenitor cell populations identifiable in culture which will exhibit 
enhanced pro-vascular activities in vivo. The specific objectives of my studies are 
described below. 
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Figure 1.3 Schematic of AldefluorTM staining and subsequent FACS purification of 
ALDHhi cells.
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Figure 1.3. Schematic of AldefluorTM staining and subsequent FACS purification of 
ALDHhi cells.  
(A) AldefluorTM passively diffuses into the cell where it is converted to a fluorescent 
anion through the enzymatic activity of ALDH. In this state, the anion can only leave the 
cell through active transport of ABC transporters on the plasma membrane. Adding ABC 
transport inhibitors will allow the accumulation of fluorescent signal in progenitor cells 
with high ALDH activity (ALDHhi). Removal of the ABC transporter inhibitors allows 
complete efflux of the ALDH dye, underscoring the clinical applicability of the 
AldefluorTM dye. (B) ALDH activity is subsequently measured via flow cytometry, an 
ALDH inhibitor, DEAB, is added to establish an ALDHlo threshold. By utilizing the 
AldefluorTM stain, cells can be efficiently sorted by fluorescence activated cell sorting 
and the dye can be effluxed thereafter making this methodology clinically applicable. 
Because ALDH is an intracellular enzyme, no other staining methodologies exist that 
maintain cell viability. 
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Figure 1.4 Schematic of the in vivo transplantation strategies for ECFC and MSC to 
determine pro-vascular potential.
 
Figure 1.4. Schematic of the in vivo transplantation strategies for ECFC and MSC to 
determine pro-vascular potential. (A) ECFC and (B) MSC were established and 
cultured on tissue culture plastic before purification using fluorescence activated cell 
sorting (FACS). ECFC were subsequently suspended in a Matrigel (a basement 
membrane extract; composed of basement membrane and ECM proteins) and injected 
into the flank of NOD.SCID mice. MSC were suspended in a basement membrane extract 
(proprietary) and loaded into ‘angioreactors’ before subcutaneous implantation. ECFC 
and MSC were incubated <10 days when the Matrigel plugs and angioreactors were 
removed from the mice for subsequent analysis.  
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1.6.1 Chapter 2: Objective/Hypothesis 
1. To compare ALDHlo versus ALDHhi MSC subsets for cell surface marker 
expression, differentiative capacity, mRNA expression profiles, and cytokine 
secretion. 
2. To assess whether endothelial cell growth and tubule formation is augmented by 
conditioned media or direct co-culture with ALDHlo versus ALDHhi MSC 
subsets. 
3. To determine the vasculogenic capacity of ALDHlo versus ALDHhi MSC subsets 
after subcutaneous implantation of DIVAA implants into immunodeficient mice. 
In chapter 2, I hypothesized that BM-derived MSC that retained high ALDH activity 
during ex vivo expansion will demonstrate enhanced pro-angiogenic factor secretion, 
will promote endothelial cell proliferation and tube forming function in vitro, and will 
promote vascularization of subcutaneously transplanted membrane extracts in 
immunodeficient mice. 
1.6.2 Chapter 3: Objectives 
1. Ascertain the frequency of common progenitor cell markers on ECFC using flow 
cytometry and identify other potential surface markers to identify endothelial 
progenitor cells. 
2. Assess colony forming capacity, tube formation, and growth kinetics of 
progenitor marker-positive ECFC.   
3. Determine the capacity for progenitor marker-positive ECFC to incorporate into 
form blood vessel networks in Matrigel after subcutaneous transplantation into 
NOD.SCID mice. 
In chapter 3, I hypothesized that umbilical cord blood-derived ECFC will contain a 
primitive cell subset with enhanced progenitor cell functions in vitro and enhanced vessel 
forming function in vivo. 
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1.6.3 Chapter 4: Objectives/Hypothesis 
1. Determine the autofluorescent properties of decellularized adipose and cartilage 
scaffold materials.  
2. Determine the enzymatic digestion methodology to maximize cell yield and cell 
viability of ECFC and MSC seeded in decellularized adipose and cartilage 
scaffolds. 
** This chapter is focused around the development of a methodology to enable the flow 
cytometric analysis of cell populations that have been seeded on decellularized scaffold 
materials in the following chapter.  
In chapter 4, I hypothesized that treatment of decellularized scaffolds with collagenase-
containing proteases would effectively digest the scaffold materials leaving both the 
ECFC or MSC in suspension suitable for flow cytometry. 
1.6.4 Chapter 5: Objectives/Hypothesis 
1. Determine phenotypic or functional changes in the ECFC and MSC when 
cultured in the DAT foam scaffolds. 
2. Assess the pro-angiogenic properties of the DAT foam scaffold, the human MSC, 
and ECFC after transplantation into femoral artery ligated NOD/SCID mice.  
3. Determine if the DAT scaffold augments human cell engraftment and overall 
vascularization of the scaffold 35 days post transplantation. 
In chapter 5, I hypothesized that human ECFC and MSC will create functional 
vasculature, increase limb perfusion, and have enhanced engraftment capacity when 
transplanted in decellularized adipose tissue scaffolds in immunodeficient mice with 
femoral artery ligation. 
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2 High aldehyde dehydrogenase activity identifies a 
subset of human mesenchymal stromal cells with 
vascular regenerative potential. 
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 Introduction 
Peripheral artery disease (PAD) is characterized by ischemia in the lower extremities due 
to narrowing of blood vessels associated with atherosclerotic plaque accumulation. PAD 
currently affects 8-12 million in North America and >200 million worldwide1. The 
clinical consequences of PAD range from intermittent claudication, to critical limb 
ischemia (CLI), the most severe form of PAD distinguished by pain at rest with non–
healing ulcers in distal extremities. Many patients with CLI are not candidates for vessel 
bypass or percutaneous interventions2, 3, and ≈30% will require limb amputation. Those 
afflicted with CLI have 6-fold increased risk of serious cardiovascular events4, and >60% 
of CLI patients will die from complications within 5 years of diagnosis5. Thus, there is a 
compelling need for improved therapies to combat CLI. 
Cell transplantation to restore perfusion in ischemic limbs is under intense investigation 
for the treatment of CLI. In 2002, the therapeutic angiogenesis by cell transplantation 
(TACT) trial first demonstrated improvements in ankle brachial pressure index and tissue 
oxygen saturation after transplantation of bone marrow mononuclear cells (BM MNC)6. 
In a follow-up study, there was significant improvement in pain scale and ulcer healing 
after 2 years post-transplantation7. Unfortunately, overall clinical benefit was considered 
modest and lower limb amputation rates were not improved. However, BM MNC contain 
cells from multiple (hematopoietic, endothelial, and mesenchymal-stromal) cell lineages 
that directly or indirectly aid in neovessel formation8. 
In efforts to purify pro-vascular progenitor cell populations from human BM and 
umbilical cord blood (UCB) with enhanced regenerative functions, we used a clinically-
applicable fluorescent substrate (AldefluorTM) of aldehyde dehydrogenase (ALDH), a 
conserved detoxification enzyme highly expressed in multiple mesodermal progenitor 
cell lineages9. Essentially, ALDH protects long-lived cells against oxidative 
environmental insults, and paradoxically represents the rate-limiting enzyme in the 
intracellular production of the lipid morphogen, retinoic acid. As progenitor cell 
differentiation occurs towards a more restricted or expendable phenotype, ALDH-activity 
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is generally reduced. Although cells with high aldehyde dehydrogenase activity 
(ALDHhi) represent a rare fraction of human BM (<0.8% of MNC) or UCB (<0.5% of 
MNC), ALDHhi cells are highly enriched for expandable progenitor cells with 
hematopoietic, endothelial, and mesenchymal colony-forming functions10. Human cells 
with high ALDH activity demonstrate a plethora of regenerative functions when 
transplanted into preclinical immunodeficient mouse models, including strong 
hematopoietic reconstituting capacity11, 12, widespread tissue distribution after 
intravenous delivery 12, elicit islet repair in models of diabetes13, 14, and demonstrate 
potent angiogenic stimulatory capacity in ischemic hindlimbs after femoral artery 
ligation10, 15. Recently, a phase I, randomized controlled trial compared unselected 
autologous BM MNC to purified BM ALDHhi cells in the treatment of CLI16. Although 
significant improvements in ankle-brachial index were observed in both groups, neither 
ischemic group showed improvement in ischemic ulcer grade or limb salvage16. 
Mesenchymal stromal cells (MSC) are defined as non-hematopoietic, progenitor cells 
that grow adherent to plastic and differentiate into bone, cartilage and adipose in vitro17. 
MSC are also considered potent bio-factories that orchestrate regenerative and 
immunomodulatory effects in a paracrine fashion at sites of tissue injury18-21. BM-derived 
MSC promote survival and proliferation of endothelial cells (EC) under hypoxic 
conditions22.  After transplantation, MSC home to sites of vascular injury, incorporate 
into vessels as perivascular cells23, 24, and secrete factors that support angiogenesis such 
as vascular endothelial growth factor (VEGF) and platelet derived growth factor 
(PDGF)25. Administration of ECs with MSC has been shown to increase vascularization 
and enhance vessel stability in multiple murine xenograft transplantation models24, 26. 
MSC have been demonstrated to be safe and well tolerated in many clinical studies27, 28. 
Early trials involving intramuscular transplantation into patients with CLI showed 
increased ankle brachial pressure index, accelerated ulcer healing, and improving overall 
quality of life and Rutherford scores29-31. In a direct comparison of autologous BM MNC 
to BM MSC administered to patients with CLI, Lu et al found that MSC-injected patients 
showed better perfusion and ulceration recovery scores at 6 months post-
transplantation32. However, limb salvage compared to MNC administration was not 
improved by MSC treatment. Overall, MSC represent an attractive cell type to promote 
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vascular regeneration because MSC can be readily obtained from autologous and 
allogeneic sources, expanded efficiently in culture, and support angiogenesis while 
demonstrating very low immunogenicity21. However, significant challenges remain that 
prevent the advancement of cellular therapies for CLI, and scientists have been 
challenged to better understand the functions of active cell subtypes that mediate 
beneficial effects within heterogenous cell populations. Here we demonstrate that 
purification using high ALDH-activity (by AldefluorTM staining) after expansion selects a 
novel MSC subset with a unique secretory profile that augments EC survival, 
proliferation, tube formation in vitro and promotes the generation of a pro-angiogenic 
niche in vivo. 
 Methods 
2.2.1 Selection of ALDHlo versus ALDHhi MSC subsets 
Human BM aspirates were obtained from healthy allogeneic sibling donors with 
informed consent from the London Health Sciences Centre (London, ON). MNC were 
isolated via hypaque-ficoll centrifugation and seeded on tissue culture plastic at 270,000 
cells/cm2. Adherent stromal colonies (CFU-fibroblast) were established within 14 days 
and expanded in Amniomax media + supplement (Life Technologies, Carlsbad, CA).  
At passage 4 (P4), MSC were purified into ALDHlo versus ALDHhi subsets by 
fluorescence activated cell sorting using the AldefluorTM assay (StemCell Technologies, 
Vancouver, BC) as previously described11, 33. The ALDHhi subset represented cells with 
≈5-fold higher fluorescence intensity compared to ALDHlo gate established using DEAB-
inhibition. Purified ALDHlo and ALDHhi MSC subsets also represented no greater than 
the top or bottom 30% of ALDH fluorescent events, respectively. All BM samples were 
sorted (FACS Aria III, Beckton Dickenson (BD), Mississauga, ON) in the London 
Regional Flow Cytometry Facility. 
2.2.2 Cell surface phenotype analysis 
ALDHlo and ALDHhi MSC were co-stained with antibodies for stromal cell markers: 
CD73, CD90, and CD105; hematopoietic lineage markers: CD45 and CD14 (monocytes), 
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and the pericellular marker: CD146. Surface marker expression was obtained using an 
LSR II flow cytometer (Beckton Dickenson), and analysis performed using FloJo 
software (Treestar, Ashland, OR).  
2.2.3 In vitro differentiation assays 
To assess multipotent differentiation, ALDHlo or ALDHhi MSC (N=3) were grown in 
adipogenesis or osteogenesis differentiation media (Life Technologies) as per 
manufacturer’s instructions. After 14 or 21 days cells were fixed in formalin and stained 
for adipocytes or osteocytes using using Oil Red O or Alizarin red respectively. For 
chondrogenic differentiation, micromasses of purified ALDHlo or ALDHhi MSC (N=3) 
were cultured for 14 days in chondrogenesis differentiation media (Life Technologies) as 
previously described33. Micromasses were frozen in OCT, sectioned, and stained with 
Alcian Blue counterstained with Nuclear Fast Red.  
2.2.4 Generation of conditioned media (CDM) 
FACS-purified ALDHlo and ALDHhi MSC subsets were plated at equal density (13,000 
cells/cm2) and allowed to recover for 8 hours in AmniomaxTM media + supplement. After 
cell adherence, media was replaced with serum and growth-factor deprived endothelial 
basal media (EBM-2, Lonza, Walkersville, MD) and conditioned for 48 hours before use 
in subsequent experiments. 
2.2.5 HMVEC expansion assays 
HMVEC (9,400 cells/cm2) were cultured in EBM-2, or in CDM generated by purified 
ALDHlo or ALDHhi MSC subsets generated as described above. As a positive control, 
HMVEC were also grown in complete Endothelial Growth Medium (EGM-2 = EBM-2 + 
5% FBS + IGF, bFGF, EGF, VEGF). Viable HMVEC were enumerated after 72 hours 
using blinded trypan blue exclusion hemocytometer counts. To assess cell survival and 
apoptosis kinetics, HMVEC were harvested at 24, 48, and 72 hours analyzed by flow 
cytometry for Annexin V/7AAD. To quantify cell proliferation, 500 nM EdU was 
supplemented into HMVEC cultures 24 hours prior to each timepoint. HMVEC were 
fixed and permeabilized using 10% formalin and 0.1% Triton X and stained for nuclear 
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EdU-incorporation using the Click-It assay as per manufacturer’s instructions (Life 
Technologies). Edu-incorporation into proliferating cells was quantified by flow 
cytometry. 
Direct contact co-cultures between HMVEC and MSC subsets were also performed. 
HMVEC (9,400 cells/mm2) were seeded at a 1:1 ratio with ALDHlo or ALDHhi MSC and 
co-cultured in EBM-2 for up to 72 hours. HMVEC alone or ALDHlo or ALDHhi MSC 
alone were cultured in EBM-2 as controls. Cell survival and proliferation for each cell 
type was quantified by flow cytometry as described above with addition of CD31 and 
CD90 antibodies to discern endothelial versus stromal cell types respectively, at each 
timepoint (24h, 48h, 72h). in mixed cultures.  
2.2.6 HMVEC tubule forming assays 
To assay for tubule forming function in vitro, 120,000 HMVEC were cultured on growth 
factor-reduced GeltrexTM matrices (Life Technologies) in EBM-2 or in CDM generated 
from ALDHlo versus ALDHhi MSC subsets. After 24 hours, 4 photomicrographs were 
taken per well, and tube formation was quantified by manual counting of complete tubes 
using ImageJ software.  
2.2.7 Directed in vivo angiogenesis assay (DIVAA) 
 To compare the pro-angiogenic capacity of ALDHlo versus ALDHhi MSC subsets in 
vivo, the directed in vivo angiogenesis assay (DIVAA) was performed as per 
manufacturer’s instructions. DIVAA inserts with 200,000 ALDHlo and ALDHhi MSC 
suspended in 20µl basement membrane extract were subcutaneously implanted into the 
flank of NOD/SCID mice. After 10 days in vivo, EC recruitment into each angioreactor 
was quantified by lectin-uptake, using a SpectraMax plate reader (Molecular Devices, 
Sunnyvale, CA). 
2.2.8 Microarray analysis 
mRNA was extracted from 5x105 ALDHlo and ALDHhi MSC (N=3) using mRNAeasy 
mini kits (Qiagen, Dusseldorf, Germany). Sample matched and early-passage (P4) MSC 
were used to minimize heterogeneity. Nanodrop readings were taken to determine mRNA 
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quality and concentration, and mRNA expression was assessed using Affymetrix 1.0ST 
human gene array chips (Affymetrix, Santa Clara, CA) at the London Regional Genomics 
Facility. Data was analyzed using Partek Genomics Suite software (Partek Inc., St. Louis, 
MO). 
2.2.9 Proteomic analysis of CDM 
CDM from purified MSC samples (N=3) was generated in biological duplicate and 
concentrated (≈50-fold) using 3kDa centrifugal filter units (Millipore). Frozen and 
lyophilized protein extracts were re-suspended in 8M urea, 50mM ammonium 
bicarbonate, 10mM dithiothreitol and 2% SDS. Protein concentration was measured 
using the Pierce protein assay (ThermoFisher), and 150 µg total protein was fractionation 
with SDS-PAGE using 8-20% gels in technical duplicate. Samples were digested using 
an in-gel protocol with trypsin/LysC (Promega) as previously described34. Prepared 
fractions were injected and separated using a nanoAcuity system (Waters, Milford, MA) 
on a 25cm long x 75μm inner diameter C18 column maintained at 35oC. All samples 
were trapped for 5 min at 99% H2O, 1% acetonitrile, and separated using a 5.0% to 
32.5% acetonitrile gradient over 74 min, followed by 60% acetonitrile over 6 min, at a 
flow rate of 300nL/min. Fractions were quantified using the BCA assay (ThermoFisher 
Scientific) and 1 μg of material was injected per fraction. Mass spectrometry was 
performed on an Orbitrap Elite (ThermoFisher Scientific). Full MS parameters are 
outlined in Table 2.1. Data analysis was performed with MaxQuant version 1.5.0.30 
using the Andromeda search engine35. MS/MS spectra were searched against the Human 
Uniprot database with trypsin specificity (20264 entries)36. Bioinformatic analysis was 
performed using Perseus version 1.5.0.8. Datasets were filtered for proteins containing a 
minimum of 1 unique peptide. 
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Table 2.1 Parameters for mass spectrometry proteomic analyses. 
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2.2.10 Cytokine arrays 
The human angiogenesis array C1 (RayBiotech, Norcross, GA) was used to compare 
angiogenesis-associated protein composition within CDM from ALDHlo and ALDHhi 
MSC (N=4). The cytokine arrays were prepared as per manufacturer’s instructions and 
imaged using the Bio-Rad Gel Documentation System (Bio-Rad, Hercules, CA). The 
relative intensity units for each array feature were quantified by densitometry using the 
microarray plugin for ImageJ.  
2.2.11 Statistical analyses 
Analysis of significance for mRNA expression was performed using Partek using 
algorithms for data normalization, ANOVA, and false discovery rates (FDR<0.05). A 
multiple sample T-test was performed in Perseus comparing the ALDHlo versus ALDHhi 
MSC CDM. Analysis of significance was performed by one-way ANOVA with Tukey’s 
multiple comparison tests for the cell survival and proliferation assays, tubule-formation 
assays, and for the DIVAA experiments.  
 Results 
2.3.1 ALDHlo and ALDHhi MSC demonstrated multipotent 
differentiation potential in vitro. 
At passage 4 (P4), bulk MSC were purified based on ALDH-activity using the 
AldefluorTM assay, selecting the top and bottom 30% of fluorescent events while 
maintaining ≈5-fold difference in fluorescence intensity between ALDHlo and ALDHhi 
subsets based on DEAB-inhibited controls (Figure 2.1A). The ALDHlo and ALDHhi 
subsets were first assessed for stromal, pericyte, endothelial, and hematopoietic cell 
surface marker expression. Both subsets showed >95% expression of the stromal markers 
CD73, CD90, CD105, and the pericyte marker CD146. In contrast, <1% of cells 
expressed endothelial (CD31) or hematopoietic cell (CD45 and CD14) markers (Figure 
2.1B, C). Thus, both subsets represented pure stromal cell populations without significant 
hematopoietic or EC contamination. Next, we performed multipotent differentiation on 
ALDHlo and ALDHhi subsets. As predicted by cell surface marker expression, both the 
ALDHlo and ALDHhi subsets equally retained multipotent differentiative capacity into 
64 
 
fat, bone, and cartilage lineages in vitro (Figure 2.1D, E). Collectively, both the ALDHlo 
and ALDHhi subsets equally fulfill the minimal criteria for MSC established by the 
International Society of Cellular Therapy17.   
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Figure 2.1 ALDHlo and ALDHhi MSC subsets expressed stromal and pericyte 
markers and demonstrated multipotent differentiation in vitro.
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Figure 2.1 ALDHlo and ALDHhi MSC subsets expressed stromal and pericyte 
markers and demonstrated multipotent differentiation in vitro. (A) Representative 
flow cytometry plots showing the selection of human BM-derived MSC with low versus 
high ALDH activity. ALDHhi MSC were defined as ≈5-fold higher fluorescence than the 
DEAB control gate, and each subset represented <30% of total events at the bottom and 
top of fluorescent intensity. (B) ALDHlo and (C) ALDHhi MSC subsets expressed cell 
surface markers indicating high stromal cell purity (>95% CD73+, CD90+, CD105+, 
CD45-, CD14-). The perivascular cell marker CD146 was also detected on >95% of 
ALDHlo and ALDHhi MSC. (D) ALDHlo and (E) ALDHhi MSC demonstrated multipotent 
differentiation to chondrocytes, adipocytes, and osteocytes. Data is representative of 
experiments comparing purified MSC from 4-6 human BM samples. 
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2.3.2 CDM generated by ALDHlo or ALDHhi MSC augmented 
HMVEC expansion in vitro. 
To compare the angiogenesis stimulatory potential of the ALDH-purified MSC subsets, 
HMVEC were grown in CDM generated by ALDHlo versus ALDHhi MSC and cell 
proliferation and survival were quantified flow cytometric analyses measuring EdU-
incorporation and 7AAD / Annexin V detection of apoptotic cells. Representative dot 
plots for each analysis are shown in Figure 2.2. Compared to HMVEC cultured under 
serum-starved, growth factor-free basal conditions (EBM-2), exposure to ALDHlo or 
ALDHhi CDM for 72h significantly increased overall HMVEC expansion (Figure 2.3A). 
After 48h exposure to ALDHlo or ALDHhi MSC CDM, HMVEC exhibited increased 
proliferation (Figure 2.3B) and decreased apoptosis (7AAD-/AnnexinV+) (Figure 2.3C). 
The frequency of dead HMVEC (7AAD+ / AnnexinV+) was also reduced after 72h 
exposure to ALDHlo or ALDHhi MSC CDM (Figure 2.3D). Thus, CDM from ALDHlo or 
ALDHhi MSC enhanced HMVEC survival and proliferation under growth-factor depleted 
conditions in vitro. 
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Figure 2.2 Flow cytometric analyses of HMVEC proliferation and survival in vitro. 
 
Figure 2.2 Flow cytometric analyses of HMVEC proliferation and survival in vitro. 
Representative flow cytometry plots showing the detection of (A) proliferating (EdU+) 
cells or (B) viable (7AAD-/Annexin V-), dead (7AAD+/Annexin V+), or apoptotic 
(7AA-/Annexin V+) cells or under serum-free, growth factor reduced conditions (EBM-
2) with or without MSC conditioned media.  
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Figure 2.3 Conditioned media generated by ALDHlo or ALDHhi MSC stimulated 
HMVEC expansion in vitro.
 
Figure 2.3 Conditioned media generated by ALDHlo or ALDHhi MSC stimulated 
HMVEC expansion in vitro. (A) Exposure to ALDHlo or ALDHhi MSC CDM for 72 
hours augmented total HMVEC number compared to serum-free, growth factor-deprived 
conditions (EBM-2). (B) ALDHlo or ALDHhi MSC CDM increased the frequency of 
proliferating HMVEC at 48 hours. (C) ALDHlo or ALDHhi MSC CDM decreased the 
frequency of apoptotic HMVEC (7AAD-/AnnexinV+) at 48 and 72 hours. (D) ALDHlo or 
ALDHhi MSC CDM reduced the frequency of dead HMVEC (7AAD+/Annexin V+) at 72 
hours. Data represents mean ± SEM using purified MSC CDM derived from 3 human 
BM samples (**p<0.01; ***p<0.001). 
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2.3.3 Contact co-culture with ALDHlo or ALDHhi MSC did not 
promote HMVEC expansion. 
To assess whether cell contact could further stimulate EC growth, purified MSC subsets 
were cultured in direct contact with HMVEC under serum-free, growth factor-deprived 
conditions. Endothelial versus stromal cell phenotype was discerned in mixed cultures 
using selective CD31 and CD90 expression alongside proliferation and apoptosis assays. 
Surprisingly, co-culture with ALDHlo or ALDHhi MSC for 72 hours did not augment total 
HMVEC number compared to uniculture in EBM-2 (Figure 2.4A). In fact, contact co-
culture with ALDHlo or ALDHhi MSC significantly decreased HMVEC proliferation 
(Figure 2.4B). Although direct co-culture with ALDHlo and ALDHhi MSC significantly 
decreased the frequency of apoptotic HMVEC at 72 hours (Figure 2.4C), there was no 
difference in the frequency of dead HMVEC over the 72-hour time course (Figure 2.4D). 
Conversely, co-culture with HMVEC significantly increased MSC expansion under 
serum-free, growth factor-deprived conditions (Figure 2.5A). During direct co-culture 
with HMVEC, the ALDHlo and ALDHhi MSC subsets significantly increased EdU 
incorporation at 72h compared to the MSC subsets cultured alone (Figure 2.5B). 
Although, no changes were observed in the frequency of apoptotic MSC over 72h 
(Figure 2.5C), the frequency of dead MSC was significantly reduced in ALDHlo and 
ALDHhi MSC co-cultures at 48 hours compared to the individual MSC controls (Figure 
2.5D). Contrary to our predicted results, HMVEC presence promoted MSC expansion, 
whereas MSC presence did not promote HMVEC survival of proliferation under growth 
factor-restricted conditions. 
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Figure 2.4 Contact co-culture with ALDHlo or ALDHhi MSC did not augment 
HMVEC expansion in vitro.
 
Figure 2.4 Contact co-culture with ALDHlo or ALDHhi MSC did not augment 
HMVEC expansion in vitro. (A) Co-culture with ALDHlo or ALDHhi MSC for 72 hours 
did not augment total HMVEC number compared to serum-free, growth factor-deprived 
conditions (EBM-2). (B) Co-culture with ALDHlo and ALDHhi MSC decreased the 
frequency of proliferating HMVEC at 24 and 72 hours. (C) Co-culture with ALDHlo and 
ALDHhi MSC decreased the frequency of apoptotic HMVEC (7AAD-/AnnexinV+) at 72 
hours only. (D) Co-culture with ALDHlo and ALDHhi MSC did not change the frequency 
of dead HMVEC (7AAD+/AnnexinV+). Data represents mean ± SEM using purified 
MSC from 3 human BM samples (**p<0.01; ***p<0.001). 
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Figure 2.5 Contact co-culture with HMVEC augmented ALDHlo and ALDHhi MSC 
expansion in vitro.
 
Figure 2.5 Contact co-culture with HMVEC augmented ALDHlo and ALDHhi MSC 
expansion in vitro. (A) Contact co-culture with HMVEC for 72 hours augmented total 
ALDHlo or ALDHhi MSC number under serum-free, growth factor-deprived conditions. 
(B) Co-culture with HMVEC increased the frequency of proliferating ALDHlo and 
ALDHhi MSC at 72 hours. (C) Co-culture with HMVEC did not alter the frequency of 
apoptotic MSC (7AAD-/AnnexinV+). (D) Co-culture with HMVEC decreased the 
frequency of dead ALDHlo and ALDHhi MSC (7AAD+/AnnexinV+). Data represents 
mean ± SEM using purified MSC from 3 human BM samples (**p<0.01). 
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2.3.4 ALDHhi MSC CDM augmented HMVEC tube formation. 
Using a similar strategy to measure HMVEC function, HMVEC were exposed to CDM 
generated from ALDHlo or ALDHhi MSC subsets and spontaneous tubule formation was 
quantified in growth factor-reduced GeltrexTM matricies (Figure 2.6A-D). Although 
proliferative and pro-survival effects were demonstrated by CDM from both MSC 
subsets, only CDM generated by ALDHhi MSC augmented tube forming capacity in vitro 
compared to the EBM-2 condition (Figure 2.6E).  
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Figure 2.6 Conditioned media generated by ALDHhi MSC augmented HMVEC tube 
formation in vitro.
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Figure 2.6 Conditioned media generated by ALDHhi MSC augmented HMVEC tube 
formation in vitro. (A-D) Representative images of HMVEC tube formation after 24 
hours culture in growth factor reduced GeltrexTM matricies supplemented with (A) EGM-
2, (B) EBM-2, (C) ALDHlo MSC CDM, or (D) ALDHhi MSC CDM. White arrows 
indicate examples of enumerated complete tubule branches. (E) Conditioned media 
derived from the ALDHhi MSC subset augmented tube formation compared to HMVEC 
grown in EBM-2. Data is represented as mean ± SEM using purified MSC from 4 human 
BM samples (*p<0.05). 
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2.3.5 ALDHhi MSC augmented EC recruitment into DIVAA inserts. 
To assess angiogenesis stimulatory function by human MSC subsets in vivo, 2x105 
ALDHlo or ALDHhi MSC were loaded into DIVAA inserts and subcutaneously implanted 
into NOD/SCID mice for 10 days. Representative images of the excised angioreactors 
shows erythrocyte invasion into the ALDHhi MSC containing angioreactor similar to 
VEGF/FGF containing controls (Figure 2.7A). After measurement of lectin uptake in 6-9 
DIVAA inserts per group, the ALDHhi MSC subset significantly increased EC content 
within the angioreactor compared to the ALDHlo MSC subset (Figure 2.7B). Next, 
concentrated CDM from ALDHlo or ALDHhi MSC subsets was loaded into angioreactors 
and subcutaneously transplanted into NOD/SCID mice. Lectin uptake was significantly 
increased in inserts containing ALDHhi MSC CDM compared to ALDHlo MSC CDM or 
concentrated EBM-2 (Figure 2.7C). Thus, CDM generated specifically by the ALDHhi 
MSC subset stimulated EC recruitment into angioreactors in vivo. 
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Figure 2.7 Implantation of ALDHhi MSC increased endothelial cell invasion into 
Directed In Vivo Angiogenesis Assay (DIVAA) Inserts.
 
Figure 2.7 Implantation of ALDHhi MSC increased endothelial cell invasion into 
Directed In Vivo Angiogenesis Assay (DIVAA) Inserts. (A) Representative images of 
DIVAA angioreactors loaded with a BME combined with ALDHhi/lo MSC, EBM, or a 
VEGF/FGF cocktail retrieved 10 days after subcutaneous implantation. EC invasion was 
measured using lectin-FITC uptake. (B) Implantation of ALDHhi MSC increased EC 
invasion into the angioreactor compared to the ALDHlo MSC. (C) Concentrated 
conditioned media generated from the ALDHhi MSC subset also increased EC invasion 
into the angioreactor. Data is represented as mean ± SEM for 3 human BM samples 
performed in triplicate (*p<0.05). 
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2.3.6 ALDHlo and ALDHhi MSC demonstrated similar mRNA 
expression. 
Affymetrix microarrays were performed to compare global mRNA expression between 
ALDHlo and ALDHhi MSC subsets. As predicted by functional analyses using HMVEC 
co-culture in vitro, purified ALDHlo and ALDHhi MSC showed remarkably similar 
mRNA expression patterns. Volcano plot analyses marked only 51 mRNAs with >1.2-
fold differential expression (p<0.05) (Figure 2.8A). Indeed, principal component 
analyses indicated considerable sample variability between each MSC line with lower 
variation between sample-matched ALDHlo and ALDHhi MSC subsets (Figure 2.8B). 
Collectively, only 29 mRNAs showed increased expression (>1.2-fold, p<0.05) 
comparing ALDHhi to ALDHlo MSC. Within these mRNAs, 11 had unknown function, 4 
were non-coding, and 4 had pseudogene classification. Conversely, only 21 mRNAs 
showed decreased expression (<-1.2-fold, p<0.05) in ALDHhi MSC. Within these 
mRNAs, 15 had unknown function, were non-coding, or had pseudogene classification. 
Table 2.2 annotates the predicted functions of the 15 differentially expressed mRNAs 
identified. Interestingly, ALDH1A3 mRNA expression was increased 2-fold in the 
ALDHhi MSC subset. Because ALDH1A3 is a predominant isoform implicated in 
Aldefluor metabolism, increased ALDH 1A3 expression is expected in MSC selected for 
high ALDH-activity and validates the accuracy of our sorting and subsequent mRNA 
expression analyses (Table 2.2), Overall, mRNA expression between the ALDHlo and 
ALDHhi MSC was remarkably similar, and the few differentially expressed mRNAs 
showed no obvious link to angiogenic secretory functions. 
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Figure 2.8 Global mRNA expression was similar comparing ALDHlo versus ALDHhi 
MSC subsets.
 
Figure 2.8 Global mRNA expression was similar comparing ALDHlo versus ALDHhi 
MSC subsets. (A) Volcano plot showing the vast majority of mRNAs had <1.2-fold 
difference in expression with a P-value >0.05. Only 51 genes met statistical criteria 
(p<0.05) with >1.2-fold expression change between ALDHlo and ALDHhi MSC subsets 
(see Table 2.2). (B) Principal component analysis indicated greater variation existed 
between individual samples than between sample-matched ALDHlo and ALDHhi MSC 
subsets.  
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Table 2.2 Differentially expressed mRNAs comparing ALDHlo versus ALDHhi MSC 
subsets. 
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2.3.7 ALDHhi MSC demonstrated a pro-angiogenic secretome. 
ALDHlo and ALDHhi MSC subsets (N=3) were incubated in EBM-2 for 48h to generate 
CDM for global secretome analyses using mass spectrometry. A total of 2482 proteins 
were detected, 501 proteins were unique to ALDHlo MSC CDM, 264 proteins were 
unique to ALDHhi MSC CDM, and 1717 proteins were commonly produced by both 
subsets. These lists were annotated and filtered using GO-cellular component terms 
associated with the extracellular space or secreted fraction or signal peptide, inclusive of 
membrane-bound proteins (92 peptides). As an additional criterion, we annotated and 
filtered based on GO-molecular function terms associated with angiogenesis (tube 
formation, EC proliferation, migration, matrix modification, etc.). These analyses 
identified 10 cytokines unique to the ALDHhi CDM (Table 2.3A) all associated with the 
positive regulation of angiogenesis. Several unique factors (VEGFB, PDGFA, Plexin D1, 
Angiogenin) were directly associated with EC proliferation, differentiation, tubule 
formation and migration, and several others were important developmental factors 
(Wnt5A, Spondin1, and activin A receptor) linked angiogenic processes. No proteins 
unique to the ALDHhi CDM had documented anti-angiogenic effects (Table 2.3A). The 
501 unique factors in the ALDHlo CDM were analyzed in an identical fashion and 
revealed 9 secreted proteins (Table 2.3B). Only one protein, angiopoietin-like 3 
(ANGPTL3), had confirmed pro-angiogenic activity, whereas 3 proteins unique to the 
ALDHlo MSC CDM (Platelet Factor 4, Tyrosine Kinase 1 (TIE1), and Plasminogen) had 
documented anti-angiogenic functions (Table 2.3B).  
A direct comparison of proteins common to the ALDHlo and ALDHhi secretome revealed 
few differences in the amount of secreted products that were >1.5-fold or <-1.5-fold 
different in ALDHhi MSC CDM compared to ALDHlo MSC CDM (Figure 2.9). Label-
free quantitation intensities in >5 of 6 sample replicates (1351 peptides) were again 
annotated and filtered using GO-cellular component terms associated with the 
extracellular space or secreted fraction, inclusive of membrane-bound proteins (698 
peptides, Figure 2.9), and a multiple sample T-test was performed to obtain differentially 
secreted proteins (Table 2.4). Interestingly, there were several factors secreted more 
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highly in the ALDHlo MSC subset with the potential to promote (myeloid derived growth 
factor and PLAUR) or inhibit angiogenic process such as ADAMTS12 (Table 2.4). 
To validate the proteomic analyses, ALDHlo and ALDHhi MSC subset CDM (48h in 
EBM-2) were also assayed for cytokine/chemokine secretion using the Human 
Angiogenesis array C1 multiplex-ELISA. ALDHhi MSC and ALDHlo MSC showed 
similar secretory patterns with both MSC subsets secreted similar quantities of 
angiogenin, GRO, IL-6, IL-8, MCP-1, RANTES, TGF-β, TIMP-1/2 and VEGF (Figure 
2.10). Overall, these secretome analyses suggested the ALDHhi MSC subset demonstrated 
a secretory profile consistent with the stimulation of EC proliferation, migration, tube 
formation and the chemoattraction of pro-angiogenic accessory cells. 
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Table 2.3 Secreted proteins unique to CDM generated by ALDHhi MSC or ALDHlo 
MSC. 
      
(A) Within ALDHhi MSC CDM, multiple unique factors were identified that were 
associated with the positive regulation of angiogenesis (bold). (B) Conversely, multiple 
proteins unique to the CDM generated by ALDHlo MSC were negative regulators of 
angiogenesis (italics). Unique peptides were identified with a false detection rate (FDR) 
of 0.01, N=3 MSC samples performed in duplicate. Primary functional annotations were 
obtained from GeneCards. 
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Figure 2.9 Comparison of protein content in conditioned media generated from 
ALDHlo versus ALDHhi MSC.
 
 Figure 2.9 Comparison of protein content in conditioned media generated from 
ALDHlo versus ALDHhi MSC. Conditioned media generated from 3 bone marrow MSC 
samples were analyzed in biological duplicate by mass spectrometry. Shared proteins 
(1717 peptides) were first filtered by label-free quantitation (LFQ) intensities in >5 of 6 
sample replicates (1351 peptides). The protein list was annotated and filtered using GO-
cellular component terms associated with the extracellular space or secreted fraction, 
inclusive of membrane-bound proteins (698 peptides). Biological replicates were 
averaged, and a multiple sample T-test was performed to obtain differentially secreted 
proteins (p<0.05).  
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Table 2.4 Proteins differentially secreted from ALDHhi versus ALDHlo MSC. 
* Peptides identified using at least one unique peptide with a false detection rate of 0.01, 
N=3, performed in duplicate. Functional annotations obtained from GeneCards.org. 
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Figure 2.10 Multiplex-ELISA of conditioned media from ALDHlo versus ALDHhi 
MSC.
Figure 2.10 Multiplex-ELISA of conditioned media from ALDHlo versus ALDHhi 
MSC. Conditioned media generated the ALDHlo or ALDHhi MSC subsets was generated 
for 48 hours in EBM-2 assayed by the human angiogenesis array C1. Both the ALDHlo 
and ALDHhi MSC subset secreted similar quantities of angiogenin, GRO, IL-6, IL-8, 
MCP-1, RANTES, TGF-β, TIMP-1/2 and VEGF. All chemo-luminescence values were 
semi-quantitative. Data is represented as mean ± SEM for 5 human BM samples 
performed in triplicate. 
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 Discussion 
Cultured MSC represent a heterogeneous mixture of stromal cells amenable to novel 
cellular therapy applications, due to purported immunomodulatory37-39 and regenerative 
paracrine effects20, 21. Here we demonstrate expanded MSC purified based on high ALDH-
activity selects for an MSC sub-fraction with enhanced pro-angiogenic characteristics. 
Direct comparison of ALDHlo versus ALDHhi MSC subsets showed identical cell surface 
marker expression and differentiation into bone, cartilage and adipose tissues in vitro. In 
addition, CDM from both ALDHlo and ALDHhi MSC subsets demonstrated remarkable 
effects on endothelial cell functions in vitro. Detailed comparison of survival / proliferation 
kinetics every 24 hours revealed MSC CDM increased HMVEC proliferation early in 
culture (48h), and subsequently reduced apoptosis and cell death later in culture (48-72h). 
Although CDM from both MSC subtypes augmented HMVEC expansion, only ALDHhi 
MSC CDM significantly increased HMVEC tubule formation in vitro. Thus, only ALDHhi 
MSC CDM was able to support both endothelial cell expansion and tubule forming 
functions in vitro. 
Surprisingly, contact co-culture with ALDHlo or ALDHhi MSC subsets did not augment 
HMVEC survival or proliferation in serum-free EBM-2 media. In fact, HMVEC 
proliferation was decreased during co-culture, while MSC subset proliferation and survival 
was increased. As previously reported by Dhahri et al40, our co-culture data suggested the 
presence of HMVEC supported MSC expansion, while the presence of MSC had little 
effect on HMVEC growth.  
After incubation for 10 days in NOD/SCID mice, subcutaneously implanted DIVAA 
angioreactors containing ALDHhi MSC or ALDHhi MSC CDM increased endogenous 
vascular cell recruitment measured by lectin uptake. Interestingly, vascularization of 
angioreactors containing the ALDHhi MSC CDM was equivalent to angioreactors 
containing a VEGF/FGF cocktail employed as a positive control. Furthermore, ALDHlo 
MSC or its CDM did not promote endogenous cell recruitment compared to control 
angioreactors. This data suggests that ALDHhi MSC uniquely support the generation of a 
pro-angiogenic niche through secretion of chemokines or cytokines that augment 
recruitment or stimulate the activation of endogenous endothelial cells in vivo. 
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Purified ALDHlo and ALDHhi MSC subsets were also compared for differences in mRNA 
expression using Affymetrix arrays. The expression patterns of the ALDHlo versus ALDHhi 
MSC subsets were strikingly similar. Interestingly, PCA analysis of the microarray data 
indicates that high variability exists between each MSC line and lower variability exists 
between ALDHlo and ALDHhi MSC within samples. Indeed, the largest mRNA expression 
difference (2-fold) between purified MSC populations was ALDH1A3, reflecting the 
enzymatic function used to sort the cells at the onset of experiments. Thus, analyses of 
transcription profiles using microarray did not account for the enhanced capacity of 
ALDHhi MSC to induce pro-angiogenic processes.  
Next, we carefully analyzed protein secretion into conditioned media generated by ALDHlo 
and ALDHhi MSC subsets using highly-sensitive proteomic techniques, as post-
transcriptional regulation may permit small changes in transcription to give rise to larger 
changes in protein secretion. Quantitative mass spectrometry analyses revealed that 
ALDHhi MSC uniquely secreted several well-known pro-angiogenic growth factors 
(VEGFB, PDGFA, and Angiogenin) not present in the secretome of ALDHlo MSC. 
Conversely, the ALDHlo MSC CDM contained potent anti-angiogenic factors (platelet 
factor-4, plasminogen) not present in the ALDHhi MSC CDM. For example, platelet factor 
4, or CXCL4, was the first chemokine shown to inhibit endothelial cell proliferation and 
migration via direct interaction and interference with bFGF, VEGFA and integrin 
signalling41. Plasminogen, through proteolytic conversion to angiostatin enables inhibition 
of angiogenesis through direct interaction with endothelial cells42, 43. Judah Folkman first 
established the principles of angiogenesis describing that vessel advancement or regression 
is controlled by a series of on/off switches within the microenvironment44. Using this 
model, the secretome of ALDHlo MSC was consistent with the promotion of anti-
angiogenic processes, whereas the ALDHhi MSC secretome was consistent with the 
promotion of pro-angiogenic processes.  
This study outlines several advances relevant to the development of pro-angiogenic 
therapies. First, ALDHhi MSC can be purified after culture based on a conserved progenitor 
function where cell surface markers have not been successful identifying MSC with 
specific regenerative functions. Second, MSC selection can reduces heterogeneity and can 
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purify an “active” MSC subset with enhanced pro-angiogenic secretory functions. Third, 
the potential use of allogeneic ALDHhi MSC for the treatment of ischemic diseases is an 
exciting possibility as mounting evidence indicates the potential for cellular dysfunction 
by autologous MSC in patients with cardiovascular co-morbidities. Finally, only the re-
selected MSC progeny with high ALDH-activity retained pro-angiogenic niche forming 
capacity after implantation in vivo. Thus, the delivery of BM ALDHhi MSC into patients 
with CLI, may be used in future clinical strategies to mediate pro-angiogenic benefit. 
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Chapter 3  
3 Characterization of CD34-expressing endothelial colony 
forming cell subsets during ex vivo expansion. 
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 Introduction 
From large caliber vessels to microvascular networks, endothelial cells form the lining of 
blood vessels and establish a highly regulated interface between circulating blood and 
systemic tissues. The heterogeneity within vessel derived endothelial cells enables artery, 
venous and capillary blood vessel networks to serve distinct functions within different 
organ systems. For example, endothelial cells lining large vessels that are responsible for 
moving higher volumes of blood interact with smooth muscle cells to tightly control 
blood pressure and vessel diameter1. Alternatively, other endothelial cells can be found 
with leaky, fenestrated endothelium, as demonstrated in the kidney2.  
Tissue-specific endothelial cell phenotypes are specified by the microenvironment 
composition and cues that endothelial cells are exposed to during vessel homeostasis3, 4. 
To illustrate this, grafts of non-neural somite tissue transplanted within neural tissues 
produced fenestrated vasculature with few tight junctions within the grafted tissue. 
Conversely, when transplanting brain tissue into the coelomic cavity, endothelial cells 
within the neural graft developed a tight blood brain barrier reflective of neural tissue5. 
Contrary to other mature cell populations, endothelial cells also demonstrate a plastic 
phenotype in vitro despite being “terminally” differentiated. For example, removing 
endothelial cells from their native environment and sub-cultured in vitro can induce a loss 
of organ-specific phenotype6, 7. Endothelial cells will rapidly change their phenotype 
based on microenvironmental cues or supplemented growth factors encountered during ex 
vivo expansion. Thus, defining a distinct progenitor cell or precursor phenotype for 
endothelial cells grown in culture has remained a challenge. 
The conceptual framework of endothelial precursor cells (EPC) had arisen from seminal 
experiments by Asahara et al. defining the ability of CD34+ peripheral blood 
mononuclear cells (MNC) to home to sites of ischemia and promote vascularization after 
transplantation8. This work subsequently inspired the isolation and propagation of 
“EPCs” from blood and/or bone marrow sources. Three distinct culture techniques 
emerged, producing three different resulting cell populations: colony  forming unit – 
endothelial cells (CFU-EC)8, 9, circulating angiogenic cells (CAC)10-12, and endothelial 
colony forming cells (ECFC)13-15. It was later uncovered that the early outgrowth 
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populations from the blood MNC sources (CFU-EC and CAC) were comprised primarily 
of hematopoietic cells (namely monocytes and macrophages) with a pro-angiogenic 
secretory phenotype10, 16-19. Only the late outgrowth ECFC from the adherent fraction of 
MNC gave rise to a highly proliferative endothelial cell population able to form vascular 
networks in vitro and in vivo20. 
Although consensus has been achieved that only ECFC give rise to endothelial cells in 
vitro, another source of confusion surrounding the term “EPC” lies in the distinction 
between freshly isolated cells versus cells expanded in culture. For example, freshly 
isolated CD34+/CD45- and/or CD146+ cells can enrich for ECFC in culture21, 22; while it 
has yet to be determined if selection based on CD34 can isolate a comparable EPC 
subpopulation following expansion in vitro. Of note, even within the freshly isolated 
EPC, there have been many different cell surface markers used to define and purify 
EPC23. Understanding the distinctions between EPC harvested from fresh and/or culture 
sources is important for accurately comparing results obtained from clinical trials using 
these cells. Thus far, there are over 350 clinical trials initiated which indicate the use of 
“Endothelial progenitor cells” (www.clinicaltrials.gov), albeit the minority of trials 
involve endothelial cell transplantation. Specifically, these trials transplanted “EPC” 
whose selection parameters ranged from CD34+ and/or VEGFR2+ and CD133+ MNC 24, 25 
to MNC cultured similar to CACs on fibronectin-coated plates in endothelial specific 
media26, 27. Regardless, most these early clinical studies demonstrated safety and modest 
therapeutic benefits, warranting further development of regenerative therapies utilizing 
EPC or ECFC. Importantly, progenitor cell phenotypes in peripheral blood MNC has 
been used as clinical diagnostic to non-invasively predict cardiovascular disease risk9 and 
recovery rates28 in patients with cardiovascular complications. Although clinical studies 
transplanting ECFC are limited, a plethora of pre-clinical studies have elucidated 
endothelial cell signaling pathways and characterized cellular responses during disease 
and regeneration, reviewed by Paschalaki et al.29. 
To date, ECFC cultures are regarded as the gold standard for the growth of EPC in vitro 
20. Although select surface markers may enrich for ECFC from fresh tissue, the initial 
establishment of ECFC contains a relatively heterogeneous mixture of starting cells, 
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including hematopoietic progeny. However, through adherence and selective culture 
conditions, highly proliferative ECFC establish a more homogeneous endothelial cell 
population. Sub-culture and ex vivo expansion are necessary steps in order to obtain large 
numbers of ECFC for cell therapies however, extended culture may stimulate EC 
maturation as cells differentiate30, 31. We hypothesized that ECFC cultures contain a 
hierarchy of rare, proliferative progenitor cells that drive expansion and subsequently 
generate more differentiated endothelial cells with lower proliferative rates and conserved 
endothelial cell functions. Our goal was to accurately define a proliferative endothelial 
progenitor cell in culture, in order to develop improved strategies to cultivate these cells 
for therapies, and to delineate a hierarchy marking primitive versus differentiated 
endothelial cells. Herein, we demonstrate that ECFC expressed CD34 in a density-
dependent manner and the expression of CD34 coincided with the increased expression 
of mature endothelial cell surface antigens, decreased clonogenicity, growth kinetics, and 
tube-forming capacity compared to the CD34- ECFC in vitro. Nonetheless, the CD34+/- 
ECFC subsets were equally able to form vessel-like structures within Matrigel plugs after 
subcutaneous transplantation into the flank of NOD.SCID mice. Collectively, this study 
describes novel phenotypic and functional characterization of ECFC subsets in vitro, 
although the identity of an endothelial precursor cell in vitro remains elusive. 
 Methods 
3.2.1 Collection and isolation of ECFC. 
Human ECFC were established from umbilical cord blood-derived MNC, as previously 
described15. Briefly, MNC were seeded on tissue culture plastic at 70,000 cells/cm2 in 
complete endothelial growth media-2 (EGM-2) + 2% FBS + cytokines (Lonza, Basel, 
Switzerland). Media was replaced every 3 days for up to 14 days when colonies became 
confluent. Colonies were lifted with TrypLETM express (ThermoFisher, Waltham, MA) 
and cells were re-plated at 4000 cells/cm2. ECFC monolayers were subsequently 
expanded in EGM-2 and passaged at ≈ 80% confluency. Cells were cryopreserved at 
passage 3 to be used for subsequent experiments. 
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3.2.2 Flow cytometric characterization of ECFC.  
To prepare ECFC for flow cytometric analyses or fluorescence activated cell sorting 
(FACS), ECFC were dissociated with trypsin and single cell suspension was treated with 
AldefluorTM (StemCell technologies, Vancouver, Canada) to measure ALDH-activity. 
Surface marker expression was analyzed by co-staining with conjugated anti-human 
antibodies for CD34, CD31, CD45, VE-Cadherin, CD105, VEGFR2, TIE-2, and CXCR4. 
Data was acquired using an LSR II flow cytometer (BD biosciences, San Jose, CA) 
analyzed using FloJo software at the London Regional Flow Cytometry Facility. 
3.2.3 Cell sorting and colony forming assays. 
An automated cell deposition unit (ACDU) on a FACSAria III cell sorter (BD 
biosciences), was used to plate single cells into each well of a 96-well plate containing 
EGM-2. ECFC were initially selected using forward and side scatter profiles to obtain 
single unpurified cells at random. In subsequent experiments, ECFC subsets were 
selected based on high versus low ALDH-activity, CXCR4, CD34, or CD143 expression. 
Single cell deposition was visually checked after plating. Media was replaced after 6 days 
and colonies were enumerated using an inverted light microscope at day 12 of culture. 
Enumerated colonies were defined as cell clusters containing >50 cells. 
3.2.4 Tube forming assay. 
To assess the tubule-forming function of ECFC subsets in vitro, 120,000 ALDHhi/lo or 
CD34+/- FACS purified ECFC were cultured on growth factor-reduced Geltrex matrices 
(ThermoFisher) in endothelial basal media without serum or cytokines (EBM-2) media or 
in complete EGM-2. After  20 hours, photomicrographs were taken by light 
microscopy, and tubule formation was quantified using manual counting of complete 
tubule number under light microscopy. Tube formation was enumerated using ImageJ 
software. 
3.2.5 Growth kinetics and surface marker kinetics. 
FACS-purified CD34+/- ECFC subsets were plated at 4000 cells/cm2 in 7 different tissue 
culture flasks. Manual hemocytometer counts and flow cytometry analyses were 
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performed every 24 hours for 7 days to assess ECFC expansion kinetics and CD34 
expression patterns. The media was changed on days 3, 5, and 6 as the near confluent 
monolayer required more frequent media changes to maintain cell growth. 
3.2.6 Preparation of cells for cell surface proteome analysis. 
Initially, 106 FACS-purified CD34+/- ECFC subsets were plated on tissue culture plastic 
for 8 hours to permit adherence, prior to plasma membrane isolation and analyses of 
surface proteins by mass spectrometry. For cell surface protein isolation a 10% solution 
of colloidal silica beads (Sigma Aldrich, St. Louis, MO) was added to ECFC in culture to 
permit non-specific colloid silica bead/membrane-bound protein interactions, as 
previously described32. A polyacrylamide catalyst (Sigma) was used to stabilize 
protein/colloidal bead interactions by cross-linking of the silica beads to the cell 
membrane. Bead-bound ECFC were manually collected using cell scrapers and 
homogenized via sonication prior to ultra-centrifugation using a HistoDenz gradient 
(Sigma) to isolate bead/proteins conjugates. The beads, containing membrane bound 
proteins were resuspended in 8 M urea, 50 mM ammonium bicarbonate, 2% SDS and 5 
mM DTT to elute and solubilize proteins off the beads in a sonication bath for 30 min. 
Protein concentrations were subsequently determined using the Pierce 660 nm protein 
assay. 
3.2.7 Mass spectrometry analysis of cell surface protein 
expression. 
Protein extracts were reduced in 10 mM DTT for 30 min in the dark. Next, samples were 
alkylated with 100 mM iodoacetamide (IAA) for 45 min at room temperature in the dark. 
To facilitate the removal of incompatible detergents, reducing and alkylating reagents, 
proteins were precipitated using chloroform methanol. After protein precipitation, 
peptides were generated through digestion using trypsin. High pH fractionation was 
performed using a Waters XBridge BEH130 C18 5µm column. After collection, the 
protein fractions were vacuum concentrated (SpeedVacTM) and acidified prior to liquid 
chromatography coupled with tandem mass spectrometry. Data analysis was performed 
with MaxQuant version 1.5.0.30 using the Andromeda search engine33. MS/MS spectra 
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were searched against the Human Uniprot database with trypsin specificity (20264 
entries)34. 
3.2.8 Surface marker identification. 
Protein expression from the CD34+ ECFC were directly compared with protein 
expression from the CD34- ECFC. Bioinformatic analysis was performed using Perseus 
software version 1.5.0.8. Datasets were filtered for proteins containing a minimum of 1 
unique peptide while also meeting the P-value requirement of P<0.05. The differentially 
expressed protein list was exported into DAVID gene ontology (GO) analysis to select 
for proteins with vascular/endothelial functions.  
3.2.9 In vivo implantation of purified ECFC in Matrigel. 
The ability of CD34-selected ECFC subsets to form functional vasculature in vivo was 
assessed after implantation into immunodeficient NOD/SCID mice. Briefly, 106 purified 
human CD34+ or CD34- ECFC were mixed with 250,000 mouse aorta smooth muscle 
cells (4:1 ratio) subcutaneously injected into the flank in 200 µL Matrigel 
(ThermoFisher) as previously described35. After 7 days incubation, the Matrigel plug was 
removed and mounted in optimal cutting temperature media for subsequent 
cryosectioning and immunofluorescence. Briefly, 10µM sections were fixed with 10% 
formalin, permeabilized and stained for CD31 and HLA antibodies to visualize human 
cell contribution to lumenized vascular structures. 
 Results 
3.3.1 ECFC express hematopoietic progenitor cell markers CD34 
and ALDH. 
To validate the purity of ECFC cultures, flow cytometry was used to assess both 
endothelial and hematopoietic cell surface maker expression. Cultured UCB-derived 
ECFC highly (>97%) expressed CD31, VEGFR2, VE-Cadherin, CD105, and <5% of 
ECFC expressed CD45, confirming minimal hematopoietic cell contamination (Figure 
3.1). Analyses of markers commonly used to assess progenitor cell (ALDH-activity, 
CD34) or migratory cell (CXCR4) surface phenotype after ex vivo expansion is shown in 
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Figure 3.2. ALDH activity assessed in 4 ECFC samples averaged 64.5 ± 17.9% ALDHhi 
cells and 28.0 ± 14.7% ALDHlo cells (Figure 3.2A, D). Notably, ALDH-activity was 
highly variable between different UCB samples. In contrast, CD34 (3.3 ± 1.3%) and 
CXCR4 (1.4 ± 0.6%) expression on cultured ECFC was consistently low (Figure 3.2B-
D). Because UCB HPC with high-ALDH activity highly co-expressed CD34 (Ref), we 
used 3-color analyses to assess each parameter simultaneously. Surprisingly, ALDHhi 
ECFC did not significantly co-express CD34 or CXCR4 (Figure 3.2E, F). In contrast, 
CD34+ ECFC co-expressed CXCR4 at 30% (Figure 3.2G). Next, we assessed 
intracellular expression of CD34 or CXCR4. After fixation and permeabilization, ECFC 
showed considerable stores of CXCR4+ whereas CD34 expression was identical on 
permeabilized or unpermeabilized ECFC (Figure 3.3). After culture expansion, ECFC 
with high ALDH activity did not co-express CD34. Although low expression of CD34 
was observed on ECFC, the CD34+ ECFC demonstrated increased CXCR4 expression 
which may represent increased migratory capacity as demonstrated in SCID-repopulating 
CXCR4+/CD34+ hematopoietic progenitor cells36, and putative circulating endothelial 
progenitor cells37. 
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Figure 3.1 Cultured UCB ECFC expressed endothelial cell surface antigens and lack 
the hematopoietic cell surface marker CD45.
 
Figure 3.1 Cultured UCB ECFC expressed endothelial cell surface antigens and lack 
the hematopoietic cell surface marker CD45. Representative flow cytometric analysis 
of ECFC established from human umbilical cord blood showed >95% expression of the 
endothelial cell markers: (A) CD31, (B) VEGFR2, (C) CD105, (D) TIE2 and (D) lacking 
expression of the pan-leukocyte marker, CD45 (N=3).  
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Figure 3.2 Identification of progenitor cell surface marker expression by flow 
cytometry. 
Figure 3.2 Identification of progenitor cell surface marker expression by flow 
cytometry. After establishment of ECFC in culture, cells were assessed for expression of 
ALDH, CD34 and CXCR4. Representative flow plots of ECFC for (A) ALDH, (B) 
CD34, and (C) CXCR4 expression. AldefluorTM fluorescence was gated using DEAB 
inhibition of ALDH-activity. Cell surface marker expression was gated based on isotype 
controls. (D) Approximately 65% of ECFC demonstrated high ALDH-activity but did not 
co-express (E) CD34 and (F) CXCR4. Conversely, (G) 28% of CD34+ cells also 
expressed CXCR4, a 19-fold enrichment compared to bulk ECFC. Data represents the 
mean ± SD using ECFC derived from 4 UCB samples (N=4).  
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Figure 3.3 ECFC contained intracellular stores of CXCR4. 
 
Figure 3.3 ECFC contained intracellular stores of CXCR4. ECFC were fixed and 
permeabilized before staining with antibodies towards CD34 and CXCR4. The fixed and 
permeabilized cells were compared to their stained live cell counterparts. Approximately 
90% of ECFC contained CXCR4 intracellularly whereas CD34 expression was 
unchanged after permeabilization of ECFC. Data represents the mean ± SD using ECFC 
derived from 4 UCB samples (N=4, ***P<0.001).  
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3.3.2 Colony forming capacity was increased in CD34-/CXCR4- 
ECFC. 
To assess progenitor-like functions in vitro, single ECFC were sorted for ALDH activity, 
CD34, or CXCR4 expression (Figure 3.4A-C) and assessed for their ability to form 
colonies after 14 days in culture. When acquired without selection using forward and side 
scatter properties, 34% of total ECFC established colonies (Figure 3.4D). After selection 
of ECFC for ALDH-activity via ACDU, the clonogenic capacity of the ALDHhi ECFC 
was not significantly different than ALDHlo ECFC (Figure 3.4D). In contrast, CD34- 
ECFC efficiently formed colonies (51.3 ± 5.85) compared to CD34+ ECFC (16.3 ± 4.7). 
Similarly, CXCR4- ECFC formed significantly more colonies than CXCR4+ ECFC. 
When sorted using both progenitor cell markers, ECFC expressing either CXCR4 and/or 
CD34 consistently demonstrated reduced colony formation (Figure 3.4E). Cells that 
were CD34-/CXCR4- or CD34-/ALDHhi formed a significantly higher number of colonies 
compared to unfractionated ECFC (Figure 3.4E). These data suggest that ECFC 
expressing CD34 or CXCR4 have a reduced ability to establish colonies from single cells 
in vitro.   
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Figure 3.4 ECFC expressing CD34 and CXCR4 exhibit deceased colony formation 
in vitro. 
 
Figure 3.4 ECFC expressing CD34 and CXCR4 exhibit decreased colony formation 
in vitro. Colony forming capacity of single ECFC purified by the expression of (A) 
ALDH, (B) CD34, or (C) CXCR4, was assessed using (D) single markers or (E) in 
combination. ECFC expressing CD34 or CXCR4 exhibited a significant decrease in 
colony forming capacity compared to the CD34 or CXCR4 negative ECFC respectively. 
CD34-/ALDHhi ECFC and CD34-/CXCR4- ECFC formed significantly more colonies 
when compared to unselected ECFC. Data represents the mean ± SD using ECFC derived 
from 3 UCB samples (N=3 **P<0.01; *p<.05).  
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3.3.3 Tube forming capacity was increased by CD34- ECFC. 
To further assess the relationship between putative progenitor marker expression and a 
conserved endothelial cell functions in vitro, we assessed the tubule-forming capacity of 
ECFC subsets purified for ALDH-activity or CD34 expression. Briefly, 120,000 purified 
CD34+/- or ALDHhi/lo ECFC were seeded in growth factor-reduced Geltrex in EBM or 
fully supplemented EGM-2. Photomicrographs were obtained 20 hours after seeding and 
total tubule number was enumerated. Regardless of whether ECFC were plated in EGM 
or EBM, selection for low versus high ALDH-activity did not alter tubule forming 
capacity of ECFC (Figure 3.5C). In contrast, CD34- ECFC demonstrated increased 
tubule formation in vitro, compared to the CD34+ ECFC (Figure 3.5D). Collectively, 
CD34 expression, and not ALDH-activity, selected ECFC with differential tubule 
forming capacity in vitro. 
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Figure 3.5 ECFC expressing CD34 exhibit decreased tube forming capacity in vitro. 
 
Figure 3.5 ECFC expressing CD34 exhibit decreased tube forming capacity in vitro. 
After ex vivo expansion, ECFC were sorted based on ALDH activity or CD34 expression 
and plated on GeltrexTM for 20 hours. Representative photomicrographs of tube formation 
for (A) ALDHhi/lo and (B) CD34+/- are presented. Whether using basal media (EBM) or 
growth media (EGM), the tube forming ability of ECFC with high or low (C) ALDH 
activity was similar. ECFC expressing (D) CD34 formed significantly less tubules than 
the CD34- ECFC. Data represents the mean ± SD using ECFC derived from 5 UCB 
samples, performed in technical duplicate (N = 5; ** P < 0.01; * P < 0.05). 
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3.3.4 CD34-expression on ECFC was increased in confluent 
culture conditions. 
We next tested the effects of cultured cell density on ECFC, which has been previously 
suggested to increase CD34 expression38. For ECFC in culture at passage 4, CD34 was 
expressed on 9% of cells when passaged at <80% confluency (Figure 3.2). When ECFC 
were cultured to >90% confluency, we CD34+ expression was markedly increased. 
Although the frequency of CD34+ ECFC increased by ~6.5-fold, the other cell markers 
assessed (ALDH, CXCR4) were not altered at any time point assessed (Figure 3.6A). We 
next sought to assess functional differences between confluent ECFC sorted for CD34 
expression compared to ECFC grown under standard culture practices.  Of note, no 
differences in colony formation were observed between CD34+ and CD34- ECFC after 
collection at high (>90%) cell density (Figure 3.6B). Similarly, the CD34-selected ECFC 
subsets confluence did not display a significant decrease in the ability to form tubes in 
vitro (Figure 3.6C). These findings indicated that culture of ECFC to confluency 
increases CD34 expression and abrogated functional differences in colony and tubule 
formation in vitro. 
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Figure 3.6 ECFC cultured at high density increased CD34 expression and altered 
ECFC colony and tubule formation in vitro.
 
Figure 3.6 ECFC cultured at high density increased CD34 expression and altered 
ECFC colony and tubule formation in vitro. (A) ECFC cultured to >80% confluency 
for 3 days exhibited ~7-fold increase in the frequency of CD34+ ECFC. (B) Colony and 
(C) tube forming function were compared to ECFC grown in standard culture conditions. 
ECFC subsets selected for CD34 = expression at high cell density formed an equal 
number of colonies or tubules compared to non-confluent counterparts. Data represents 
the mean ± SD using ECFC derived from 4 UCB samples (N=4; ****p<0.0001; 
**P<0.01). 
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3.3.5 CD34-expression was reversible and CD34- ECFC showed 
increased growth kinetics. 
Based on the previous observation that the CD34 expression was correlated to cell 
density, we investigated CD34 expression dynamics over 7 days alongside the expansion 
of CD34+ and CD34- purified ECFC. Interestingly, the frequency of CD34+ ECFC 
gradually decreased to <20% over the first 72 hours of culture (Figure 3.7A). Notably, 
the exponential growth phase of the CD34- ECFC concluded by around day 4.5 whereas 
exponential growth ended at day 6 for the CD34+ cells. To further illustrate, the number 
of CD34- ECFC was significantly greater than the CD34+ ECFC subset at days 2-5 of 
expansion in vitro (P<0.05) (Figure 3.7A, B). During the expansion of the CD34- ECFC, 
the frequency of CD34+ ECFC increased over 7 days (Figure 3.7B). In contrast, the 
CD34+ ECFC population showed a dramatic loss of CD-expression over the first 4 days, 
followed by increased CD34 expression during the final 3 days as cell density increased 
(Figure 3.7B). These data indicate that CD34 expression on ECFC was reversible and 
correlated to cell density during expansion. Based on the growth curves, CD34+ ECFC 
initially expanded at a slower rate but reached a similar cell number after 6 -7 days 
expansion. 
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Figure 3.7 CD34-expression increased with endothelial cell density. 
       
Figure 3.7 CD34-expression increased with endothelial cell density.  Cultured ECFC 
were purified into (A) CD34+ and (B) CD34- and plated for 7 days to assess CD34 
expressional changes and ECFC growth. After being plated at the same density post-sort, 
the CD34+ ECFC gradually lost the expression of CD34 (red line) which recovered as the 
cell density (grey shaded area) increased. Similarly, the CD34 expression of the CD34- 
ECFC also increased (green line) in response to an increase in cell density (grey shaded 
area) over 7 days. Notably, the CD34- ECFC growth curve reached its linear phase by 
day 4.5 of culture whereas the CD34+ ECFC reached this stage of growth at day 6, 
indicating a faster growth rate of for the CD34- ECFC. Data represents the mean ± SD 
using ECFC derived from 4 UCB samples (N=4). 
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3.3.6 The frequency of CD34+ ECFC remained stable over several 
passages. 
After observing changes in CD34 expression that occurred as cells were expanded, we 
also wanted to determine if CD34 frequency was altered over multiple cell passages at 
<80% confluency. Once the ECFC became established in culture, the first passage of 
these cells occurred with 40% of the ECFC expressing CD34 (Figure 3.8). The 
frequency of CD34+ ECFC decreased below 20% for each cell line by passage 2 but 
remained at a steady state for the remainder of the experiment. Thus, the CD34+ ECFC 
frequency remained at a steady state for each cell line after the establishment of a 
proliferative monolayer in culture. 
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Figure 3.8 CD34-expression reached a steady state for each cell line. 
 
Figure 3.8 CD34-expression reached a steady state for each cell line. During the 
isolation and establishment of ECFC in culture, the CD34 frequency was determined at 
the time of passage and was assessed over 5 passages on a per cell line basis. All ECFC 
lines tested began with higher levels of CD34 expression which rapidly decreased to as 
low as 3% by passage 1 and remained at a steady state throughout the remaining 4 
passages. ECFC were derived from 3 UCB samples (N=3). 
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3.3.7 ECFC surface proteomics revealed enrichment of known 
endothelial cell pathways on CD34+ ECFC. 
After observing functional differences between the CD34+ and CD34- ECFC, we sought 
to identify additional surface markers that may be used to identify ECFC subpopulations 
with progenitor-like functions. We used mass spectrometry to identify differential cell 
surface protein expression between CD34- or CD34+ ECFC. We identified 148 
differentially expressed proteins (P<0.05), with 67 proteins showed >2-fold increased 
expression on CD34+ ECFC compared to CD34- ECFC. Conversely, we identified only 
21 proteins >2-fold increased expression on the CD34- ECFC compared to the CD34+ 
ECFC. To validate our cell purification procedures, the proteomic comparison between 
sorted CD34- and CD34+ ECFC subsets revealed a 36-fold increase in CD34 expression 
on the CD34+ ECFC. Interestingly, after selecting proteins using GO terms associated 
with known endothelial cell pathways (Table 3.1), the CD34+ ECFC expressed many 
proteins associated with pro-vascular endothelial cell functions, summarized in Table 
3.2. 
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Table 3.1 List of gene ontology (GO) terms by DAVID gene enrichment analysis for 
the CD34- versus CD34+ ECFC surface proteomics. 
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Table 3.2 Comparison of the surface proteomics of CD34- versus CD34+ ECFC by 
DAVID gene enrichment analysis. 
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3.3.8 Angiotensin converting enzyme expression was enriched on 
CD34+ ECFC but did not impact colony forming capacity.  
Angiotensin converting enzyme (ACE or CD143) was shown to have 27-fold greater 
expression on CD34+ ECFC. Therefore, we sought to determine whether ACE was could 
be used as a biomarker of mature endothelial cells. When assessing the frequency of ACE 
expression on ECFC subsets, 88% of CD34+ cells expressed ACE while only 12.6% of 
CD34- ECFC expressed ACE by flow cytometry (Figure 3.9A). Next, we purified ECFC 
subsets based on CD143 expression, and used single cell deposition to assay for colony 
formation. Both CD143+ and CD143- subsets demonstrated equal colony forming 
capacity (Figure 3.9B). Finally, we tried to validate the expression of AXL and Col 
13A1 by flow cytometry because both proteins showed increased expression on CD34- 
ECFC. Unfortunately, very few unfractionated ECFC demonstrated expression of 
Col13A1 or AXL on the external cell surface membrane, Cell fixation and 
permeabilization revealed that >90% of ECFC expressed these proteins on the inside of 
the cell (Figure 3.10). Of the validated hits from the proteomic screen, the expression of 
ACE (CD143), Col13A1, and AXL did not provide useable markers for the identification 
of ECFC after culture with colony forming functions. 
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Figure 3.9 Angiotensin converting enzyme co-localized with CD34 expression on 
ECFC and did not affect the colony forming capacity of ECFC. 
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Figure 3.9 Angiotensin converting enzyme co-localized with CD34 expression on 
ECFC and did not affect the colony forming capacity of ECFC. (A) Cultured ECFC 
were demonstrated to express angiotensin converting enzyme (ACE) in both the CD34+ 
and CD34- subsets. The CD34+ ECFC demonstrated >80% expression of ACE with 
<10% of CD34- ECFC expressing ACE. (B) After purification of ACE+/- ECFC, the 
colony forming capacity for each ECFC subset was equivalent. Data represents the mean 
± SD using ECFC derived from 3 UCB samples (N=3).  
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Figure 3.10 ECFC contain intracellular stores of collagen 13A1 (Col13A1) and 
tyrosine-protein kinase receptor UFO (AXL). 
 
Figure 3.10 ECFC contain intracellular stores of collagen 13A1 (Col13A1) and 
tyrosine-protein kinase receptor UFO (AXL). After culture, ECFC were stained for the 
presence of cell-surface and intracellular content of Col13A1 and AXL to validate 
findings from the ECFC surface proteomics. On the live cells, <2.5% of the cells 
expressed Col13A1 and <1% of the cells expressed AXL at the cell surface. Once fixed 
and permeabilized, ECFC demonstrated >90% expression for both markers (N=1). 
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3.3.9 In vivo transplantation of CD34+/- ECFC subsets in Matrigel 
enabled the formation of vessel-like structures. 
To assess the function of CD34+ versus CD34- ECFC subsets to form tubes in vivo, 
CD34+ or CD34- ECFC were purified and injected subcutaneously into the flank of 
immunodeficient NOD/SCID mice within a Matrigel plug. After harvesting the plugs at 7 
days, Matrigel plug implanted with both the CD34+ and CD34- ECFC showed 
macroscopic areas of erythrocyte infiltration (Figure 3.11). Indeed, Matrigel plugs 
implanted with CD34+ or CD34- ECFC showed vessel-like structures that were HLA 
positive (Figure 3.12A) and infiltration of murine CD31 cells within the Matrigel was 
rare. The recruitment of murine endothelial cells into the Matrigel plug was equivalent to 
vehicle control (Figure 3.12B). Albeit a rare occurrence, the only interaction between 
human and mouse endothelial cells was found in the Matrigel plugs containing the CD34- 
ECFC (Figure 3.12C). These data suggested that in an in vivo setting, both the CD34+ 
and CD34- ECFC subsets equally generate vasculature at the site of transplantation. 
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Figure 3.11 ECFC had the capacity to vascularize Matrigel plugs in vivo. 
 
Figure 3.11 ECFC had the capacity to vascularize Matrigel plugs in vivo. Removal of 
7-day old subcutaneously transplanted Matrigel plugs revealed vascularized sites in 1 out 
of 5 Matrigel plugs containing CD34+ and CD34- ECFC (black arrows). (N=5). 
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Figure 3.12 Purified CD34+/- ECFC did not improve vascularization of Matrigel 
plugs after subcutaneous injection into immunodeficient mice. 
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Figure 3.12 Purified CD34+/- ECFC did not improve vascularization of Matrigel 
plugs after subcutaneous injection into immunodeficient mice. CD34+/- ECFC were 
purified and combined with mouse smooth muscle cells (SMC) and subcutaneously 
transplanted into NOD.SCID mice. The Matrigel plugs were extracted after 7 days and 
assessed for vessel formation within the implants. Vessel structures were visualized by 
(A) Immunofluorescent staining of human (HLA+) or mouse (HLA-) endothelial (CD31+) 
cells. Subsequent (B) quantification of human and mouse CD31+ cells revealed negligible 
recruitment of mouse-derived endothelial cells and a similar number of human cells 
within the scaffolds. Only the CD34- ECFC were observed to co-localize with mouse 
CD31+ cells as seen by (C) Immunofluorescent imaging (human cells – orange arrow; 
mouse endothelial cells – white arrows) Data represents the mean ± SD using ECFC 
derived from 5 UCB samples (N=5, P=0.16). 
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 Discussion 
ECFC remain the gold-standard of cultured progenitor-like endothelial cells that harbour 
potent pro-angiogenic properties in vitro and in vivo. Even though ECFC can be 
efficiently expanded in culture, the progeny of these cells lose proliferative capacity as 
the culture becomes more heterogeneous20. Therefore, the ability to define and propagate 
highly proliferative progenitor cells within heterogeneous ECFC cultures would enable 
the use of a potent pro-vascular cell population for vascular therapies. In this study we 
assessed a combination of known progenitor cell functions and cell surface markers39, 40 
to elucidate a distinct progenitor cell subpopulation within ECFC cultures. By using in 
vitro assays to assess putative progenitor cell functions, we observed a reduced cell 
growth rate, tube-formation, and colony forming ability in the CD34+ ECFC. Next, we 
used an unbiased proteomic approach to compare membrane proteins between the 
CD34+/- ECFC subsets by mass spectrometry to identify novel cell surface markers which 
may enrich for progenitor-like cells in culture. Of the proteins identified, the membrane 
proteins highly expressed on CD34+ ECFC suggested a mature endothelial cell surface 
phenotype. However, after sub-cutaneous transplantation into NOD.SCID mice, both the 
CD34+/- ECFC formed vessel-like structures in the Matrigel plugs.  
After assessing the expression of progenitor cell markers: ALDH, CD34, and CXCR4, 
both CD34+ and CXCR4+ cells were rare while >60% of ECFC demonstrated high 
ALDH-activity. Interestingly, ALDH-activity did not correlate with the expression of 
CD34 or CXCR4 as previously suggested by Ferreras et al.41. We next tested for the 
presence of intracellular stores of CXCR4 or CD34; a potential for rapid surface 
localization. Indeed, CXCR4 expression was located within the majority of ECFC which 
may be likely to localize to the membrane as a rapid response to microenvironmental 
changes42. After confirming the presence of the three prospective progenitor cell markers, 
we then determined the colony forming capacity of single ECFC purified from using each 
prospective progenitor marker. Due to the intracellular content of CXCR4, co-
localization with CD34, and similar colony forming ability to the CD34-sorted ECFC, we 
did not pursue other functional assays with the CXCR4-sorted ECFC.  
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Using our culture conditions, sorting based on ALDH-activity did not significantly 
change colony forming capacity of the ECFC subsets. We also demonstrated that 
selection based on ALDH function did not impact the tube forming capacity of the cells. 
However, purified CD34+ ECFC formed significantly fewer colonies and tubules in vitro 
than the CD34- ECFC, similar to Ferraras et al.41. Conversely, other studies have 
suggested that CD34+ ECFC have an increased capacity to form tube-like structures in 
vitro38, 43. The divergence of our results from the other studies may have been due to the 
differences in ECFC tissue source and/or differences in culture technique. Next we 
identified a relationship between cell density and CD34 expression as proposed by Tasev 
et al.38. However, the expression of other progenitor cell markers was unaffected after 
growing the ECFC at high density. To further demonstrate the dynamic nature of CD34 
expression, we assessed ECFC proliferative capacity alongside the CD34+ cell frequency 
over the course of a 7-day culture without passaging the cells. This enabled us to identify 
that ECFC could up- or down-regulate CD34 expression based on the density of the 
ECFC in culture. Of note, the CD34+ cell frequency began to increase after the 
exponential phase of the ECFC growth ended, indicating that CD34 expression increases 
rapidly upon confluence. While monitoring cell expansion, we also noted that the CD34- 
ECFC expanded faster than the CD34+ ECFC but the stationary phase of ECFC 
expansion occurred at approximately the same cell density between the CD34+ and the 
CD34- ECFC. These findings suggest that CD34- ECFC demonstrated higher proliferative 
potential41 during the exponential phase of cell expansion but the ECFC growth arrested 
at a similar density. We also assessed the potential for the CD34+ cell frequency to 
increase or decrease during culture expansion of ECFC over several passages. Although 
the CD34 frequency was highest immediately after expansion (40% at passage 1), our 
previous results suggested that the high density of the established colonies may increase 
the CD34 cell frequency before re-plating the cells as a monolayer. After this point, the 
CD34+ cell frequency decreased to a steady state at passage 2 - 5 for each ECFC line 
tested. Finally, because the CD34 expression on ECFC was dynamic and increased 
during confluency, we wanted to assess the impact of confluency on endothelial cell 
function in vitro. Although CD34+ cell frequency increased in confluent conditions, the 
statistical differences in clonogenicity and tubule forming capacity observed between the 
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CD34+/- ECFC in non-confluent conditions were abrogated when ECFC were cultured in 
confluent conditions. Thus, this transient state of increasing CD34 expression on ECFC 
appeared to be in response to the microenvironment while lacking a functional 
consequence. These findings suggest the need to standardize culture conditions to 
minimize culture artifacts when comparing studies with ECFC isolated across different 
tissue types. 
Given the functional differences observed between the CD34+ and CD34- ECFC subsets 
in vitro, we compared global cell surface protein expression using mass spectrometry 
identify prospective progenitor cell surface markers. Interestingly, mature endothelial cell 
surface markers such as CD31, ACE, VEGFR2, and ANGPT2 were expressed at 
significantly higher levels in CD34+ ECFC compared to CD34- ECFC. Alternatively, the 
proteins more highly expressed on the surface of the CD34- ECFC were not proteins with 
obvious endothelial cell association. One protein of interest on the CD34- ECFC was 
AXL; a protein tyrosine kinase which regulates cell proliferation and survival44. AXL is 
also a protein postulated to attenuate immune responses45, a function of progenitor cell 
pools in tissues with low turnover rates46; a characteristic of endothelial cell populations 
in vivo47. Ultimately, a major limitation in this study was the lack of available human-
specific antibodies for flow cytometry as a means of prospective cell isolation. For 
example, the antibodies we tested for COL13A1 and AXL did not detect cell surface 
expression for these proteins. However, once permeabilized, these antibodies detected the 
protein expressed in almost 100% of ECFC. This may be due to either the antibody 
binding to an intracellular epitope or that the protein is anchored on the membrane but is 
only exposed intracellularly; a limitation of the methodology used for isolating 
membrane-bound proteins. We also tested an antibody for ACE which we validated to be 
highly co-expressed with CD34 with reduced expression on the CD34- ECFC. This 
marker was a promising prospect because the CD34+ ECFC which could form colonies 
and tubules in vitro may have been explained by the ACE-/CD34+ ECFC. Unfortunately, 
sorting ACE+/- ECFC, revealed no differences in the generation of colonies after single 
cell deposition. Similar to CD34 expression on endothelial cells, the expression of ACE 
has been previously demonstrated to be linked to cell density48.  
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Our study suggests that CD34 expressed on endothelial cells after culture in vitro does 
not represent the same populations mentioned in studies where CD34 is used to 
prospectively isolate endothelial progenitor cells directly from tissue sources. Endothelial 
cell phenotype plasticity is also described in the literature with changes in endothelial cell 
phenotype after establishment in vitro49, 50. The results of the in vivo transplantation 
studies suggest that CD34+ and CD34- ECFC subsets responded to the in vivo 
environment equally even though obvious functional differences were observed in vitro. 
Thus, this may be suggestive that in vitro assays, need to be supported by in vivo studies 
to assess the functions of endothelial progenitor cells relevant to cell therapy applications. 
Collectively, our in vitro data suggest that CD34+ ECFC represent a more functionally 
mature endothelial cell population with a diminished ability to form tubes/colonies in 
vitro. In addition, CD34+ ECFC showed increased expression of mature endothelial cell 
surface markers. However, after transplanting the CD34+ and CD34- ECFC subsets in 
vivo, functional differences in cell survival, tube formation and murine endothelial cell 
recruitment were minimal between these populations. Both ECFC subsets formed vessel-
like structures in the Matrigel plugs containing a similar number of human cells per mm2. 
Although contradictory to similar experiments performed on placental derived ECFC, we 
observed functional overlap similar to CD34+ peripheral blood-derived ECFC. Thus, 
differences in cell source, isolation procedure and culture techniques could be responsible 
for functional differences between these studies. Alternatively, these differences could be 
due to cultivating different endothelial cell populations that are commonly defined as 
ECFC by their late outgrowth, expression of endothelial cell markers and high 
proliferative potential. Nevertheless, standardization for the isolation, culture, and 
phenotype of ECFC should be addressed for continuity in the potential use of these cells 
in regenerative therapies.  
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Chapter 4  
4 Methods for the analysis of cells seeded in matrix-
derived bioscaffolds using flow cytometry. 
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 Introduction 
Decellularized biomaterials have proven useful in a diverse array of cell therapy 
applications ranging from the development of wound healing matrices to the generation 
of intact organ scaffolds suitable for tissue engineering1, 2. Although diverse sources of 
biomaterials exist, the use of naturally-derived materials have provided insight into the 
supportive interactions between the cell and external environment3-6. 
Immunohisochemistry (IHC) has been an extremely useful tool to elucidate cellular 
distribution and functions within bioscaffolds7, 8. However, IHC is laborious and 
relatively low throughput and does not enable absolute quantification of cell 
populations/frequencies unless serial sections are analyzed. Thus, novel methodologies 
are required to enable high throughput analyses of seeded biomatrices. The utility of flow 
cytometry in a decellularized bioscaffold setting is far reaching as it could enable the 
investigation of protein and/or gene expression from selected cell types. Furthermore, 
flow cytometry used in conjunction with IHC analyses of decellularized bioscaffolds can 
provide insight into cellular distribution as well as quantifying the frequencies of cell 
phenotypes in vitro and in vivo. 
Flow cytometry is a powerful technique for the multi-parametric analysis of individual 
cells within heterogeneous cell populations. Furthermore, flow cytometry has proven 
instrumental in the identification of rare cell types isolated within whole tissues or 
cultured cells9. Although flow cytometry is a very sensitive and high-throughput 
technique, there are limitations associated with any modality that uses visible light to 
interrogate cell phenotype. Both autofluorescence and spectral overlap of fluorochromes 
are important considerations when developing a multichromatic flow cytometric panel10. 
The source for autofluorescence within tissue matrices arises largely from the type and 
abundance of aromatic amino acids within protein structures11. Although many proteins 
are fluorescent in nature, collagen is a highly abundant ECM protein with strong 
fluorescent properties that complicates the analyses of cellular components from any 
solid tissue or ECM-derived scaffold12. Moreover, many ECM proteins demonstrate 
broad emission spectral patterns between 350 and 550 nm, which makes wavelengths 
closer to the far-red end of the spectrum most practical for imaging purposes12.  
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Various techniques have been developed to help minimize autofluorescence, but many of 
these methods rely on the addition of dyes to quench the autofluorescent signals13, 14. The 
caveat with these methods is that many of the quenching dyes are also fluorescent in the 
visible light spectra, which make them cumbersome in multichromatic flow cytometric 
applications. Having to deal with background autofluorescence from the ECM forces the 
selection of epitopes producing the most intense signal to maximize the resolution 
between background autofluorescence and true fluorescent signal. Thus, there remains an 
unmet need to develop protocols whereby ECM contamination is minimized to enable the 
high-throughput characterization of cells extracted from ECM-derived scaffolds by 
multichromatic flow cytometry without the use of quenching dyes. 
Historically, immunohistochemistry or immunofluorescence microscopy has been 
typically performed to characterize protein expression by cells seeded within ECM-
derived scaffolds7, 15. Recognizing the potential utility of flow cytometry as a 
complementary method for high throughput cell analysis, this study focused on the 
development of protocols for the efficient extraction and analysis of adherent human cell 
populations seeded within decellularized scaffolds. The objective was to identify 
conditions that would enable the isolation of highly purified cell populations with 
retained cell viability and phenotype. To demonstrate the broad utility of these methods, 
cell viability and immunophenotype were assessed by flow cytometry using highly 
adherent human endothelial colony forming cells (ECFC) or mesenchymal stromal cells 
(MSC) seeded on ECM-derived foams fabricated from human decellularized adipose 
tissue (DAT), porcine decellularized cartilage tissue (DCT), or commercially-available 
purified bovine collagen (COL). The selection of the foam format provided a more 
uniform platform for exploring the effects of the different ECM sources16. Enzymatic 
digestion with TrypLE expressTM, LiberaseTM, or collagenase were compared to identify 
the protease formulation that generated the purest cell preparations while minimizing 
background interference associated with autofluorescent scaffold debris, to enable 
reliable population analyses throughout the visible spectrum.  
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 Methods 
4.2.1 Human adipose tissue decellularization. 
Human adipose tissue was obtained with informed consent from elective lipo-reduction 
surgeries at the London Health Sciences Centre with Human Research Ethics Board 
approval from Western University (REB # 105426). Fresh adipose samples were 
transported on ice in sterile cation-free Dulbecco's phosphate buffered saline (Wisent 
Inc., Montreal, Quebec) supplemented with 2% bovine serum albumin (BSA). Adipose 
tissue was prepared by removing cauterized segments and large blood vessels and then 
processed following an established 5-day detergent-free decellularization protocol that 
involves mechanical disruption, enzymatic digestion, and polar solvent extraction17.  All 
DAT was rinsed with double distilled water (DDH2O) and frozen at -80 
oC before being 
lyophilized and stored for use. 
4.2.2 Porcine cartilage decellularization. 
Fresh porcine ears were collected from a local abattoir. The dermis was removed, and the 
porcine auricular cartilage was surgically extracted and cryomilled to enhance the contact 
area with the decellularizing agents. The cartilage was decellularized following methods 
adapted from Xu et al18. All steps were performed at 37 oC. In brief, the tissue was 
subjected to three freeze-thaw cycles in 10 mM Tris buffer (pH 8.0) (Sigma Aldrich, St. 
Louis, Missouri) before being placed in an extraction solution containing 1.5 M KCl and 
2% Triton X-100 (Sigma Aldrich) for 48 h, with solution changes twice per day. 
Subsequently, the tissue was rinsed 3 times in Sorensen’s phosphate buffer (SPB) 
solution (Sigma Aldrich) for 30 min, followed by digestion in SPB supplemented with 
12.5 mg RNase Type III A (from bovine pancreas) and 15,000 U DNase Type II (from 
bovine pancreas) (Sigma Aldrich) for 5 h. After digestion, the samples were transferred 
into 50 mM Tris buffer supplemented with 1% tributyl phosphate (TBP) (Sigma Aldrich) 
for 48 h, replaced twice per day. Subsequently, the samples were rinsed three times in 
DDH2O for 30 min, and three times in Dulbecco's phosphate buffered saline (D-PBS) for 
30 min. Finally, the tissue was incubated for 48 h in 50 mM Tris buffer (pH 9.0), with 
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solution changes 2 times per day. At the end of the process, the DCT was rinsed 3 times 
in DDH2O, and frozen at -80 
oC before being lyophilized.  
4.2.3 Bovine collagen scaffolds. 
Commercially available, lyophilized bovine tendon collagen type 1 (Advanced 
Biomatrix, Carlsbad, California) was used as a third extracellular matrix source. 
4.2.4 ECM-derived foam fabrication. 
DAT, DCT, or commercially-available purified bovine collagen (COL; Tendon source, 
Advanced Biomatrix, Carlsbad, California) were lyophilized for a minimum of 48 h and 
minced finely with scissors to 1-2 mm2 pieces. Following established methods, the ECM 
samples were cryomilled, digested with 1% (w/w) α-amylase, resuspended in 0.2 M 
acetic acid (Sigma Aldrich), homogenized and stored at 4 oC until use19, 20. The ECM 
suspensions were diluted with 0.2 M acetic acid to a concentration of 25 mg/mL based on 
the starting mass of ECM. Following previously-established protocols17, 200 μL of each 
ECM suspension was transferred into individual wells in 48-well plates and frozen at -80 
oC before being lyophilized. Prior to cell seeding, the scaffolds were slowly rehydrated 
through an ethanol series (95, 90, 85, 80, 75, 70, 50, 25, and 0% diluted in sterile D-
PBS). Rehydrated foams were incubated in cell-type specific culture media overnight 
prior to use.  
4.2.5 Human progenitor cell isolation and culture. 
Mesenchymal stromal cells. Human bone marrow aspirates were obtained from healthy 
donors with informed consent from the London Health Sciences Centre (London, ON). 
All studies were approved by the Human Research Ethics Board at Western University 
(REB # 12934). Mononuclear cells (MNC) were isolated via Hypaque-ficoll 
centrifugation and seeded on tissue culture polystyrene at 270,000 cells/cm2. Adherent 
stromal colonies (CFU-fibroblast) were established within 14 days and expanded in 
Amniomax media + supplement (Life Technologies, Carlsbad, CA). Established MSCs 
were cryopreserved at passage 2 used for experiments at passage 4. 
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Endothelial colony forming cells. Human ECFC were derived from lineage-depleted 
(Lin-) MNC from umbilical cord blood, as previously described21. Briefly, the Lin- MNC 
were plated on tissue culture polystyrene at 70,000 cells/cm2 in endothelial growth media 
(EGM) (Lonza). Media was changed every 3 days for up to 14 days when colonies 
became confluent. Cells were lifted with TrypLETM express and re-plated at 4000 
cells/cm2. ECFC were cryopreserved at passage 2 and used for experiments at passage 4.  
4.2.6 Scaffold Seeding. 
The day before seeding, the scaffolds were incubated overnight in the cell-type specific 
media (37 oC, 5 % CO2). Each cell type was harvested with TrypLE
TM Express enzyme, 
counted, and 250,000 cells were seeded onto each scaffold in 48-well plates containing 1 
mL of growth media for their respective cell types and the plates were incubated at 37 oC 
overnight. 
4.2.7 Protease preparation. 
To extract cells from each scaffold type, 3 different proteolytic enzyme preparations were 
used: TrypLE expressTM (ThermoFisher), LiberaseTM TL research grade (Sigma Aldrich), 
and Worthington’s Type I Collagenase (Wisent). The TrypLE expressTM was used in 
stock concentration containing EDTA. Both the LiberaseTM TL and Worthington’s Type I 
collagenase were reconstituted within 2 h of use. To reconstitute the LiberaseTM TL, 5 mg 
of LiberaseTM TL was dissolved in 25 mL of Dulbecco's PBS (ThermoFisher) to obtain a 
concentration of 0.5 Collagenase Wünsch units/mL. Briefly, LiberaseTM is a proteolytic 
cocktail containing highly purified collagenase I and II, blended in specific ratios with the 
neutral protease, Thermolysin. Worthington’s type I collagenase was reconstituted at 2 
mg/mL (Worthington, Columbus, Ohio) in Krebs Ringer bicarbonate buffer 
supplemented with 20 mg/mL bovine serum albumin, 3 mM glucose, and 25 mM 
HEPES, equaling 0.25 Collagenase Wünsch units/mL. 
4.2.8 Determining scaffold autofluorescence. 
Acellular DAT, DCT or COL scaffolds were incubated at 37 oC in 1 mL of TrypLE 
expressTM, LiberaseTM, or collagenase for 1 hour. Samples were vortexed every 15 
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minutes and subsequently filtered using a 50 µM cell strainer prior to analysis. For the 
flow cytometric analyses, an unstained cell suspension collected from tissue culture 
plastic (TCP) was used to set the fluorescence thresholds prior to measuring fluorescence 
of the scaffold samples.  
4.2.9 Cell extraction methodologies for flow cytometry. 
Cell filtration. Seeded DAT, DCT, and COL scaffolds were rinsed once in PBS and 
transferred to a 5 mL tube containing 1 mL of either Collagenase, LiberaseTM, or TrypLE 
expressTM. The samples were incubated in a 37oC water bath and agitated gently every 15 
min for 1 h. Samples were incubated for 30 min, 45 min, and 1 h to determine what 
incubation time maximized cell purity and yield. Subsequently, samples were filtered 
using 50 µM filters (Sysmex, Kobe, Japan) and centrifuged at 350 x g for 5 min. To 
determine sample purity, each cell preparation was incubated in Calcein AM (Sigma) 
stain for 15 min to distinguish cellular content from debris by flow cytometry. All flow 
cytometric data was obtained using an LSR II flow cytometer (Beckton Dickenson), and 
analysis was performed using FlowJo software (Treestar, Ashland, OR). 
Density gradient. Seeded DAT, DCT, and COL scaffolds were rinsed in PBS and 
transferred to 5 mL tubes containing 1 mL of LiberaseTM. To maximize cell dissociation, 
LiberaseTM was used because it was the strongest protease cocktail containing the most 
diverse combination of proteases. Samples were incubated in a 37oC water bath and 
vortexed every 5 min for 15 min until the scaffold structure was evenly homogenized. 
Sample preparations were layered on 500 µL of Hypaque ficoll density gradient (GE 
Healthcare, Chicago, IL) and centrifuged at 450 x g for 10 min. Cells were collected at 
the ficoll-sample interface and filtered using a 50 µM filter. Sample preparations were 
washed in PBS to dilute residual ficoll and samples were spun at 450 x g for 5 min to 
pellet the cell sample. 
4.2.10 Determining cell viability. 
For the cell filtration method, cells were extracted from each of the decellularized 
scaffold types (DAT and DCT) using TrypLE express TM to minimize the generation of 
scaffold debris. Cells extracted from the COL scaffolds were incubated in collagenase as 
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it contained the least amount of non-collagenase proteases. For the density gradient 
method, cells were extracted from each of the decellularized scaffold types (DAT and 
DCT) using LiberaseTM because it contained the highest amount of Wünsch units/mL of 
the collagenase-containing enzyme cocktails. Cell viability from the scaffolds was 
determined by staining the extracted cells with Annexin V (Biolegend, San Diego, 
California), DRAQ5 (ThermoFisher), and Calcein AM. The frequency of apoptotic cells 
was assessed by enumerating Calcein AM+Annexin V+ cells, while dead cell frequency 
was determined by quantifying Calcein AM-DRAQ5+ cells. Cell staining was performed 
according to the manufacturer’s instructions. 
4.2.11 Antibody staining. 
To determine if cell phenotype was affected by the proteolytic enzyme digestion 
methods, MSC were stained with a multichromatic flow cytometric panel 22 containing 
conjugated antibodies targeting stromal cell markers: CD73, CD90, and CD105 and the 
pan leukocyte marker: CD45. 
4.2.12 MSC and ECFC co-culture on scaffolds. 
To determine if the enzymatic treatment preferentially released MSC or ECFC seeded 
within scaffolds, the cells were co-cultured at a 1:2, 1:1, and 2:1 ratio. After cell 
extraction, cells were stained with CD31 and CD90 to discern ECFC and MSC 
respectively. 
4.2.13 Statistics. 
Each assay was repeated a total of 3 times. All data is presented as the mean ± standard 
deviation (SD). For the analysis of significance, a one-way ANOVA with Tukey’s 
multiple comparisons test was performed using Graphpad Prism software. 
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 Results 
4.3.1 Digested bioscaffolds produce autofluorescent debris that 
complicate flow cytometric analyses.  
The characterization of cells extracted from ECM-derived scaffolds with optics-based 
modalities can be impeded by the autofluorescent properties of the ECM materials. To 
assess the extent of non-specific event detection associated with debris from scaffolds 
fabricated with varying ECM sources, the autofluorescent properties of 3 bioscaffolds 
(human DAT, porcine DCT, and purified bovine COL) digested for 1 hour with the three 
different enzyme formulations were first assessed in the absence of cells. Due to the 
heterogeneous makeup of the decellularized ECM, debris particles generated by the 
TrypLE expressTM-digested DAT scaffolds showed significant autofluorescence 
throughout the visible spectrum (450 nm - 780 nm). Autofluorescence was most 
pronounced using the violet – blue excitation lasers (>95% of events were 
autofluorescent at 450 – 610 nm emission) and was reduced when using yellow - green or 
red excitation lasers (~60% – 70% of events were autofluorescent at 582 – 780 nm 
emission) (Figure 4.1A). In a side-by-side comparison, LiberaseTM and collagenase-
digested DAT showed considerable autofluorescent events in all emission wavelengths 
from every excitation laser source (Figure 4.1B, C). Similar to the DAT scaffold, the 
autofluorescent spectra of the DCT digested with TrypLE expressTM was most 
pronounced using the violet – blue excitation lasers (>90% of events at 450 – 610 nm 
emission) compared to the yellow-green or red excitation lasers (~20% – 50% of events 
at 582 – 780 nm emission) (Figure 4.2A). Similarly, use of LiberaseTM or collagenase on 
the DCT generated more autofluorescent scaffold particles across every channel (Figure 
4.2B, C). Finally, LiberaseTM TL or Worthington’s Type 1 Collagenase treatment 
resulted in complete digestion of the more homogeneous bovine COL scaffolds (Figure 
4.3B, C). In contrast to the other ECM sources, TrypLE expressTM digestion was the only 
condition that generated autofluorescent particles for this material. Autofluorescent 
particles were most pronounced using the violet laser (~75-95% of events at 450 – 610 
nm emission), as compared to the blue, yellow – green, or red excitation lasers (~15% – 
80% of events at 530 – 780 nm emission) (Figure 4.3A). Thus, the presence of 
autofluorescent scaffold debris within each sample preparations had the potential to 
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complicate flow cytometric analyses of cells enzymatically extracted from the scaffold 
after seeding. 
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Figure 4.1 Enzyme digested DAT particles were autofluorescent across the visible 
spectrum. 
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Figure 4.1 Enzyme digested DAT particles were autofluorescent across the visible 
spectrum. After treating unseeded DAT with (A) TrypLE ExpressTM, (B) LiberaseTM, or 
(C) Collagenase for 1 hour at 37oC, the digested scaffold was analyzed for 
autofluorescent particles by flow cytometry. Digested DAT produced autofluorescent 
events across the visible spectrum (450 - 780 nm). Autofluorescence was most 
pronounced when excited by the violet – blue laser (>95% of total events at 450 – 610 
nm emission), reduced when using yellow - green or red excitation lasers (~60% – 70% 
of total events at 582 – 780 nm emission). However, the autofluorescent properties were 
most pronounced across all emission spectra when collagenase was used. Data represents 
mean ± SD (N=3). 
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Figure 4.2 Enzyme digested DCT was autofluorescent across the visible spectrum. 
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Figure 4.2 Enzyme digested DCT was autofluorescent across the visible spectrum. 
After treating unseeded DCT with (A) TrypLE ExpressTM, (B) LiberaseTM, or (C) 
Worthington’s type I collagenase for 1 hour at 37oC, the digested scaffold was analyzed 
for autofluorescent particles by flow cytometry. Digested DCT produced autofluorescent 
events across the visible spectrum (450 - 780 nm). Autofluorescence was most 
pronounced across all channels when the DCT was digested using collagenase. In all 
cases, scaffold autofluorescence was the most pronounced when excited by smaller 
wavelength light sources (i.e. Violet-Blue) while autofluorescence from longer 
wavelength excitation sources was produced to a lesser degree. Data represents mean ± 
SD (N=3). 
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Figure 4.3 Enzyme digested pure bovine collagen was autofluorescent across the 
visible spectrum. 
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Figure 4.3 Enzyme digested pure bovine collagen was autofluorescent across the 
visible spectrum. After treating unseeded collagen with (A) TrypLE ExpressTM, (B) 
LiberaseTM, or (C) Worthington’s type I collagenase for 1 hour at 37oC, the digested 
scaffold was analyzed for autofluorescent particles by flow cytometry. Digested collagen 
produced autofluorescent events across the visible spectrum (450 - 780 nm). When 
digested with trypsin, collagen autofluorescence was the most pronounced when excited 
by smaller wavelength light sources (i.e. Violet-Blue) while autofluorescence from longer 
wavelength excitation sources was produced to a lesser degree. Due to complete 
solubilization of the collagen scaffold, digest preparations with Liberase and collagenase 
were unable to be detected via flow cytometry. Data represents mean ± SD, (N=3). 
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4.3.2 Scaffold debris obscures cell populations visualized by flow 
cytometry. 
Next, ECFC (Figure 4.4) or MSC (Figure 4.5) seeded within scaffolds for 24 hours were 
enzymatically extracted and analyzed by flow cytometry for relative cell size (forward 
scatter) and cell complexity (side scatter). Calcein AM was used to discern live cellular 
content from the scaffold debris. Because protease cocktails such as LiberaseTM TL or 
Worthington’s Type I Collagenase primarily digest scaffold proteins, sample preparations 
from DAT (Figure 4.4A, Figure 4.5A) or DCT (Figure 4.4B, Figure 4.5B) were 
comprised of a heterogeneous mixture of cells and scaffold debris. Although filtering the 
sample preparation was required to ensure large debris particles did not clog the fluidics 
system on the flow cytometer, filtering in fact, did not eliminate debris events that 
obscured cells usually discerned by forward versus side scatter selection. In contrast, 
LiberaseTM or Collagenase treatment of more highly purified bovine COL scaffolds 
resulted in complete scaffold digestion, yielding primarily cellular events (Figure 4.4C, 
Figure 4.5C).  Taken together, these data indicated that digestion of decellularized 
tissue-based scaffolds using collagenase-containing enzyme cocktails produced 
autofluorescent debris that could obscure cellular events.  
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Figure 4.4 Debris particles from digested ECM obscured ECFC detected by flow 
cytometry. 
Figure 4.4 Debris particles from digested ECM obscured ECFC detected by flow 
cytometry. ECFC were seeded into DAT, DCT or bovine collagen matrices, cultured for 
24h, and processed using digestive enzymes to release cells for subsequent analyses by 
flow cytometry. Cells (red dots) were visualized using Calcein AM and overlaid with the 
Calcein AM negative scaffold debris (blue dots) for each enzymatic treatment. Seeded 
(A) DAT and (B) DCT scaffolds treated with LiberaseTM or collagenase produced 
forward scatter (FSC) and side scatter (SSC) profiles where cellular events were obscured 
by scaffold particles. In contrast, DAT and DCT scaffolds treated with TrypLE 
ExpressTM generated discernable cellular events with fewer contaminating scaffold 
particles. (C) Bovine collagen scaffolds showed almost complete digestion with few 
contaminating events after LiberaseTM or collagenase treatment. Flow cytometry plots are 
representative of 3 ECFC samples (N=3) seeded into each scaffold type and digested by 
each enzyme.  
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Figure 4.5 Debris particles from digested ECM obscured MSC detected by flow 
cytometry. 
Figure 4.5 Debris particles from digested ECM obscured MSC detected by flow 
cytometry. MSC were seeded into DAT, DCT or bovine collagen matrices, cultured 
overnight, and processed using digestive enzymes to release cells for subsequent analyses 
by flow cytometry. Cells (red dots) were visualized using Calcein AM and overlayed 
with the Calcein AM negative scaffold debris (blue dots) for each enzymatic treatment. 
Seeded (A) DAT and (B) DCT scaffolds treated with LiberaseTM or collagenase produced 
forward scatter (FSC) and side scatter (SSC) profiles where cellular events were obscured 
by scaffold particles. In contrast, DAT and DCT scaffolds treated with trypsin generated 
discernable cellular events with fewer contaminating scaffold particles. (C) Bovine 
collagen scaffolds showed almost complete digestion with few contaminating events after 
LiberaseTM or collagenase treatment. Flow cytometry plots are representative of 3 MSC 
samples (N=3) seeded into each scaffold type and digested by each enzyme.  
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4.3.3 TrypLE expressTM digestion enabled cell preparation suitable 
for flow cytometry 
To optimize the methodology to extract cells from bioscaffolds, ECFC or MSC were 
seeded into DAT, DCT and COL scaffolds for 24 hours. After extraction, cellular events 
were clearly identified by gating for Calcein AM+ events (Figure 4.6A). Although use of 
collagenase-containing proteases on DAT and DCT bioscaffolds produced sample 
preparations with abundant scaffold debris (<30% of total events detected were cells), 
TrypLE expressTM -digestion, generated sample preparations with >92% cellular events 
as measured by Calcein AM positive cells (Figure 4.6B, C). However, for the COL 
scaffolds, TrypLE expressTM digestion yielded substantial debris (<70% cell purity), 
while the collagenase-containing proteases completely digested the ECM resulting in cell 
purities of >95% (Figure 4.6D). The purity of the sample preparations did not differ 
significantly with treatment time or when comparing endothelial or mesenchymal cell 
types seeded in bioscaffolds. Therefore, digestion with TrypLE provided the purest 
sample preparation for the decellularized tissue-based materials, while cells within the 
more homogeneous COL matrices were best released by collagenase-containing enzyme 
cocktails. 
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Figure 4.6 TrypLE ExpressTM-treated bioscaffolds produced cell preparations 
suitable for flow cytometry.
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Figure 4.6 TrypLE ExpressTM-treated bioscaffolds produced cell preparations 
suitable for flow cytometry. To broadly determine the best methodology to extract cells 
from various bioscaffolds, we seeded ECFC or MSC into DAT, DCT, or bovine collagen 
preparations for 24h. In addition, (A) Representative flow cytometry dot plots 
demonstrate our gating strategy using Calcein AM to distinguish live cellular events from 
debris after treatment with LiberaseTM. We then tested 3 protease cocktails: TrypLE 
expressTM, LiberaseTM, and Worthington’s type I collagenaseTM treatment for 30 minutes, 
45 minutes, or 1 hour. Trypsin-treatment of (B) DAT and (C) DCT preparations achieved 
high cell purity (>92%) by flow cytometry. In contrast, (D) bovine collagen preparation 
achieved optimal purity (>95%) using Liberase or collagenase. Data represents mean ± 
SD for 3 ECFC and MSC samples (N=3).  
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4.3.4 Cell extraction efficiency was proportional to the length of 
enzymatic treatment. 
To assess cell yield after seeding and culture, cells were extracted using the most 
favourable enzymatic conditions identified in the previous studies for each scaffold group 
and cell viability was enumerated by trypan blue exclusion. The highest MSC and ECFC 
yield was achieved from scaffolds treated for 1 hour at 37 oC (Figure 4.7A, B). Cell 
extraction efficiency was quantified by the cell yield from the scaffolds divided by the 
seeding efficiency. Briefly, the seeding efficiency is equal to the minuend between the 
initial plating number and the cell number that did not seed into the scaffolds. Notably, 
MSC extraction efficiency was ~46% in TrypLE expressTM -treated DAT and was further 
reduced in DCT bioscaffolds. In contrast, cell yield extracted from bovine collagen was 
nearly 100% of the initially seeded dose. This suggests that not all MSC were being 
completely liberated from the DAT or DCT scaffolds. Interestingly, ECFC did not 
efficiently detach from the DAT or DCT scaffolds (Figure 4.7A), with only ~15% cell 
extraction efficiency achieved at 1-hour TrypLE expressTM digestion. Because of the 
differences observed between the yields of each cell type, the potential for the enzyme 
efficiency to vary on a cell-type basis was assessed. The MSC and ECFC were mixed and 
seeded in specific ratios on both DAT and DCT scaffolds (Figure 4.7C, D) and the cell 
frequencies of extracted cells from both scaffolds matched the starting ratios, indicating 
that there was no cell-specific selectivity after TrypLE expressTM treatment.  
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Figure 4.7 Cell extraction efficiency is proportional to protease treatment time. 
 
Figure 4.7 Cell extraction efficiency is proportional to protease treatment time. For 
cell extraction efficiency quantification, the enzymatic conditions that yielded the highest 
purity for each scaffold type was selected. For DAT and DCT, trypsin was used and for 
bovine collagen scaffolds, collagenase was used. For the extraction of (A) ECFC and (B) 
MSC from the DAT scaffolds, trypsin treatment of 1 hour produced the greatest cell 
yield. The dotted line represents the number of cells plated. To determine if MSC or 
ECFC were selectively liberated from the DAT or the DCT upon exposure to trypsin, we 
seeded specific ratios of ECFC and MSC and analyzed the ratio of cells coming off the 
scaffolds using flow cytometry. Both of the (C) DAT and (D) DCT scaffolds produced 
nearly identical ratios from what was initially seeded in the scaffolds. During these 
experiments, the pure bovine cartilage scaffolds were used as a positive control for cell 
yield because the scaffolds dissolved in solution. Data represents mean ± SD; (** P<0.01, 
*** P<0.0001, N=3). 
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4.3.5 Cell extraction using a density gradient improved cell purity, 
yield, and viability. 
Because the filtration method shown in Figure 4.7 produced suboptimal cell yield using 
trypLE expressTM treatment, another approach was used to try and improve cell yield. 
Given the impressive cell yield from the collagenase-treated condition in COL, digestion 
of the whole scaffold into small fragments may be the most efficient means to maximize 
the cell yield. To separate cells from debris, a density gradient was used in conjunction 
with LiberaseTM treatment. LiberaseTM was used as it contains a diverse set of proteases 
and caused substantial breakdown of the scaffold. The increased surface area of the 
homogenized scaffold material may maximize cell yield while minimizing protease 
exposure time. To remove the scaffold debris, the sample preparations were centrifuged 
on Hypaque-Ficoll and subsequently filtered after collecting cells from the mononuclear 
cell layer.  MSC purity of >99% was achieved, and the MSC yield was increased to 
approximately 75% in DAT scaffolds and approximately 50% in DCT scaffolds (Figure 
4.8A, B). Interestingly, the extraction efficiency of ECFC in either DAT or DCT did not 
improve using the ficoll-based isolation, suggesting ECFC extraction remained less 
complete compared to MSC. Because the COL scaffolds fully digested after protease 
treatment, this condition served as a positive control for determining cell yield. 
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Figure 4.8 Cell extraction using Hypaque-Ficoll improved cell purity, yield, and 
viability.
 
Figure 4.8 Cell extraction using Hypaque-Ficoll improved cell purity, yield, and 
viability. Both DAT and DCT were treated with LiberaseTM at 37oC and agitated every 5 
minutes for a total of 15 minutes until scaffolds dissociated. The (A) purity of the 
extracted ECFC and MSC was >99% and the (B) cell yield was >50% of cells seeded for 
MSC in either DAT or DCT. Interestingly, the cell yield for ECFC was <25% from either 
the DAT or DCT scaffolds. Assessing the viability of the MSC and ECFC in (C) DAT or 
(D) DCT resulted in a higher proportion of ECFC death. The frequency of apoptotic 
MSC was approximately 20% of cells in both the DAT and DCT. Data represents mean ± 
SD, (N=3). 
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4.3.6 Cell extraction did not impair detection of cell viability or cell 
surface phenotype. 
Although >95% cell purity was achieved after TrypLE expressTM treatment, the potential 
for enzymatic treatment to alter cell viability or surface antigen expression was assessed. 
Our gating strategy to determine cellular content was through selection using DRAQ5+ 
events (Figure 4.9A, B). Subsequently, cell viability was assessed through Calcein AM 
and Annexin V staining (Figure 4.9C, D). After treating the DAT scaffolds with TrypLE 
expressTM for 1 h at 37oC, the frequency of viable cells (Calcein+/DRAQ5+/Annexin V-) 
was high for both ECFC and MSC at 88 ± 2.9% and 85 ± 1.5% respectively (Figure 
4.9E, Figure 4.10), with ~12% apoptotic cells identified (Calcein+/DRAQ5+/Annexin-
V+). Importantly, when extracting ECFC and MSC from bovine COL scaffolds, the 
frequency of apoptotic cells was 63.9 ± 5.7% and 45.0 ± 10.6%, respectively indicating 
prolonged exposure to collagenase negatively affected cell viability (Figure 4.9D, E).  
When isolating cells using the density gradient isolation methods with LiberaseTM, the 
viability of MSC was 77 ± 8.7% while the ECFC was 76.3 ± 5.5%. Isolated MSC 
contained a negligible frequency of dead cells (0.3%) while the ECFC had ~10% dead 
cell content from both DAT and DCT sample preparations (Figure 4.8C, D).  
To assess if prolonged enzymatic treatment altered the detection of cell surface marker 
expression, MSC extracted from DAT scaffolds were stained using a multichromatic flow 
cytometry antibody panel consisting of 4 lineage-specific cell surface markers and for the 
viability marker Calcein AM. Each of the antibodies used in the multichromatic panel 
yielded nearly identical expression frequencies compared to previous work performed on 
tissue culture plastic22 using well-accepted stromal cell markers (>95% CD73+, CD90+, 
CD105+; Figure 4.11C, E) and lack of expression of the pan-leukocyte marker (<5% 
CD45+; Figure 4.11D, E). Thus, detection of cell surface antigen expression was not 
impaired by prolonged enzymatic treatments used for extraction. Taken together these 
data indicate viable cells expressing known cell surface markers could be quantified after 
prolonged enzymatic cell extraction procedures. 
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Figure 4.9 Prolonged enzymatic extraction reduced ECFC survival in collagenase-
treated bovine collagen bioscaffolds.
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Figure 4.9 Prolonged enzymatic extraction reduced ECFC survival in collagenase-
treated bovine collagen bioscaffolds. ECFC extracted from DAT bioscaffolds were 
stained with Calcein AM, Annexin V, and DRAQ5. Our gating strategy selected cells 
based on (A) forward versus side scatter, with (B) DRAQ5 to discern cells from debris, 
and ECFC seeded in (C) DAT or (D) bovine collagen were analyzed for Calcein AM to 
label viable cells and Annexin V to label phosphatidyl serine in the external leaflet of the 
plasma membrane of apoptotic cells. (E) Despite exposure to trypsin for 1 hour, 88 ± 
2.9% of ECFC were viable with 11 ± 2.8% of cells undergoing apoptosis. In contrast, 
prolonged exposure of the ECFC in collagenase resulted in 35.2 ± 5.6% ECFC viability, 
with 63.9 ± 5.7% of the cells undergoing apoptosis. Data represents mean ± SD for 4 
ECFC samples (N=4). 
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Figure 4.10 MSC viability was reduced in collagenase-treated bovine collagen 
bioscaffolds.
 
Figure 4.10 MSC viability was reduced in collagenase-treated bovine collagen 
bioscaffolds. To assess cell viability, we stained MSC extracted from decellularized 
adipose tissue scaffolds with Calcein AM, Annexin V, and DRAQ5. MSC seeded in 
decellularized adipose tissue or pure bovine collagen were subsequently analyzed for 
positive Calcein AM and Annexin V staining to determine sample viability. MSC 
extracted from DAT using TrypLE ExpressTM for 1 hour 85 ± 1.5% were viable with 14.9 
± 1.5% of the cells undergoing apoptosis. However, prolonged exposure of the collagen-
extracted MSC in collagenase resulted in 45 ± 10.6% of the cells becoming apoptotic. 
Data represents mean ± SD, (N=4). 
163 
 
Figure 4.11 Prolonged enzymatic treatment did alter predicted cell surface antigen 
detection.
 
Figure 4.11 Prolonged enzymatic treatment did alter predicted cell surface antigen 
detection. For DAT and DCT bioscaffolds, seeded MSC were extracted using TrypLE 
expressTM and LiberaseTM was used for MSC seeded in bovine collagen. Cell surface 
phenotype analyses using a 5-color flow cytometry panel revealed that (A, B) viable 
(Calcein+) MSC highly expressed (C, D) mesenchymal stromal markers (CD73, CD90, 
and CD105), but did not express the pan-leukocyte marker (CD45). Using this gating 
strategy each sample preparation was >98% viable. Similar to culture of MSC on tissue 
culture plastic, the frequency of stromal marker expression was >99% with hematopoietic 
marker expression (CD45) <6.5%. Data represents mean ± SD for 3 MSC samples (N=3). 
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 Discussion 
In this study, protocols were developed for the analysis of extracted cell populations 
seeded in decellularized adipose, cartilage, and collagen bioscaffolds using flow 
cytometry. The primary challenge was to acquire reliable data from adherent cells 
detached from 3-dimensional bioscaffolds while minimizing the generation of digested 
scaffold debris. When using enzymes with collagen-digestive functions, digestion of 
heterogeneous DAT and DCT scaffolds produced a plethora of autofluorescent particles 
with a forward versus side scatter profile that obscured analyses of the released cells. 
Importantly, analyses with contaminating autofluorescent debris could generate false 
positive events and aberrantly alter the detection of important biomarkers. Therefore, 
development of consistent methods to discern true cellular events from autofluorescent 
scaffold debris required careful optimization using scaffold-specific enzymatic digestion 
protocols and cell marking dyes to minimize false positive events detected by flow 
cytometry.  
By altering 3 tested parameters: cell type, bioscaffold composition, and digestive enzyme 
exposure, we determined that adherent cell types (ECFC or MSC), seeded into 
bioscaffolds sourced from varying ECM sources (DAT or DCT), required prolonged 
digestion with TrypLE expressTM to generate a cell suspension suitable for flow 
cytometric analyses. If more aggressive protease treatments such as LiberaseTM is 
utilized, the duration of exposure should be reduced by dissociating the sample to 
maximize cell viability. The debris generated by LiberaseTM treatment required the use of 
density gradient centrifugation to purify the cell preparation and improve cell yield. To 
quantify the purity of sample preparations, Calcein-AM viability dye was an effective 
tool for discerning live cellular events from contaminating scaffold debris. Calcein AM 
exposure resulted in fluorescent accumulation in viable cells as the compound is 
metabolized by cytosolic esterase activity23. Fortunately, Calcein AM produced a signal 
notably brighter than the autofluorescence exhibited by contaminating scaffold particles. 
Ultimately, this allowed us to modify cell extraction methodologies and maximize the 
signal to noise ratio. Using these optimized protocols, sample purity of >95% was 
consistently achieved when extracting cells from DAT and DCT using the filtration 
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method, potentially eliminating the requirement for Calcein-AM which occupies one of 
the most common detectors used for fluorochrome-conjugated antibody-mediated cell 
surface phenotype analyses by flow cytometry.   
The scaffolds used in these studies were fabricated from suspensions of cryomilled 
decellularized tissue particles pre-molded for use. The ability to shape these natural, cell-
supportive constructs greatly increases their versatility for use as a delivery vehicle for 
pro-regenerative cells in a clinical setting. However, milled constructs can also result in 
the generation of considerable debris after enzymatic digestion. Interestingly, differences 
between ECM composition were evident through distinct autofluorescent spectra 
observed between each tissue-derived scaffold type utilized in this study. 
If density gradients are not being utilized during sample preparation, TrypLE expressTM 
was the most effective enzyme treatment for producing a discernable cell suspension 
from the complex decellularized scaffolds such as DAT and DCT. Although Trypsin is 
unable to degrade intact collagen triple helices24, TrypLE expressTM can potentially 
degrade ECM-associated proteins. Both the DAT and DCT scaffolds treated with TrypLE 
expressTM did not generate scaffold fragments in solution, and large particle debris could 
be minimized by filtration prior to flow cytometry analyses. In agreement, previous 
studies have demonstrated that trypsin was unable to physically alter collagen-rich 
tissues25. In contrast, when collagenase or LiberaseTM were used, these enzyme mixtures 
primarily targeted abundant bioscaffold components and the macroscopic structure of the 
scaffolds readily broke down after collagen fragmentation, leaving behind debris that 
could obscure true cellular events assessed by flow cytometry. To minimize scaffold 
debris when using LiberaseTM, the use of a density gradient was required to effectively 
remove contaminating debris. The exception to this was the use of collagenase on the 
purified bovine COL scaffolds. This enzymatic treatment resulted in complete digestion 
and solubilization of the COL bioscaffold with minimal detectable autofluorescent 
scaffold debris. However, gentle digestion conditions with short duration are 
recommended when using commercially available enzyme cocktails as we observed cell 
viability was reduced after prolonged enzymatic treatment with collagenase. 
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Two cell types, MSC and ECFC were compared to determine if interactions between 
different cell types seeded within the various scaffolds would require different enzymatic 
treatments or exposure durations. Both adherent cell types required TrypLE expressTM 
incubation for an extended period (1h) to obtain sufficient cellular events for flow 
cytometric applications. When exposed to LiberaseTM, the ECFC and MSC required only 
15 minutes incubation before density gradient centrifugation. Regardless of the scaffolds, 
enzymatic treatment or methodological approach used, ECFC consistently showed a 
reduced cell yield. Because different enzymatic treatments did not preferentially liberate 
either ECFC or MSC when co-cultured, the low ECFC yield was likely due to reduced 
cell survival after enzymatic treatment. Although detected cell viability was similar 
between the MSC and ECFC, these methods cannot account for cells that have 
completely broken down after cell death. Interestingly, the disconnect between the ECFC 
cell yields and the ratio between ECFC and MSC after seeding may be explained by the 
pro-survival effect MSC exerts on ECFC26. Collectively, the most efficient methodology 
to maximize cell numbers was the use of collagenase-containing protease cocktails used 
in conjunction with density gradient centrifugation. For example, LiberaseTM produced 
higher cell yields from decellularized scaffold materials because the scaffolds were 
broken down entirely. Subsequent use of a density gradient was required to separate all 
the cellular components from the scaffold debris in solution. Importantly, prolonged 
exposure of cells to a collagenase-containing enzymatic digestion negatively impacted 
cell viability.  
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Chapter 5  
5 Transplantation of endothelial and mesenchymal 
progenitor cells in decellularized adipose tissue 
scaffolds for the recovery of acute ischemic injury. 
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 Introduction 
Peripheral artery disease (PAD) is characterized by atherosclerosis-induced ischemia in 
the extremities, and approximately 10 million individuals in North America are 
diagnosed with PAD1, 2. Although many PAD cases go unrecognized, critical limb 
ischemia (CLI), the most severe form of PAD, can develop. CLI is characterized by 
resting pain, non-healing ulcers, and increased risk of infection in the ischemic limb, 
leading to amputation in 25-30% of patients within one year of diagnosis. Within five 
years of diagnosis > 60% of patients will have died from cardiovascular complications3. 
The development of an effective means to treat PAD is critical to improve patient 
outcomes and reduce related health care costs associated with ischemic vascular diseases. 
Cellular therapies that promote the stimulation of angiogenesis, or the formation of new 
blood vessels from pre-existing vessels, is an attractive strategy to combat severe 
vascular diseases.  
The architecture and function of the cardiovascular system is crucial in maintaining 
homeostasis of all organ systems. The basic vascular structure is comprised of multiple 
cell types including endothelial cells, smooth muscle cells, and pericytes. In order to 
maintain well-functioning vasculature, these cell types synergistically function with 
hematopoietic cells to balance blood vessel growth and regression. In the context of 
vascular disease, these interactions are disrupted4. Endothelial colony forming cells 
(ECFC) spontaneously form tubules in vitro and directly incorporate into newly forming 
blood vessels in vivo5, 6. Although generally accepted as a pro-vascular cell type, other 
studies lack demonstration of ECFC incorporation into blood vessels7. Importantly, 
several studies have implicated ECFC as the building blocks of blood vessels during 
angiogenic processes after injury to the vasculature8. However, during chronic 
cardiovascular disease  ECFC numbers are depleted and ECFC dysfunction impairs 
angiogenic response to ischemia9.  
Perivascular cells, or pericytes, reside adjacent to the endothelial cell layer of blood 
vessels and act to promote vessel stability through paracrine and direct contact signaling 
mechanisms10. Although closely associated with endothelial cells, pericytes do not 
express common endothelial markers such as CD31, CD44, or von Willebrand factor 
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(vWF). However, CD146 is expressed on all pericytes and has been used to isolate 
pericytes from almost every adult organ and from fetal human tissue, including the 
umbilical cord and placenta. CD146+ cells expanded in vitro also express multipotent-
stromal cell (MSC) markers: CD73+, CD90+, and CD105+ without the expression of 
hematopoietic antigens (CD45)11. Importantly, expanded CD146+ pericytes associate 
with blood vessels after intramuscular (I.M.) transplantation into rats subjected to 
vascular injury12.  Whether referred to as pericytes or MSC, CD146+ cells efficiently 
expand adherent to plastic and can differentiate into three distinct mesenchymal lineages: 
fat, bone, and cartilage in vitro. Furthermore, allogenic MSC have been safely 
transplanted in patients following myocardial infarction to aid in repair and 
revascularization of cardiac tissue13. MSC are a readily available cell source which can be 
isolated from various human tissue such as bone marrow (BM), adipose tissue and 
umbilical cord blood.  
BM-derived MSC promote survival and proliferation of endothelial cells under hypoxic 
conditions in vitro14.  After transplantation, BM-MSC may incorporate into vascular 
structures as pericytes12, 15. However, the therapeutic benefit of BM-MSC is contingent 
on the local microenvironment such as ECM composition, growth factors and conditions 
such as hypoxia. Regardless, BM-MSC are able to home to sites of vascular injury 
signaling-axis and secrete factors such as vascular endothelial growth factor (VEGF) and 
platelet derived growth factor (PDGF) to support angiogenesis16. Mice receiving 
combinatorial xenograft transplantation comprised of endothelial cells with BM-MSC 
have shown increased vascularization and increased vessel stability15, 17. Multiple factors 
make combinatorial transplantation of MSC and ECFC an attractive strategy. Both MSC 
and ECFC can be readily obtained from autologous or allogeneic sources, they can be 
efficiently expanded ex vivo, and combined to support robust angiogenesis when 
transplanted into pre-clinical models of ischemic disease18.  
Many clinical trials have experienced modest outcomes after cell transplantation which 
may be attributed to transient cell engraftment or poor integration within host tissues19. 
Therefore, transplantation strategies which promote cell engraftment may provide long 
term benefit in a clinical setting. Due to recent development of innovative biomaterial 
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solutions, biological scaffolds have emerged as a promising means to augment recovery 
in patients while minimizing immunological responses in the patient. Biological scaffolds 
resemble the ECM component of a tissue encompassing structural proteins, cell-adhesion 
proteins, glycoproteins, and other extracellular signaling molecules found in native 
tissues20. These components of ECM are highly conserved across species and thus do not 
elicit detrimental immune responses in host tissues during xenotransplantation21. There 
are several commercially available biological scaffolds currently used in clinical trials 
demonstrating both safety and efficacy22. Clinically-relevant biological scaffolds can be 
derived from both synthetic and decellularized tissue sources23, where each scaffold type 
provides both advantages and disadvantages. Principally, synthetic scaffolds can be mass-
manufactured, physical properties can be tailored to meet the demands of specific 
applications, and synthetic scaffolds can be transplanted using minimally invasive 
techniques such as injection. However, synthetic scaffolds have been unable to entirely 
recapitulate the ECM of the tissues they are designed to mimic. The native ECM in many 
different tissue types differs not only by protein composition, but they also differ in their 
structural and spatial arrangement of the ECM proteins24. Another advantage to using 
biological scaffolds in a regenerative context is to improve the engraftment and survival 
of cells loaded into these matrices25.  Lastly, previous studies have demonstrated that 
biological scaffolds can be designed to degrade within tissues after exerting their 
regenerative effect, thus addressing any concern that foreign scaffold materials will 
remain within the patient26, 27.  
Biomaterial design and production is continuously improving and currently permits the 
manipulation of several physical and chemical properties of decellularized bioscaffolds. 
For example, the additional processing of decellularized adipose tissues (DAT) to be 
tailored into any size, shape, or concentration for transplantation28. These novel 
processing steps enables the scaffold material to be manipulated like synthetic scaffolds 
while retaining the chemical and biological composition reflective of native adipose 
tissue. Human adipose tissue is relatively easy to obtain in the form of discarded tissue 
from human procedures, such as liposuction clinics. Thus, adipose-derived scaffolds 
could serve as a readily available tool to promote tissue regeneration at local sites of 
ischemia29. Because adipose tissue is effectively vascularized and immunologically inert, 
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seeding scaffolds with vessel-forming cell types (MSC and ECFC) may prolong donor 
cell engraftment, and prolong the capacity for transplanted cells to stimulate 
revascularization of ischemic tissues30. The use of biological scaffolds derived from 
tissue sources provides a composition which closely represents the endogenous ratios of 
ECM and embedded proteins of biological tissues as compared to some of the synthetic 
options available24. In this study, we demonstrate that DAT foam scaffolds act as an 
effective carrier to improve the survival and retention of vessel-forming MSC and ECFC 
after transplantation into an immunodeficient mouse model with femoral artery/vein 
ligation-induced (FAL) hind limb ischemia. 
 Methods 
5.2.1 MSC and ECFC isolation and culture. 
MSC and ECFC were isolated from human bone marrow and human umbilical cord 
blood, respectively. Briefly, MNC from each tissue were obtained after centrifugation on 
hypaque-ficoll density gradient (GE Healthcare, Chicago, USA), and MNC were plated 
on tissue culture plastic at 270,000 cells/cm2. Cells were incubated for 14 days in 
Amniomax media + supplement (Life Technologies, Carlsbad, USA) or in endothelial 
growth media (EGM-2; Lonza, Basel, Switzerland) to obtain MSC or ECFC colonies 
respectively. After colony outgrowth, cells were dissociated using trypsin, MSC and 
ECFC were re-plated at 4000 cells/cm2 and subsequently passaged when cultures reached 
80% confluency. Cell lines were cryopreserved at passage 3 prior to use in experiments. 
5.2.2 DAT preparation and seeding. 
Collection and preparation of human adipose tissues into DAT foam scaffolds was 
performed as previously described27, 31. Briefly, the adipose tissue was subjected to a 
detergent-free, 5-day processing protocol beginning with multiple freeze-thaw cycles 
followed by enzymatic digestion to detach the cells from the ECM. Next, the tissues were 
subjected to several polar solvent washes to remove lipid content from the ECM scaffold. 
After rinsing out the polar solvent, the tissues were exposed to another enzymatic 
digestion, rinsed, and exposed to another series of polar solvent washes and final rinses 
before the solubilization protocol. After the decellularization process, the scaffolds were 
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then subjected to α-amylase for 72 hours. After rinsing the α-amylase, 0.2M acetic acid 
was used to solubilize the DAT. 500 µL of the solubilized DAT was loaded into a well of 
a 48-well plate where it was lyophilized and stored for further use32. To seed cells, the 
foams were re-hydrated and 250,000 MSC and/or ECFC were dispensed on the DAT 
foams and incubated for 24 hours at 37o.C. 
5.2.3 Determining cell proliferation and cell surface phenotype via 
flow cytometry. 
MSC and/or ECFC were seeded on DAT foams or tissue culture plastic and incubated at 
37oC + 5% CO2 for 12 hours before adding 1 µMolar of EdU to the cultures. To assess 
MSC or ECFC surface marker expression after seeding on the DAT foam scaffolds via 
flow cytometry, the samples were prepared to minimize scaffold debris. Briefly, seeded 
scaffolds were incubated in LiberaseTM TL (Sigma-Aldrich, St. Louis, USA) at 37oC for 
15 minutes with intermittent vortexing every 5 minutes until the sample preparation 
dissociated in suspension. Next, the sample was layered on a Hypaque-ficoll density 
gradient where the cell fraction was centrifuged, collected, and filtered using a 50 µM 
filter (Sysmex, Kobe, Japan). To decipher between MSC and ECFC in coculture 
experiments, the cells were stained with antibodies against CD90 and CD31, respectively. 
In conjunction with CD90 and CD31, CD73 and CD105 were used to phenotype the 
MSC while TIE2 and CD105 (BD Biosciences) were used to phenotype ECFC. To detect 
proliferating ECFC, 1 µMolar of EdU (Thermo Fisher Scientific, Waltham, USA) was 
added to the EGM-2 for 72 hours before analysis of proliferation. For co-culture assays, 
MSC proliferation was not measured because the MSC required >20-fold higher 
concentrations of EdU in which impaired ECFC viability. To measure cell proliferation 
by EdU incorporation, cells were fixed in 10% formaldehyde (ThermoFisher) for 5 
minutes before permeabilization with saponin buffer for 15 minutes. The Alexafluor 647 
azide cocktail was prepared as per manufacturer’s instructions (ThermoFisher) and 
applied to the samples for ½ hour before analysis by flow cytometry. 
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5.2.4 Femoral artery ligation and transplantation. 
Immunodeficient NOD/SCID mice at 8-12 weeks of age were used as 
xenotransplantation recipients to model hind limb ischemia induced by FAL surgery as 
previously reported33. Under anaesthesia an incision was made in the right thigh and the 
fat pad cauterized to reveal the femoral artery and vein. The femoral artery and vein were 
separated from the sciatic nerve and ligated on both the proximal and distal ends to allow 
for a 5mm section to be excised as previously described34. Seeded or unseeded DAT 
foam scaffolds with 250,000 MSC and/or ECFC were subcutaneously transplanted 
directly after excision of the femoral artery/vein. For intramuscular transplantation 
groups, 250,000 ECFC were injected into the quadriceps muscle at 3 locations around the 
site of injury at equal doses in 20 µL of PBS 24 hours after surgery. 
5.2.5 Measurement of perfusion by laser doppler perfusion 
imaging. 
Measurement of limb perfusion was assessed by laser Doppler perfusion imaging (LDPI, 
Moor Instruments, Devon, UK). Briefly, shaved NOD.SCID mice were placed on a 
heating pad at 37oC for 5 minutes prior to LDPI acquisition. LDPI was performed on 
anaesthetized mice at days 0, 7, 14, 21, 28, and 35 post-transplantation where flux images 
were obtained of the distal hindlimbs. To quantify the kinetics of blood flow recovery, 
the average flux units per foot were used to generate the perfusion ratios between the 
ischemic and non-ischemic limb. 
5.2.6 Analysis of hind limb and scaffold tissue by 
immunofluorescence. 
After euthanasia, tissue from the ischemic and non-ischemic quadriceps and 
gastrocnemius muscle was harvested and embedded in optimal cutting temperature 
medium (ThermoFisher) and frozen at -80oC. Each tissue block was cryosectioned at 12 
µm thickness across 3.6 mm of tissue. Immunofluorescence was performed on tissue 
sections to assess human cell engraftment using the pan-HLA-A, B, C primary antibody 
(BD Biosciences) and visualized using a secondary antibody conjugated to Cy-5 (Vector 
Labs, Burlingame, USA). Cells were counter stained with DAPI prior to imaging on the 
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Leica-TSC SP8 confocal microscope (Leica, Wetzlar, Germany). Human cell 
quantification using HLA-A, B, C was also performed on tissue sections generated from 
the DAT scaffolds 14 days post-transplantation. To quantify the vessel density within 
tissue sections, an anti-mouse CD31 antibody (BD Bioscience) was used and visualized 
using a secondary antibody conjugated to Texas red (Vector). Tissue sections were 
counter-stained with DAPI (Sigma-Aldrich, St. Louis, USA) to visualize cell nuclei. 
Human cell engraftment and/or CD31+ blood vessel density was quantified in a blinded 
fashion from 12 photomicrographic fields at 20x magnification. 
5.2.7 Immunohistochemical analysis of human cell engraftment 
and blood vessel recruitment within DAT foam scaffolds. 
Immunohistochemistry was performed on DAT scaffold tissue sections due to a high 
degree of autofluorescence produced by the ECM. To quantify the vessel density within 
the scaffolds, an anti-mouse CD31 antibody (BD Bioscience) was used and visualized 
using an alkaline phosphatase-labeled secondary antibody stained with Vector blue 
(Vector). Tissue sections were counter-stained with methyl green (Vector Labs, 
Burlingame, USA) to visualize cell nuclei. Human cell engraftment was assessed using 
the NOD.SCID MPS type VII mouse lacking functional beta glucuronidase activity. To 
visualize human cells in this mouse model, tissue sections were stained with 
pararosaniline (Sigma). Human cell engraftment was quantified in a blinded fashion from 
12 photomicrographic fields at 20x magnification. CD31 density within the scaffolds was 
quantified using ImageJ analysis of RGB-converted photomicrographs where signal 
intensity was measured by threshold gating. 
5.2.8 Statistical analyses. 
For the analysis of significance across assays, a one-way ANOVA with Tukey’s multiple 
comparisons test was performed using Graphpad Prism software. A two-tailed T-test was 
performed to determine significance between the blood vessel density within the normal 
and ischemic thigh of the NOD.SCID mice. A two-way ANOVA with Tukey’s post-hoc 
test was performed to determine significance between the HLA+/MAC-1+ cells compared 
to the HLA+/MAC-1- cells from the DAT scaffold transplants. 
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 Results 
5.3.1 Seeding and culture in DAT scaffolds altered the surface 
marker expression of ECFC and MSC.  
Because the DAT scaffold is a bio-active substrate, we wanted to assess whether the 
ECFC or MSC surface phenotype was altered after culture on DAT foam scaffolds 
compared to tissue culture plastic (TCP) controls. ECFC and MSC were co-seeded and 
cultured on DAT scaffolds or TCP for 72 hours before assessing ECFC and MSC surface 
phenotype using a multichromatic flow cytometry panel for: CD31, CD90, CD73, 
CD105, and TIE2. ECFC were distinguished from MSC using CD31 and CD90 
expression, respectively (Figure 5.1A). ECFC demonstrated consistently high expression 
of CD73 (99.9 ± 0.1%) and CD105 (98.5 ± 2.2%) under all conditions. However, 84.2 ± 
7.1% of ECFC expressed TIE2+ when co-cultured with MSC on TCP, and the frequency 
of TIE2+ ECFC increased to 99.1 ± 0.1% after co-culture on DAT foam scaffolds 
(Figure 5.1B). Alternatively, MSC demonstrated consistent expression of TIE2 (94.9 ± 
0.9%) and CD73 (99.9 ± 0.1%) cells where the CD105+ cell frequency significantly 
decreased from 99.1 ± 0.2% to 88.2 ± 3.6% after co-culture in the DAT foam scaffolds 
(Figure 5.1C). Collectively, these results suggest that DAT scaffolds may modulate the 
phenotypes of ECFC and MSC during culture in vitro. 
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Figure 5.1 ECFC and MSC expression of TIE2 and CD105 was altered by culture in 
DAT foam scaffolds. 
Figure 5.1 ECFC and MSC expression of TIE2 and CD105 was altered by culture in 
DAT foam scaffolds. The cell surface phenotype of ECFC and MSC cultured on tissue 
culture plastic or on DAT scaffolds for 72 hours was assessed using a multichromatic 
flow cytometry panel for: CD31, CD90, CD73, CD105, and TIE2. (A) Representative 
flow cytometry plots demonstrate the gating strategy to identify ECFC (CD31+) and MSC 
(CD90+) prior to analysis of other cell surface markers. (B) ECFC demonstrated 
consistent expression of CD73+ (99.9 ± 0.1%) and CD105+ (98.5 ± 2.2%) across all 
conditions. The frequency of TIE2+ ECFC during co-culture with MSC on TCP was 84.2 
± 7.1% and was significantly increased to 99.1 ± 0.1% after co-culture on DAT foam 
scaffolds. (C) MSC demonstrated consistent expression of TIE2+ (94.9 ± 0.9%) and 
CD73+ (99.9 ± 0.1%) while the frequency of CD105 expression was decreased from 99.1 
± 0.2% after culture on TCP to 88.2 ± 3.6% after culture in the DAT foam scaffolds. Data 
represents the mean ± SD using cells from 3 UCB (ECFC) and 3 BM (MSC) samples 
(N=3; ***P<0.001 by one-way ANOVA using a Tukey’s post hoc test).  
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5.3.2 ECFC proliferation was diminished during culture with MSC 
or on DAT scaffolds. 
To determine whether ECFC proliferation was affected by either the DAT foam scaffolds 
or direct co-culture with MSC, ECFC were grown in the nucleotide analogue EdU for 72 
hours prior to analysis. To assess ECFC proliferation under direct co-culture conditions, 
cells were stained with a multichromatic panel containing CD31, CD90, and Alexafluor 
647 azide to detect EdU incorporation during DNA replication (Figure 5.2A). 
Unfortunately, the concentrations of EdU required to measure MSC proliferation were 
toxic to the ECFC which prevented the quantification of MSC proliferation in co-culture 
conditions. After seeding into DAT scaffolds, ECFC division was decreased during the 
72-hour culture (2.8 ± 2.0%) compared to ECFC expansion on tissue culture plastic (74 ± 
14%). In co-culture with MSC, the rate of ECFC proliferation was minimal in the DAT 
foam scaffolds (10 ± 6.7%) and on TCP (6.3 ± 2.3%) (Figure 5.2B). Taken together 
these data indicate that ECFC proliferation was impaired when co-cultured with MSC 
and when cultured on DAT scaffolds. 
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Figure 5.2 ECFC proliferation was decreased by culture on DAT scaffolds and by 
co-culture with MSC. 
Figure 5.2 ECFC proliferation was decreased by culture on DAT scaffolds and by 
co-culture with MSC. ECFC were cultured on TCP or DAT scaffolds with or without 
MSC for 72 hours in media containing 1 µMolar EdU. (A) Representative flow 
cytometry plots demonstrate the gating strategy to identify ECFC (CD31+) and MSC 
(CD90+) prior to analysis of EdU-incorporation. During culture on tissue culture plastic, 
the 74 ± 14% of ECFC divided within 72 hours. During co-culture with MSC on TCP, 
only 6.3 ± 2.3% of ECFC divided within 72 hours. ECFC proliferation was also 
significantly decreased when cultured in DAT scaffolds alone (2.8 ± 2.0%) or with MSC 
(10 ± 6.7%). Data represents the mean ± SD using cells from 3 UCB (ECFC) and 3 BM 
(MSC) samples (N=3; ***P<0.001 by one-way ANOVA using a Tukey’s post hoc test). 
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5.3.3 Intramuscular injection of ECFC and/or MSC did not improve 
perfusion in NOD.SCID mice with FAL. 
To determine whether ECFC and/or MSC could enhance the recovery of perfusion in a 
FAL-induced ischemic limb, 250,000 ECFC, MSC or 125,000 ECFC with 125,000 MSC 
were transplanted via intramuscular injection. Blood flow was quantified by LDPI and 
the perfusion ratio between the ischemic and non-ischemic limbs was compared every 7 
days for 35 days post-surgery. The recovery of the PBS-injected controls plateaued by 
day 14 (37.5 ± 17.3%), with a final perfusion ratio of 37.0 ± 14.9% by day 35. Similarly, 
intramuscular injected ECFC, MSC, and ECFC/MSC co-transplantation did not 
significantly improve perfusion over the 35-day time-course compared to PBS-injected 
controls (Figure 5.3). These results indicated that intramuscular injection of ECFC 
and/or MSC did not enhance the recovery of blood flow in the ischemic hind limb. 
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Figure 5.3 Intramuscular injection of ECFC and/or MSC did not improve limb 
perfusion in NOD.SCID mice after FAL.
 
Figure 5.3 Intramuscular injection of ECFC and/or MSC did not improve limb 
perfusion in NOD.SCID mice after FAL. ECFC and/or MSC were injected into the 
ischemic thigh muscle of NOD.SCID mice following FAL-induced ischemia. (A) The 
recovery of limb perfusion was monitored every 7 days for 5 weeks by LDPI. (B) The 
recovery of perfusion in the ischemic limb of PBS-injected control mice plateaued at day 
14 and reached a final perfusion ratio of 37.0 ± 14.9% at day 35. Intramuscular injection 
of ECFC, MSC, and ECFC/MSC did not significantly alter perfusion with perfusion 
ratios of 23.4 ± 8.6%, 39 ± 24.2%, and 33.7± 6.8% at day 35, respectively. (C) Similarly, 
area under the curve (AUC) analyses did not reveal any significant changes in blood 
perfusion compared to PBS-injected controls. Data represents the mean ± SEM using 
cells from 6 UCB (ECFC) and 6 BM (MSC) samples (N=6). 
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5.3.4 ECFC and/or MSC seeded DAT foam scaffolds did not 
improve perfusion in NOD.SCID mice with FAL. 
Accordingly, we wanted to determine whether ECFC and/or MSC could enhance blood 
perfusion recovery in vivo after transplantation seeded on DAT foam scaffolds. Similar to 
the intramuscular transplantation, NOD.SCID mice with FAL-induced hind limb 
ischemia were transplanted with scaffold alone or seeded DAT foams with ECFC and/or 
MSC. After scaffold-only implantation, perfusion ratios plateaued by day 14 (42.0 ± 
21.6%), reaching a final perfusion ratio of 36.6 ± 19.9% by day 35. DAT-seeded with 
ECFC, MSC, and ECFC/MSC did not significantly improve blood perfusion over the 35-
day time-course with perfusion ratios at day 35 at 42.2 ± 17.4%, 48.5 ± 17.6%, and 37.3 
± 23.2%, respectively (Figure 5.4). Collectively, these results indicated that 
transplantation of ECFC and/or MSC seeded within DAT foam scaffolds did not improve 
the recovery of blood perfusion in the ischemic hind limb of NOD.SCID mice. 
Collectively, the cellular transplantation treatment groups for both I.M. injection and 
DAT scaffold transplantation did not enhance the recovery of blood perfusion as 
measured by an area under the curve analysis (Figure 5.3C, 5.4C). 
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Figure 5.4 Implantation of ECFC and/or MSC seeded into DAT scaffolds did not 
improve limb perfusion in NOD.SCID mice with FAL.
 
Figure 5.4 Implantation of ECFC and/or MSC seeded into DAT scaffolds did not 
improve limb perfusion in NOD.SCID mice with FAL. ECFC and/or MSC seeded 
DAT scaffolds were implanted subcutaneously into the ischemic limb of NOD.SCID 
mice following FAL-induced ischemia. (A) The recovery of limb perfusion was 
monitored every 7 days for 5 weeks by LDPI. (B) Control mice implanted with scaffold-
only reached a final perfusion ratio of 36.6 ± 19.9% at day 35. Implantation of DAT 
scaffolds seeded with ECFC, MSC, and ECFC/MSC did not significantly improve 
perfusion with perfusion ratios of 42.2 ± 17.4%, 48.5 ± 17.6%, and 37.3 ± 23.2% at day 
35, respectively. (C) Similarly, area under the curve (AUC) analyses did not reveal any 
significant changes in blood perfusion compared to scaffold-only controls Data represents 
the mean ± SEM using cells from 6 UCB (ECFC) and 6 BM (MSC) samples (N=6). 
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5.3.5 Transplantation of ECFC and/or MSC increase blood vessel 
density within the ischemic thigh muscle. 
Because DAT scaffolds have been previously demonstrated to promote murine 
endothelial cell recruitment, we next wanted to determine if the ECFC and/or MSC could 
potentiate murine vessel formation in the ischemic hind limb at the site of implantation. 
After euthanasia, the ischemic and contralateral thigh muscles were collected, 
cryosectioned, and analyzed by immunofluorescence using HLA-A,B,C and CD31 to 
quantify human cell engraftment alongside mouse blood vessel density, respectively. 
Representative photomicrographs showing CD31+ vessel density in the ischemic limb for 
each treatment group are shown in Figure 5.5A, 5.6A.  Interestingly, intramuscular 
injection of ECFC and MSC (256.8 ± 6.9 cells/mm2) significantly augmented blood 
vessel density in the ischemic limb compared to PBS-injected (213.6 ± 24.9 cells/mm2) 
controls. Alternatively, the ECFC (255.6 ± 43.4 cells/mm2) and MSC (233.8 ± 24.2 
cells/mm2) injected mice demonstrated blood vessel densities similar to the PBS controls 
(Figure 5.5B). Interestingly, mice transplanted with the DAT scaffold alone (212.4 ± 
11.5 cells/mm2) had similar CD31+ vessel density in the ischemic limb compared to the 
ECFC (244.3 ± 12.9 cells/mm2), MSC (218.0 ± 27.7 cells/mm2), and ECFC/MSC (239.8 
± 42.8 cells/mm2) seeded scaffolds (Figure 5.6B). After comparing the blood vessel 
density within the ischemic versus non-ischemic limb, only the PBS-injected and DAT 
scaffold-alone transplanted controls showed significantly decreased vessel densities 
compared to the non-ischemic limb. Conversely, all the cellular transplantation 
conditions showed statistically equivalent blood vessel densities compared to the non-
ischemic limb (Table 5.1). Collectively, intramuscular injection of ECFC/MSC 
significantly increased blood vessel density within the ischemic limb. Moreover, all 
cellular transplantation conditions, with and without the use of DAT scaffolds showed 
recovered blood vessel density similar to the non-ischemic limb. 
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Figure 5.5 Intramuscular injection of ECFC with MSC increased blood vessel 
density in the ischemic limb of NOD.SCID mice after FAL.
 
Figure 5.5 Intramuscular injection of ECFC with MSC increased blood vessel 
density in the ischemic limb of NOD.SCID mice after FAL. ECFC and/or MSC were 
injected into the ischemic thigh muscle of NOD.SCID mice following FAL-induced 
ischemia. (A) Blood vessel density was quantified using immunofluorescent 
photomicrographs of thigh muscle sections enumerating the number of CD31+ cells co-
localized with a nuclear signal (DAPI). Mice I.M.-injected with ECFC and MCS together 
(256.8 ± 6.9 cells/mm2) showed significantly increased blood vessel density in the 
ischemic limb compared to mice I.M.-injected with PBS (213.6 ± 24.9 cells/mm2). In 
contrast, blood vessel density in mice I.M.-injected with ECFC (255.6 ± 43.4 cells/mm2), 
or MSC (233.8 ± 24.2 cells/mm2) alone was not significantly different when compared to 
PBS controls. Data represents the mean ± SEM using cells from 6 UCB (ECFC) and 6 
BM (MSC) samples (N=6, *P<0.05 by one-way ANOVA using Tukey’s post hoc test). 
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Figure 5.6 DAT scaffolds seeded with ECFC and/or MSC improved blood vessel 
density in the ischemic limb of NOD.SCID mice with FAL.
 
Figure 5.6 DAT scaffolds seeded with ECFC and/or MSC did not improve blood 
vessel density in the ischemic limb of NOD.SCID mice with FAL. ECFC and MSC 
seeded on DAT scaffolds were implanted into the ischemic limb of NOD.SCID mice 
following FAL-induced ischemia. Blood vessel density was quantified on 
immunofluorescent photomicrographs by enumerating the number of CD31+ events co-
localizing with a nuclear signal (DAPI). The ECFC (244.3 ± 12.9 cells/mm2), MSC 
(218.0 ± 27.7 cells/mm2), or both ECFC/MSC (239.8 ± 42.8 cells/mm2) seeded in DAT 
scaffolds recovered blood vessel density comparable to the scaffold-treated (212.4 ± 11.5 
cells/mm2) mice. Data represents the mean ± SEM using cells from 6 UCB (ECFC) and 6 
BM (MSC) samples (N=5-6, measured by one-way ANOVA using Tukey’s post hoc 
test). 
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Table 5.1 T-test comparison of CD31+ vessel density between the ischemic and 
normal thigh within treatment groups 35 days post FAL surgery. 
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5.3.6 Human ECFC or MSC engraftment was improved within the 
DAT scaffolds.  
To ensure sensitive detection of human cell engraftment without the use of human-
specific cell surface marker detection, ECFC or MSC were transplanted into NOD.SCID 
MPS type VII mice that lack functional beta glucuronidase (GUSB) activity. Because the 
human ECFC and MSC transplanted ubiquitously expressed GUSB, human cells can be 
tracked at single cell sensitivity using this unique mouse model using pararosanalin (red) 
staining for GUSB enzymatic activity33, 35.  Similarly, immunohistochemical staining of 
the DAT scaffolds from the NOD.SCID MPS type VII mice was performed to avoid 
tissue autofluorescence impeding human cell detection. At 14 days after I.M.-injection, 
single GUSB+ human cells were rarely detected within the ischemic thigh. The detection 
of GUSB+ cells occurred in only one of three transplanted mice throughout 0.35 mm of 
sectioned thigh muscle tissue (Figure 5.7A, C). Interestingly, human cell engraftment 
within the ischemic thigh was also observed within mice transplanted with ECFC or 
MSC-seeded DAT scaffolds (Figure 5.7B, D). In contrast, human GUSB+ cells were 
abundantly detected within DAT scaffolds at 14 days post-transplantation (Figure 5.8A, 
B). The amount of human cell engraftment within the DAT scaffolds averaged 6.12 ± 2.9 
cells/mm2 for ECFC and 5.7 ± 6.0 cells/mm2 for MSC (Figure 5.8C). Prolonged human 
cell engraftment within the DAT scaffolds was detected 35 days post-transplantation 
(Figure 5.9). Furthermore, human cell engraftment was detected and quantified within 
the DAT scaffolds using flow cytometry after 14 days post-transplantation. Cells 
extracted from the DAT scaffolds were stained with CD31, CD90, and Calcein AM to 
stain the live human ECFC and MSC (Figure 5.8D). The frequency of ECFC seeded 
within DAT scaffolds was 0.46 ± 0.56% which was significantly improved when seeded 
in DAT scaffolds with MSC (3.44 ± 1.49%). MSC frequency was unaffected with or 
without the presence of ECFC (1.65 ± 0.50% versus 1.82 ± 1.40%, respectively) (Figure 
5.8E). These data suggest that human ECFC and MSC survival and retention was 
increased within the implanted DAT scaffold compared to intramuscular injection. 
Moreover, the survival of ECFC within the DAT scaffolds was augmented in the 
presence of MSC. In addition, human cell extravasation from the DAT scaffold into 
surrounding muscle tissue was detectable but extremely rare. 
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Figure 5.7 Human cell engraftment was rare in the ischemic thigh after scaffold 
implantation or I.M injection.
 
Figure 5.7 Human cell engraftment was rare in the ischemic thigh after scaffold 
implantation or I.M injection. ECFC or MSC were transplanted intramuscularly or 
implanted subcutaneously within DAT scaffolds in MPS type VII NOD.SCID mice. At 
14 days post-transplantation, human cells were detected using pararosaniline staining for 
beta glucuronidase activity. Within the ischemic thigh, only one of the three I.M or 
scaffold-transplanted mice contained detectable human cells (red) within 350um of 
sectioned tissue. When transplanted via I.M injection, the presence of human ECFC or 
MSC were exceedingly rare within the ischemic thigh. Although extremely rare, human 
cells were also detected in the ischemic thigh of mice transplanted with DAT scaffolds 
seeded with ECFC or MSC. Photomicrographs show human cells detected within 3 mice 
transplanted using cells from 3 UCB (ECFC) and 3 BM (MSC) samples per group (N=3). 
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Figure 5.8 Human cell engraftment was increased in DAT scaffolds at 14 days post-
transplantation. 
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Figure 5.8 Human cell engraftment was increased in DAT scaffolds at 14 days post-
transplantation. ECFC or MSC were seeded in DAT scaffolds and implanted 
subcutaneously at the site of FAL surgery in MPS type VII NOD.SCID mice. After 14 
days, the presence of human cells was detected using pararosaniline staining for 
functional beta glucuronidase activity. Human (A) ECFC or (B) MSC seeded into DAT 
scaffolds were abundantly detected at 14 days post-transplantation into MPS type VII 
NOD.SCID mice. (C) Within the ischemic thigh, only one of the three I.M or scaffold-
transplanted mice contained a single human cell across three stained tissue sections. 
Human cells were detected at 6.1 ± 2.9 ECFC/mm2 and 5.7 ± 6.0 MSC/mm2 within the 
DAT scaffolds at 14 days post-transplantation. (D) Flow cytometry was performed on 
DAT scaffolds 14-days post-transplantation to assess the frequency of human ECFC 
(CD31+) and MSC (CD90+) persisting within the scaffolds. (E) The frequency of ECFC 
seeded within DAT scaffolds was 0.46 ± 0.56% which was significantly improved when 
seeded in DAT scaffolds with BM-MSC (3.44 ± 1.49%). MSC frequency was unaffected 
with or without the presence of ECFC (1.65 ± 0.50% versus 1.82 ± 1.40%, respectively). 
Data represents the mean ± SEM using cells from 3 UCB (ECFC) and 3 BM (MSC) 
samples (N=3; *P<0.05, ***P<0.01 by two-way ANOVA using a Tukey’s post hoc test). 
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Figure 5.9 Human cell detection in the DAT scaffolds at 35 days post-
transplantation in MPS type VII NOD.SCID mice.
 
Figure 5.9 Human cell detection in the DAT scaffolds at 35 days post-
transplantation in MPS type VII NOD.SCID mice. ECFC were seeded in DAT 
scaffolds and implanted subcutaneously at the site of FAL surgery for 35 days in MPS 
type VII NOD.SCID mice. Numerous human cells were detected within the scaffolds 
(Black arrows) at 35 days post-transplantation.  
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5.3.7 The murine cells recruited to the DAT scaffolds were 
primarily MAC-1+ and took up HLA from the DAT scaffolds. 
After 14 days post-transplantation, unseeded DAT scaffolds or DAT scaffolds seeded 
with ECFC and MSC were stained for HLA and DAPI to observe human cell engraftment 
via confocal microscopy. A line-scan analysis was performed to quantify HLA+ features 
in each image (Figure 5.10A, B). In both the Scaffold-only and cell-seeded conditions, 
several HLA+/DAPI+ cells were observed throughout the scaffolds (Figure 5.10A-iii, B-
iii). To validate these findings, flow cytometry was performed to broadly assess the types 
of cells recruited to the scaffold using MAC-1 and whether murine cells were presenting 
HLA. First, we compared the MAC-1+ cell content between murine bone marrow and the 
cells extracted from unseeded DAT scaffolds (Figure 5.11A). The frequency of observed 
MAC-1+ cells from unseeded DAT scaffolds totaled 80.9 ± 5.2%, similar to DAT seeded 
with ECFC (79.9 ± 3.0%) or MSC (69.3 ± 2.7%) alone. Interestingly, DAT scaffolds 
seeded with ECFC and MSC recruited significantly fewer MAC-1+ murine cells (52.8 ± 
13.5%) (Figure 5.11B). Upon further analysis, we compared the HLA+ cell frequency 
within the MAC-1- and MAC-1+ cells from bone marrow and DAT scaffolds (Figure 
5.11C, D). Within the MAC-1+ cells, the frequency of HLA+ cells totaled >80% while 
<3% of the MAC-1- cells were HLA+ across all DAT transplant conditions (Figure 
5.11E). 
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Figure 5.10 Human leukocyte antigen was detected in DAT scaffolds and invading 
murine cells 14 days post-transplantation. 
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Figure 5.10 Human leukocyte antigen was detected in DAT scaffolds and invading 
murine cells 14 days post-transplantation. ECFC and MSC-seeded DAT scaffolds or 
unseeded DAT scaffolds were implanted subcutaneously at the site of FAL surgery in 
NOD.SCID mice. After 14 days, the DAT scaffolds were retrieved, cryosectioned and 
stained for the presence of HLA. Confocal images were taken at 63x magnification and a 
line-scan analysis was performed to quantify HLA+ features in each image. A 
representative photomicrograph indicates where the line scan analyses were performed 
for (A) unseeded DAT scaffolds and (B) ECFC + MSC-seeded DAT scaffolds. 3 
Different regions for each photomicrograph was chosen to represent (A-i, B-i) DAPI-only 
events, (A-ii, B-ii) HLA-only events, and (A-iii, B-iii) HLA in close proximity to DAPI. 
In both the Scaffold-only and cell-seeded conditions, several HLA+/DAPI+ cells were 
observed throughout the scaffolds. Photomicrographs represent 3 different transplant 
conditions of unseeded DAT scaffolds and DAT scaffolds seeded with 3 UCB (ECFC) 
and 3 BM (MSC) samples (N=3). 
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Figure 5.11 Murine cells recruited to DAT scaffolds were primarily MAC-1+ and 
presented the human-specific marker, HLA. 
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Figure 5.11 Murine cells recruited to DAT scaffolds were primarily MAC-1+ and 
presented the human-specific marker, HLA. Unseeded DAT scaffolds or DAT 
scaffolds seeded with ECFC and/or MSC were implanted subcutaneously for 14 days at 
the site of FAL surgery in NOD.SCID mice. After retrieval, the DAT scaffolds were 
stained for MAC-1 and HLA and quantified by flow cytometry. (A) A representative dot 
plot represents the MAC-1+ murine cell content overlaid with the MAC-1+ cell content of 
the DAT scaffold. (B) Quantification of the MAC-1+ cells in the DAT scaffold revealed 
a significant decrease in the frequency of recruited MAC-1+ cells to DAT scaffolds 
seeded with ECFC and MSC (52.8 ± 13.5%) compared to unseeded DAT (80.9 ± 5.2%) 
and DAT seeded with ECFC (79.9 ± 3.0%). After quantifying the HLA+ cell content 
within the (C) MAC-1- and (D) MAC-1+ cells, a notable amount of HLA+ cells were 
observed (>80%) within MAC-1+ murine cells obtained from the DAT scaffolds (E). 
Data represents the mean ± SEM using cells from 3 UCB (ECFC) and 3 BM (MSC) 
samples (N=3; ***P<0.01 by one-way ANOVA in panel B and two-way ANOVA in 
panel E. Both statistical tests were performed using a Tukey’s post hoc test). 
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5.3.8 DAT scaffolds contained CD31+ vessel-like structures. 
At 35 days post-transplantation, DAT scaffolds were removed from the mice, sectioned 
and stained with a mouse anti- CD31 antibody to determine the vessel density within the 
scaffold. Contiguous vessel-like structures were observed within both human cell-seeded 
and DAT-only transplanted conditions (Figure 5.12A). When comparing the average 
CD31 signal intensity or CD31 signal area, no differences were observed between any of 
the cell-transplanted conditions and the un-seeded DAT scaffolds (Figure 5.12B, C). 
Together, these data suggested that the DAT foam scaffolds alone could support 
primitive vessel formation after implantation into an ischemic microenvironment. 
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Figure 5.12 DAT scaffolds transplanted at the site of FAL surgery contained CD31+  
vessel-like structures after 35 days post-transplantation. 
Figure 5.12 DAT scaffolds transplanted at the site of FAL surgery contained CD31+ 
vessel-like structures after 35 days post-transplantation. DAT scaffolds were 
transplanted with or without ECFC and/or MSC at the site of FAL surgery. Scaffolds 
were recovered 35 days post-transplantation and stained for CD31+ cells. (A) 
Representative photomicrographs of stained scaffolds revealed CD31+ vessel-like 
structures throughout the DAT scaffolds. Both the (B) CD31+ signal intensity and (C) 
CD31+ signal area was quantified using image-J threshold analyses on monochrome RGB 
scaffold photomicrographs. CD31+ signal intensity and signal area were not significantly 
different between cell-seeded and un-seeded DAT scaffolds. Data represents the mean ± 
SEM using cells from 6 UCB (ECFC) and 6 BM (MSC) samples (N=3-6).   
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 Discussion 
In the current study, we demonstrated the utility of DAT scaffolds as a novel modality for 
the transplantation of human ECFC and MSC into the ischemic limb of immunodeficient 
NOD.SCID mice after FAL surgery. We also documented a change in cell surface marker 
expression of ECFC and MSC when seeded in decellularized adipose scaffolds in vitro. 
Additionally, the proliferative potential of ECFC was attenuated upon co-culture with 
MSC and after seeding on DAT scaffolds. Unfortunately, we did not observe enhanced 
recovery of limb perfusion following the transplantation of ECFC and/or MSC 
intramuscularly or when seeded in DAT scaffolds implanted subcutaneously into FAL-
induced ischemic hind limbs. Although no changes in limb perfusion was observed, co-
transplantation of ECFC and MSC improved blood vessel density in the ischemic limb at 
the site of intramuscular injection, suggesting that these cells may exert a localized pro-
angiogenic effect in the ischemic tissue. These findings did not indicate that the 
combination of ECFC and MSC could support the enhanced recovery of blood perfusion 
in the ischemic hind limb as suggested by Kang et al.36. The authors demonstrated that 
intramuscular injection of 2 million ECFC and MSC combined promoted the recovery of 
blood perfusion in the ischemic limb, a result that was not observed when the dose of 
cells transplanted was >2 million cells. Thus, the number of cells injected by Kang et al. 
were 8-fold higher than our cell dose and may indicate a minimal threshold of 
transplanted cells may be required to elicit a therapeutic effect. Although we transplanted 
substantially fewer cells (due to the low frequency of CD34+ cells), we observed 
increased blood vessel density within the ischemic thigh muscle recovered to levels 
comparable to the non-ischemic limb. Another reason for our observed differences in the 
recovery of perfusion may be due to the differences in transplantation methodology. 
Here, we describe implantation of ECFC and/or MSC within DAT scaffolds or after 
direct intramuscular injection. In Kang et al.36 cells were mixed within liquid Matrigel 
and injected into the muscle tissue permitting gelation at body temperature.  
In intramuscular transplanted mice, we did not observe human cell engraftment in the 
ischemic thigh tissues after 35 days post-transplantation. The decline of human cell 
engraftment after intramuscular transplantation has also been observed previously for 
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ECFC37 alone or co-transplanted with MSC36. We also observed an extremely low level 
of human cell engraftment within ischemic thigh muscles at 14 days post-transplantation 
using the sensitive NOD.SCID MPSVIII mouse model. Human cells within the ischemic 
muscle was exceedingly rare whether the cells were transplanted within DAT scaffolds or 
by intramuscular injection. Alternatively, we demonstrated robust survival of both ECFC 
and MSC within DAT scaffolds at 14 days post-transplantation into the ischemic 
hindlimb of NOD.SCID MPS VII mice. Furthermore, the NOD.SCID MPS VII mouse 
model enabled the detection of human cell survival within DAT scaffolds up to 35 days 
post-transplantation. As an alternative methodology, the detection of human cells within 
the DAT scaffold by using an HLA-A, B, C antibody was complicated by the presence of 
HLA throughout the scaffold. Interestingly, the murine cells recruited to the unseeded 
DAT scaffolds appeared to up-take HLA which appeared throughout the cytosol of the 
cells. To confirm this phenomenon, flow cytometry was used after extracting the murine 
cells from the DAT scaffolds 14 days post-transplantation. To address the question of the 
types of cells observed within the DAT scaffold, a MAC-1 antibody was used which has 
been noted to mark neutrophils, NK cells, monocytes, and macrophages38. Compared to 
mouse BM-MNC, we observed a dramatic enrichment of MAC-1 positive cells 
throughout the DAT scaffolds. We further dissected the MAC-1+/- populations to 
determine that HLA+ cells were enriched within the MAC-1+ cells obtained from the 
DAT scaffolds. Of note, the cell populations stained and analyzed by flow cytometry 
were live cells which suggests that HLA+ murine cells are presenting the HLA antigen on 
the cell surface for the antibody staining to occur. Fortunately, anti-CD31 and anti-CD90 
antibodies were able to accurately quantify ECFC and MSC engraftment within the DAT 
scaffolds, respectively. In any given transplantation condition with human cells seeded 
within the DAT scaffolds, <4% of the total detected events were human cells while the 
remaining >96% were murine cells. Although the frequency of human cells was low, a 
significant improvement of ECFC engraftment was observed when co-transplanted with 
MSC. In summary, DAT scaffolds robustly recruit MAC-1+ cells which interact with the 
scaffold as measured by HLA presentation on these cells. Furthermore, the DAT 
scaffolds augmented human cell survival where ECFC survival was further improved 
upon seeding the cells in combination with MSC. 
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To determine if ECFC or MSC altered cell surface marker expression in response to 
contact culture within the DAT scaffolds, ECFC and MSC were cultured together for 72 
hours on DAT scaffolds. MSC cultured in the DAT scaffolds showed a notable decrease 
in endoglin (CD105) expression after 72 hours compared to MSC cultured on tissue 
culture plastic in vitro. CD105 has been implicated to be involved in TGF-β signaling but 
also contains the integrin binding sequence, RGB39. Other studies suggest a connection 
between CD105 expression, TGF-β signaling and changes in integrin expression40. Our 
findings indicate that the interactions between DAT and MSC may provide cues that 
decrease CD105 expression by MSC. Interestingly, these results were not observed in 
ECFC that maintained CD105 expression. However, the frequency of TIE2+ ECFC after 
culture in the DAT scaffolds was significantly increased. Further studies are warranted to 
determine if  ECFC establish a vascular niche within DAT scaffolds, as previous studies 
have demonstrated TIE2 signaling pathways promote vessel stability and prevent vessel 
regression in vivo41. Similarly, in vitro culture of the highly proliferative ECFC on DAT 
scaffolds or ECFC with MSC on TCP both resulted in drastically diminished 
proliferation. Thus, MSC-ECFC, ECFC-DAT interactions may promote ECFC 
quiescence given the documented role of MSC to demonstrate pericyte properties 42-44.  
Within the transplanted DAT scaffolds, we observed many invading murine cells as early 
as 14 days post-transplantation, detected by hematoxylin staining. This was anticipated as 
host cell invasion has been previously noted in other transplantation studies utilizing 
DAT scaffolds45. We also observed robust vascularization within unseeded DAT 
scaffolds, indicating that the bioactive properties of DAT scaffolds may have potent pro-
vascular effects in vivo. Our observations corroborate previous studies that demonstrated 
endothelial cell recruitment to the transplanted DAT bioscaffolds46. Murine CD31+ cell 
recruitment was further improved in the DAT scaffolds seeded with MSC, measured by 
flow cytometry. The transplantation of DAT scaffolds did not recover blood vessel 
density in the ischemic thigh to levels measured within the non-ischemic limb. However, 
when the DAT scaffolds contained ECFC and/or MSC, blood vessel density within the 
ischemic thigh was comparable to the non-ischemic contralateral limb. These data 
suggest that DAT scaffolds alone can mediate a local angiogenic effect, whereas the 
ECFC and MSC were necessary to promote vascularization of the ischemic limb 
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potentially through secreted paracrine factors47, 48. Although we did not observe blood 
perfusion recovery using this transplantation strategy, the blood vessel density within the 
ischemic thigh recovered to levels similar to the non-ischemic limb after transplantation 
with as little as 250,000 ECFC and/or MSC. The findings reported throughout this study 
suggest that the localized pro-vascular effects of the ECFC and MSC may have 
alternative clinical benefits. For example, the DAT foam scaffolds have been 
demonstrated to promote vascularization in wound healing setting45 alongside ECFC 
seeded on bioscaffold constructs49, 50. Given our observations that the DAT scaffolds 
promote human cell survival, co-transplantation of ECFC and MSC to synergistically 
promote vascularization51, 52 may improve wound healing through paracrine angiogenic 
effects. 
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Chapter 6  
6 Summary and Discussion 
 Summary of findings. 
The overall objective of my thesis was to improve the revascularization potential of 
culture expanded ECFC and MSC by assessing variables that improve engraftment and/or 
pro-vascular function following transplantation into an ischemic microenvironment. First, 
I employed a conventional strategy to determine if FACS-purification could select more 
potent pro-angiogenic progenitor cell subsets from clinically-applicable human MSC and 
ECFC populations after expansion.  In Chapter 2, I discovered that MSC selected for high 
ALDH-activity, a conserved progenitor cell function, demonstrated enhanced pro-
angiogenic secretory functions and represented a further purified, more homogeneous 
MSC subset amenable for vascular regenerative applications. In contrast, high ALDH-
activity did not select for ECFC with enhanced colony or tubule forming capacity in 
vitro. Therefore, in Chapter 3, I used selection by the best-known EPC marker, the 
sialomucin CD34, to FACS-purify CD34+/- ECFC subsets with both phenotypic and 
functional differences after expansion in vitro.  In Chapters 4 and 5, I utilized 
decellularized adipose-derived bioscaffolds as a novel cell delivery modality to improve 
the survival and engraftment of ECFC and MSC in vivo. Importantly, this research has 
demonstrated that DAT scaffolds enhance the survival of pro-angiogenic ECFC and MSC 
compared to intramuscular injection of either cell population.  Ultimately, I predict the 
information generated in this thesis will contribute to the development of improved 
regenerative medicine strategies to combat ischemic diseases. 
Clinical use of both EPC and MSC in clinical applications has been delayed due to the 
rarity of the cells and the lack of a selective cell surface marker that identifies therapeutic 
cells. Previously, our lab has demonstrated effective methods to purify progenitor cells 
from heterogeneous cell populations by selecting for cells with high ALDH-activity1. 
ALDH-activity provides cytoprotective function to protect progenitor cell pools of 
multiple lineages from damage or deletion after exposure to oxidative stressors2, 3. Thus, I 
210 
 
sought to purify a pro-vascular progenitor cell subset from both ECFC and MSC cultures 
using high ALDH-activity. Notably, MSC selected for high ALDH-activity demonstrated 
enhanced pro-vascular capabilities in vitro and in vivo. Specifically, conditioned media 
generated from the ALDHhi MSC promoted endothelial cell survival and proliferation in 
vitro and increased endothelial cell recruitment to areas of ischemia in vivo. On the other 
hand, high ALDH-activity did not enrich for ECFC with colony forming capacity in 
vitro. Similar to ALDH-activity, FACS purification using CD34 has isolated putative 
progenitor cell populations from the hematopoietic and endothelial lineages. Therefore, I 
investigated whether CD34+ ECFC demonstrated enhanced primitive (colony formation) 
or mature (tube formation) endothelial cell functions compared to CD34- ECFC in vitro. 
Surprisingly, CD34+ ECFC showed reduced colony and tube forming function in vitro, 
thus suggestive of the existence of a potential endothelial hierarchy. Conversely, the 
capacity of CD34+ ECFC to form vessel-like structures in Matrigel plugs was equivalent 
to CD34- ECFC 7-days after implantation in Matrigel into immunodeficient mice. Thus, 
the identity of a definitive marker (ALDH or CD34) to purify the elusive endothelial 
precursor cell after ECFC expansion in vitro remained elusive. Collectively, these studies 
demonstrated the feasibility of using progenitor cell functions (i.e. ALDH-activity) to 
FACS purify expanded MSC subsets with enhanced pro-vascular functions, whereas 
FACS was unable to segregate ECFC subsets with enhanced pro-angiogenic function in 
vivo. After combining ECFC and MSC as a transplantation strategy in a murine model of 
hindlimb ischemia, my results suggested that alternative strategies were needed to 
improve the engraftment of ECFC or MSC transplanted into an ischemic 
microenvironment. Ultimately, cell selection using high ALDH-activity, or the lack 
CD34-expression may help refine cell-based revascularization therapies currently under 
intense pre-clinical and clinical investigation for severe ischemic diseases4-6. 
6.1.1 Chapter 2 – ALDHhi MSC demonstrate enhanced vascular 
regenerative potential. 
In chapter 2, I investigated whether high ALDH-activity could be used as a marker to 
segregate a pro-vascular MSC subset from cultured BM-MSC. We have previously 
demonstrated the prospective purification of ALDHhi cells from BM-MNC enriched for 
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MSC with CFU-F capacity7. However, as MSC are expanded in vitro, cell progeny have 
been shown to differentiate and lose their regenerative capacity8. Therefore, we 
hypothesized that MSC selection based on ALDH-activity after ex vivo expansion may 
reduce heterogeneity by segregating an MSC subset with enhanced vascular regenerative 
functions both in vitro and in vivo. 
Initially, I demonstrated that both ALDHlo versus ALDHhi MSC expressed equivalent 
expression of ‘classical’ MSC surface markers and showed mesodermal multipotency 
generating bone, cartilage and adipose tissues in vitro. However, conditioned media 
generated by ALDHhi MSC demonstrated a potent pro-survival and proliferative 
stimulation of human microvascular endothelial cells (HMVEC) under serum-free 
conditions. In addition, ALDHhi MSC conditioned media exposure augmented HMVEC 
tube-forming capacity in growth factor-reduced matrices. After subcutaneous 
implantation within DIVAA implants into the flank of immunodeficient mice, DIVAA 
implants supplemented with ALDHhi MSC (or conditioned media generated by ALDHhi 
MSC) significantly promoted murine vascular cell recruitment and vessel infiltration 
compared to ALDHlo MSC. Although both subsets demonstrated strikingly similar 
mRNA expression patterns by microarray, quantitative proteomic analyses performed on 
subset-specific conditioned media revealed ALDHhi MSC robustly secreted several 
proteins associated with pro-angiogenic, chemo-attractant, and matrix-modifying 
functions. Collectively, MSC selected for high ALDH-activity demonstrated enhanced 
pro-angiogenic secretory function and represent a novel MSC subset, isolated after 
culture, that is amenable to vascular regenerative applications. 
Utilization of high ALDH-activity to select for MSC with enhanced pro-regenerative 
functions holds promise for future clinical applications. The fluorescent ALDH substrate 
is non-toxic and has been used in clinical cell therapies in the past 9, 10. Furthermore, 
selecting for cells with high ALDH-activity provides a means to isolate pro-regenerative 
cell populations that lack definitive cell surface markers for selection. Furthermore, 
selecting cells based on ALDH function also reduced heterogeneity commonly observed 
during the expansion primary cells. The heterogeneity of bulk-expanded MSC has been 
suggested to contribute to the lack of therapeutic efficacy of MSC in vivo11, 12. Therefore, 
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selecting for ALDHhi MSC to reduce cellular heterogeneity may contribute to the 
development of more efficacious vascular cell therapies. 
6.1.2 Chapter 3 – CD34+ ECFC have attenuated vascular 
functions in vitro. 
Because ECFC also lack markers to robustly identify primitive progenitor cell content, 
high ALDH-activity was also tested to identify an endothelial progenitor cell population 
with enhanced pro-vascular function. ECFC are highly proliferative endothelial cells 
isolated from human umbilical cord blood, peripheral blood, and bone marrow MNC13. 
ECFC primarily express endothelial cell surface markers, effectively form tubules in 
vitro, and  can integrate into vasculature after transplantation in vivo14. Similar to MSC, 
we envision ECFC cultures as a heterogenous populations that will gradually lose 
progenitor cell functions with continuous passaging8, 13. Therefore, I hypothesized that 
FACS-purification of cultured ECFC based on ALDH-activity and/or primitive 
progenitor cell surface markers (CD34) would segregate a primitive progenitor cell 
subset with enhanced regenerative functions in vitro and in vivo. 
In this study, I purified ECFC using FACS based on ALDH-activity and EPC markers 
(CD34, CXCR4) previously associated with the capacity to integrate into neovessels in 
vivo. After purification based on high versus low ALDH-activity, single ALDHlo and 
ALDHhi cells established colonies at a frequency equal to unpurified ECFC. In contrast, 
ECFC lacking CD34 or CXCR4 expression generated significantly more colonies 
compared to CD34+ or CXCR4+ ECFC. When seeded in growth factor-reduced GeltrexTM 
media, purified CD34+ ECFC also demonstrated a reduced tubule forming capacity 
compared to CD34- ECFC. Comparing the cell surface proteome of CD34- versus CD34+ 
ECFC revealed increased expression of several pro-angiogenic endothelial cell pathways 
on CD34+ ECFC including VEGFR2 and Jagged. Despite these functional differences 
between CD34+ versus CD34- ECFC tested in vitro, both ECFC subsets equally 
orchestrated the formation of vessel-like structures within Matrigel plugs implanted 
subcutaneously into immunodeficient NOD.SCID mice. Moreover, detection of human 
cells was comparable between CD34+ and CD34- ECFC, suggesting both ECFC subsets 
survived for 7 days following transplantation. Collectively, we demonstrated that CD34+ 
213 
 
versus CD34- ECFC subsets exhibited unexpected differences in clonogenicity and tubule 
formation in vitro; however, both ECFC subsets could assemble into vessel-like 
structures in vivo. Thus, the purification of ECFC subsets with enhanced vessel forming 
functions in vivo was not easily predicted by surrogate progenitor cell phenotypes. Thus, 
functional assays in vitro and in vivo, are encouraged to better predict pro-vascular 
potency for expanded ECFC populations. 
6.1.3 Chapter 4 – Purification of human cells seeded within 
decellularized bioscaffolds for analysis by multiparametric 
flow cytometry. 
In preparation of using flow cytometry to analyze cell populations implanted within DAT 
scaffolds in Chapter 5, the development of methods to generate cell preparations for flow 
cytometry that contained minimal scaffold debris were required. In this chapter, I 
demonstrated that enzymatic release of seeded cells from decellularized scaffolds 
produced debris with high levels of autofluorescence across the visible spectrum (450-
780nm) that could obscure the assessment of cellular phenotype and function. In order to 
limit the enumeration of false positive events caused by scaffold debris, I developed a 
methodology to maximize cell retrieval and minimize cell debris, without impacting cell 
survival or phenotype, as these are two of the most insightful parameters to be measured 
during preclinical testing in vitro and in vivo. 
Initially, I compared enzymatic digestion with trypLE expressTM, LiberaseTM, and 
collagenase to identify the protease formulation that generated pure cell preparations 
while minimizing the background generated by the autofluorescent scaffold debris. To 
demonstrate the broad utility of these methods, cell viability, and immunophenotype were 
assessed using human ECFC and MSC seeded on ECM-derived foams fabricated from 
human DAT, porcine DCT, or commercially-available bovine tendon collagen. The 
liberation of cells using TrypLE expessTM incubation produced consistent sample 
preparations with high cell viability and minimized debris; however, the recovery 
remained lower relative to initial seeding density (<50%). In contrast, scaffold targeted 
digestion with collagenase-containing protease cocktails (>1 hr) negatively impacted cell 
viability and generated large amounts of debris that could interfere with sample analysis. 
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In order to maximize cell viability, scaffolds seeded with cells were digested with a 
collagenase-containing protease cocktails for less time. Next, cells could be effectively 
segregated from scaffold debris using Hypaque Ficoll density gradient centrifugation 
(>99% purity). In addition to increasing sample purity, the developed methodology 
supported both ECFC and MSC viability; in return, improving the total recoverable cell 
yield. Collectively, the development of these methods enabled the accurate detection and 
quantification of multiple cellular parameters during the co-culture of MSC and ECFC 
DAT scaffolds, described in Chapter 5. 
6.1.4 Chapter 5 – ECFC and MSC demonstrate pro-vascular 
properties in vivo. 
The aim in chapter 5 was to determine if the utilization of decellularized adipose tissue 
scaffolds could augment the pro-vascular function of ECFC and MSC following 
subcutaneous implantation of scaffold and cells into a murine model of FAL-induced 
hind limb ischemia. Previous pre-clinical studies have demonstrated the clinical potential 
for ECFC and MSC utilized as individual therapeutic cell populations15-17. Despite 
promising results, clinical trials testing therapeutic potential of ECFC or MSC have only 
observed modest benefits to date18, 19. One possibility for decreased cellular efficacy 
following transplantation may include how ECFC and MSC are isolated, cultured, and 
processed prior to transplantation. For example, endothelial cells expanded in vitro do not 
retain the same phenotype prior to isolation in vivo which may negatively impact cell 
function20, 21. This phenomenon may occur as a result of standard culture conditions 
being devoid of  3-D architecture, ECM-related signaling molecules, and/or the activation 
of mechano-sensing pathways during culture on  stiff substrates (i.e. tissue culture 
plastic)22-24. For these reasons, I investigated the potential benefit of biological active 
decellularized scaffolds derived from a readily available tissue type (i.e. adipose tissue)25. 
I hypothesized that DAT scaffolds would augment ECFC and MSC survival and enhance 
vascular regenerative functions following transplantation into a murine model of 
hindlimb ischemia. 
Initially culturing ECFC and MSC within DAT-foam scaffolds led to significant changes 
in the frequency of ECFC expressing TIE2 and MSC expressing CD105. I also observed 
215 
 
a marked decrease in ECFC proliferation when cultured on the DAT scaffold, measured 
by EdU incorporation into dividing ECFC. Similarly, ECFC cultured with MSC also 
showed little ECFC proliferation with or without DAT scaffolds. Next, I investigated the 
pro-vascular potential of transplanted human ECFC and MSC, injected intramuscularly 
or within seeded DAT scaffolds, into our well-established NOD.SCID model of unilateral 
hindlimb ischemia. Subsequently, the recovery of blood perfusion was measured using 
LDPI on the distal hind limbs. Whether intramuscularly injected or seeded in DAT 
scaffolds, transplanted ECFC and/or MSC did not improve recovery of blood perfusion in 
the ischemic hind limb compared to PBS-injected controls. Next, I performed a 
histological analysis of the thigh muscles to screen for human cells and to enumerate the 
blood vessel density in both the ischemic and non-ischemic limbs. Human cell 
engraftment within the ischemic thigh tissue was not observed in any cell-treated mice 35 
days post transplantation. Although exceedingly rare, both ECFC and MSC could be 
detected within the ischemic thigh 14 days post-transplantation after delivery within DAT 
scaffolds or by intramuscular injection. Conversely, human ECFC and MSC were 
abundantly detected within the DAT scaffolds 14 days post-transplantation and 
engraftment was easily observed up to 35 days post-transplantation. Although human cell 
engraftment was not observed 35 days after direct cell injection into murine muscle 
tissue, all mice receiving ECFC and/or MSC recovered blood vessel density to levels 
comparable to the non-ischemic contralateral limb. Only the mice intramuscularly 
injected with both ECFC and MSC significantly improved blood vessel density compared 
to the PBS-injected ischemic thigh. Mice receiving ECFC and/or MSC seeded within 
DAT scaffolds also recovered blood vessel density within the ischemic thigh comparable 
to the non-ischemic limb. Moreover, the scaffolds promoted murine cell recruitment into 
the DAT and showed the formation of vessel-like structures throughout the scaffold. 
Taken together, this data indicated that the ECFC and MSC are pro-vascular cell types 
which may only exert their effects in the local tissue environment immediately 
surrounding the site of transplantation. Although recovery of hind limb perfusion was not 
observed, increased vessel density in the ischemic thigh suggested that combinatorial 
transplantations of ECFC and MSC may provide local, vessel-forming benefit. 
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To summarize the data generated, Figure 6.1 provides a theoretical model for the pro-
vascular processes of ECFC and MSC transplanted into an ischemic setting. Here, I 
postulated that hypoxic signals in local muscle tissue recruits both ECFC and MSC to 
promote the formation of new vasculature. This is supported by my observation of human 
cell engraftment within the ischemic thigh of scaffold-implanted mice, indicating the 
migration of human cells from the scaffold towards the ischemic muscle. Concurrently, 
the bioscaffold itself promoted mouse endothelial cell recruitment likely due to bioactive 
substrates within DAT scaffolds. These findings were supported by my observation that 
unseeded DAT scaffolds displayed similar recruitment of CD31+ murine cells within the 
scaffold compared to the ECFC and/or MSC seeded DAT scaffolds. Unfortunately, 
engraftment was extremely rare by day 14 within the ischemic thigh of the mouse and 
human cells were not detected by day 35 post-transplantation. These observations suggest 
that the human cells are targeted by murine innate immune cells, such as NK cells or 
residual macrophages. Human cells were subsequently diluted by murine cells which 
enables the increase in blood vessel density while diminishing human cell engraftment6. 
Lastly, DAT scaffolds stimulated the recruitment of murine endothelial cells, leading to 
vascularization of the transplanted bioscaffolds. Nonetheless, I also postulate that DAT 
scaffolds may provide additional survival cues within the ECM that promotes human cell 
survival during transplantation into harsh microenvironments. 
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Figure 6.1 A working model of DAT-seeded ECFC and MSC contribution to 
revascularization after transplantation in an ischemic hindlimb.
 
 Figure 6.1 A working model of DAT-seeded ECFC and MSC contribution to 
revascularization after transplantation in an ischemic hindlimb. (A) After 
transplantation, human ECFC (green cells) and MSC (red cells) migrate from the DAT 
scaffold (yellow/orange lines). (B) Human ECFC and MSC also recruit mouse 
endothelial cells (brown cells) and mediate the formation of new vasculature. 
Concurrently, DAT scaffolds also recruit mouse endothelial cells and other cell types into 
the DAT scaffold. (C) Human cells integrated into newly formed vessels may be selected 
against by residual innate immune cells of the mouse (Blue cells). (D) Mouse cells 
replace any human cells integrated into vascular structures while some human cells 
persist within the revascularized DAT scaffolds. 
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 Clinical significance 
MSC harbor multifaceted regenerative functions that have been utilized in numerous 
clinical trials, ranging from heart repair following cardiac infarction to treating life-
threatening autoimmune diseases26-28. MSC are a highly secretory cell type that release 
multiple stimuli with pro-regenerative functions, and also possess the capacity to 
suppress the immune system29. In this thesis, I demonstrate that ALDHhi MSC possess a 
pro-vascular secretory phenotype that enhanced the survival and function of endothelial 
cells in vitro. Considering MSC have been safely transplanted in the clinic for over a 
decade and demonstrate pro-regenerative functions in pre-clinical models of vascular 
disease30, 31, MSC hold promise in the development of pro-vascular therapies. 
Unfortunately, the first trials using autologous MSC transplantation for treating CLI have 
only provided modest benefits18, 19. A likely reason for this may be the induction of MSC 
dysfunction due to chronic exposure to damaging stimuli associated with atherosclerosis 
and type 2 diabetes, which is documented to restrict circulating progenitor cell function in 
patients with CLI32. Transplanting a pro-vascular cell type such as healthy allogeneic 
ALDHhi MSC may provide pro-regenerative stimuli to a non-responsive tissue 
environment shaped by chronic illness.  
Initial clinical and pre-clinical studies indicated a lack of vascular response within elderly 
and/or diabetic patients treated with pro-angiogenic therapies. The diminished cellular 
response in these settings provided rationale for Asahara to investigate the existence of 
EPC to replace the exhausted tissue32, 33. After the discovery of circulating cells with 
post-natal vasculogenic potential, ECFC were subsequently isolated and expanded ex 
vivo and provided promise for the treatment of vascular dysfunction in the adult13. With 
expandable human ECFC available for pre-clinical testing, utilizing the pro-vascular 
signaling properties of MSC in conjunction with ECFC to promote vascularization in a 
mouse model of hind limb ischemia became the focus of my study. Interestingly, the 
intramuscular injection ECFC and/or MSC did not improve perfusion in the FAL-induced 
ischemic hindlimb mouse model. Based on a similar study, the pro-vascular effects of the 
ECFC and MSC could have been improved with the transplantation of more cells6. 
Although a significant improvement of limb perfusion was not observed, blood vessel 
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density in the ischemic hindlimb was significantly increased compared to PBS-injected 
controls. These findings suggest that the ECFC and/or MSC demonstrate cooperative pro-
vascular effects at the site of transplantation but had limited impact on downstream 
ischemia areas. Because this mouse model is subjected to a severe and immediate 
ischemic event, there likely exists sites of varying ischemia all throughout the afflicted 
limb. Thus, it is likely that the ECFC and/or MSC are responding to these localized 
ischemic microenvironments at the point of transplantation and fail to influence the distal 
ischemic sites. Previous studies have indicated that injection of 2-million ECFC and 
MSC (8-fold more than our studies) within Matrigel demonstrated recovery of perfusion 
in the distal hindlimb6. Thus, the number of cells injected in this context may be critical 
as more cells may migrate to benefit distal regions of the limb where perfusion was being 
measured. Our studies add that using decellularized bioscaffolds that provide supportive 
architecture and/or bioactive stimuli can increase the survival and engraftment of the 
human cells following transplantation. After implantation of the DAT with ECFC and/or 
MSC, the blood vessel density in the ischemic thigh was observed to be equivalent to the 
non-ischemic limb, again suggesting revascularization was stimulated by the local 
paracrine effects of the delivered ECFC and MSC.  
Considering DAT scaffolds can improve the engraftment of ECFC and MSC with pro-
angiogenic functions localized to the site of transplantation, cell-supplemented DAT 
scaffold implantation may have therapeutic potential in a wound healing setting. Wound 
healing in the human body requires the temporal organization of multiple cell types, 
including the initial invasion of immune cells that function to clear cellular debris and 
minimize the risk of infection. Next, cells surrounding the wound edge will proliferate 
into the wound and generate a provisional ECM network to facilitate endothelial cell 
invasion and angiogenesis34. At this early stage in the healing process, supplementation 
of ECFC and MSC within DAT may augment a localized re-vascularization process and 
augment wound healing. Similarly, bioactive stimuli embedded within transplanted DAT 
scaffolds may further augment tissue regeneration35. Likewise, purification of cells with 
enhanced pro-regenerative functions such as the ALDHhi MSC subset may further 
enhance the wound healing process. Collectively, this proposed strategy warrants pre-
clinical testing to investigate the role of ECFC and MSC in a wound healing setting.  
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 Limitations of in vitro culture. 
It is well established that endothelial cells will undergo phenotypic changes when 
removed from their native microenvironment subjected to culture expansion20, 21. 
Similarly, MSC also lose progenitor cell functions while undergoing drastic phenotypic 
and molecular changes in vitro36, 37. Although these are inherent limitations of in vitro 
culture, valuable in vitro assays have been developed to elucidate fundamental biological 
processes and cell-cell interactions of both ECFC and MSC17. The data presented in 
chapter 3 demonstrated functional differences between the CD34+ versus CD34- ECFC in 
vitro. Although, functional differences were observed in vitro, CD34+ and CD34- ECFC 
exhibited comparable endothelial functions when transplanted in vivo. In my opinion, the 
disconnect between established in vitro and in vivo assays used in these studies exist for 
several reasons. First, I observed dynamic CD34 expression on ECFC in vitro that was 
contingent on cell density. Given the functional differences between the CD34+ and 
CD34- ECFC, the dynamic nature of CD34 expression suggests that the cellular functions 
of CD34+ ECFC may also be dynamic. Secondly, the microenvironment that an 
endothelial cell experiences in vivo is vastly different to the surrogate microenvironment 
in vitro. For example, in vitro conditions fail to recapitulate the 3-dimentional cell-ECM 
and cell-cell interactions in tissues38, 39. For these reasons, I speculate that our 
observations that CD34+ ECFC resemble an endothelial cell phenotype with ‘decreased 
function’ may be due to the cell density in culture. Specifically, as the endothelial cells 
proliferate and become confluent in culture, the number of cell-cell contacts may promote 
the expression of mature endothelial cell markers. Moreover, our results suggest that 
culture conditions and/or cell density may regulate states of activation or quiescence in 
ECFC. Although identifying a progenitor cell subset within ECFC remained elusive, the 
plasticity and high proliferative potential of ECFC in vitro may be a good metric for 
vasculogenic potential in vivo.  
Despite the inherent challenges of maintaining progenitor cell phenotype and function in 
vitro, expansion serves as an efficient means to generate large-scale quantities of 
therapeutic cell populations for regenerative therapies. In chapter 5, I demonstrated that 
the culture of ECFC on DAT scaffolds or in co-culture with MSC attenuated ECFC 
221 
 
proliferation. This suggests that ECFC assume in vivo-like phenotype as endothelial cell 
turnover in vivo is limited40. If this hypothesis is true, using culture expansion to generate 
high cell numbers and subsequently ‘conditioning’ the cells in co-culture and/or on 
decellularized scaffolds may be efficacious to enhance the cellular response in vivo. 
Although in vitro assays can provide valuable insight to cellular processes within or 
between cell populations, but care must be taken to ensure in vitro findings are validated 
in vivo. 
 Future directions 
The results obtained following ECFC/MSC co-transplantation within DAT suggested 
promising pro-vascular responses that could be optimized by the purification of pro-
angiogenic ALDHhi MSC prior to implantation into the NOD.SCID mouse model of 
FAL-induced ischemia. Furthermore, increasing the number of transplanted ECFC and/or 
MSC may improve the recovery of hind limb blood perfusion, as supported by previous 
studies6. As postulated earlier, transplantation of ECFC and/or MSC seeded on DAT 
scaffolds into a cutaneous wound healing model to study the local revascularization 
properties of these therapeutic strategies is warranted.  
We did not identify human cells incorporating into murine vasculature within the 
ischemic hind limb of NOD.SCID mice. This may be due to a transient survival of human 
cells while revascularization of the microenvironment was stimulated, suggested by the 
rare occurrence of human cells within mouse ischemic muscle at 14 days post-
transplantation. This is followed by the recruitment of murine endothelial cells in 
response to signals contained within the DAT or generated by engrafted human cells, as 
suggested by the increase in blood vessel density in the ischemic thigh after 
intramuscular injection of ECFC and MSC together. Because the thickness of the mouse 
thigh is close to 1 cm, the limit of bioluminescent detection within tissue (< 1cm) would 
allow for effective cell tracking methodologies to track the human cells post-
transplantation41, 42. Cell tracking experiments would provide insight to determine if the 
human cells are migrating from the site of transplantation or being selected against within 
the tissue microenvironment. Furthermore, transplanting human cells within an 
interleukin 2 receptor gamma null NOD.SCID mouse would address whether residual 
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innate immune cells in NOD.SCID mice are potentially selecting against the human 
ECFC or MSC43. Last, we noted a plethora of mouse cells recruiting to the DAT 
scaffolds, indicated by hematoxylin-stained nuclei throughout the scaffolds 14 days post-
transplantation. Many of these cells were not CD31 positive and were not detected by 
pararosaniline staining. Thus, in order to fully describe the murine response to the DAT 
scaffold, we must identify the phenotype of these CD31- mouse cells recruited to the 
scaffolds.   
Ischemia induced in the hindlimb of mice is acute and may not accurately reflect the 
ischemic microenvironment created by chronic atherosclerosis in CLI patients. 
Atherosclerosis-induced CLI in humans has many contributing factors to the disease state 
such as: dyslipidemia, smoking, lack of exercise, etc.44 that are difficult to recapitulate in 
pre-clinical models. Notably, lifestyle choices may also contribute to the manifestation of 
co-morbidities such as type II diabetes. Accumulating research has demonstrated that the 
microenvironment of chronic disease will lead to stem/progenitor cell exhaustion, 
ultimately attenuating the regenerative functions of stem cell pools in systemic tissues45, 
46. Although it is possible to promote an atherosclerotic environment in mice with a high-
fat diet, the physiology of the mouse makes it resistant to developing life-threatening 
plaques as observed in human patients47. To better recapitulate stem cell exhaustion, 
comorbidities of CLI (i.e. diabetes) could be mimicked by the induction of 
hyperglycemia following streptozotocin (STZ)-induced beta cell ablation48. 
Hyperglycemic mice, conditioned with a high-fat diet, would be subjected to FAL-
induced hind limb ischemia to mimic human CLI patients with common comorbidities. 
Ultimately, a more fine-tuned murine model of CLI may help to improve the translation 
of efficacy from pre-clinical research to clinical applications aimed at treating severe 
ischemic disease. 
During in vitro studies comparing the colony and tube forming function of CD34+ versus 
CD34- ECFC, I observed functional responses which contradicted other studies in the 
literature49, 50. In these published studies, ECFC were derived from various tissue sources 
(peripheral blood, placenta) which may contribute to functional differences observed. For 
this reason, a thorough head-to-head comparison between endothelial cell populations 
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derived from different tissue sources is warranted. For example, proteomic, 
transcriptomic, and functional comparisons of peripheral blood ECFC, human 
microvascular endothelial cells (HMVEC), human umbilical vein endothelial cells 
(HUVEC), and human aortic endothelial cells (hAEC) would provide valuable insight 
into functional differences observed between endothelial cell populations in vitro and in 
vivo51. Collectively, in-depth molecular and functional comparisons between endothelial 
cell populations may elucidate functional and phenotypic characteristics which may 
confirm the existence of a putative endothelial cell hierarchy in vitro.  
Finally, our lab has previously demonstrated the pro-vascular potential of the ALDHhi-
purified hematopoietic progenitor cells (HPC) from umbilical cord blood MNC52. Given 
the documented contribution of hematopoietic cells to promote vessel formation53, 
transplantation of the ALDHhi HPC may provide secretory cues that direct and augment 
the pro-vascular activity of the ECFC or MSC. During this transplantation strategy, the 
ECFC and MSC could be seeded on DAT scaffolds and transplanted at the surgical site 
after FAL surgery. HPC would be injected intravenously to utilize systemic circulation 
and to home to sites of ischemia52. I propose the functions of infused HPC would be to 
provide instructional cues to promote vessel formation by ECFC and stabilization by 
MSC during the revascularization of ischemic tissues.   
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